var title_f26_11_26800="Full thick quad tear";
var content_f26_11_26800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Full thickness tear of the quadriceps tendon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This sagittal proton density magnetic resonance image of the knee demonstrates complete discontinuity of the quadriceps tendon (arrow) consistent with full thickness tear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26800=[""].join("\n");
var outline_f26_11_26800=null;
var title_f26_11_26801="Noninvasive thymoma Gross";
var content_f26_11_26801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Noninvasive thymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADyAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6ZNtKel7cj6CP/wCJrMcGY5jvtQGy6+zPllX64wvTpUreJ9AXrrel/wDgXGf61l/2z4Yikmlj16yV5rhbh83QYZXHAGcDIHareHqvaL+5nF7ekt5L70XtYhXTrBrpru9ZUeMOXuGAVC6qzHHoCT+FY9rqonS8Md80SQhWaV3lkEY85k5GecqFb2zk8VozeO/DEALPrNscHHybn/kDVM/ErwoP+YqT/wBu8v8A8TVrBV3qoP7mRLGYdb1I/ev8y/au+p6Rcx3QcebYglSWwd3mLnB5AIAOD0zXzFX0NJ8RfCe+aVdRkMkkYjI+zyYwNxH8P+0a+ea+kyKjVpRmqkWtt1bufM5/WpVXTdKSe+zv2Cig8DmsV9VubudodJtvNUKSZ5DtVTnHIPb8vavaq1oUo803ZHi4fDVcRLkpK7NqkZ1XlmAHuawp9H1i6gCXerpagAA+R95/xGP0rkNa0W5gvHjtbHUbzPzNdSqWRmwCSAuPXqTXmvOKDlywdz3IcN1+Xmqu3yv/AJHpayIwyrqR6g0oIPQj868/0jw9eb98tqFJ+8WB6Z5wMfjXU2mjzxqqwCZCuSGxn6cHr781E83ivhRdPh5yesnb0sbFFVHiuoIgWkmkUHkCIc/TjpTrWS6nTcbORBnAMhxk+gAyaulnFCS/ePlMK/D2Jg/3S5l8k/z/AFLNFXotOkkUHOGIzjHSmy6bcxgHZuB4+Xmt6eaYSo7RqL8vzOOrk2NpK8qb+Wv5FOinyRSRnEiMh9CMUyu2E4zV4u6PPqU503yzTT8woooqiAooooAKKKKACitix0C7uFWSRfLibkE9T+Far+FoxGMPMH79D/SvMrZxhKMuSUrvy1PYoZFja8OdQsvPQ5KivTtD8O2UMQYRo7Efef5m/wDrVY1HSY9rK6bR6ADI/SvNrcTUYP3YNr1senR4VqzXv1En6X/VHlNFdfNpduZHVoyAOQV6Z+lUz4UvZFd4TGFzwrHBH1rowuf4es7VPdOfF8NYigr0nz/gznKKsXtncWUvl3MRRu2eh+h71Xr24TjNc0XdHz04SpycZqzQUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUN20oiK2+BK/AYnAQd2/AVnVqKlBzlsjSlTlVmoR3Zm3TXOp6kdNsztiGPMkUkMDnkDB9v5119jppitY4LOFBEv8AEwzn1Jz1NM8C+GU0mweUAtLM2N7dT/gO/wCddzYWKmOMkHJORx0Hqa/O8zzKWMqb+6tj9QyrLoZfRSS957nJQ6aPNYGPLdSSASavxaD9o27FHAycjIHpXaLYQpFwmSx5+vrVuC0jijbYSOdxGBzXmvEytaOh3OKerONttFSM5ZcSjqNvBFaJ060ZM7NrdPlrcdI5d3k87R8xx0qnsZAzAAiPgjvg9DWTqyluXZIyItPszexx30KmMjAbpg0SJE0u6KFY4DgKoHOcdCau6hCz5YAhSA2Cc9fSmpZM1m0pzuBJA+lU6krWEoxvcrR2MTSBvLyxGA1aJ0oxSDcoORjg5qzptm8tukwPL5wP89K0IYy2wMu75scdqjmKZyWqWfmxyRmAF8gAjGMda5+58OYWMo+0uCRxkcdfxruLqGZb5lc/IBkNjkg1R8sLc7m+ZG67j0/wrqw2YV8LK9OTRhisDQxceWtFNf19x5xdWk1sf3i/KejDpVevUJdOtZnClRtLYGBjNch4r0CTSZ/MQEwPzwOEOelfaZVnscXL2VVWl07P/gnw+b8PvCRdag249V1Xn5r8jnqKKK+iPmDQ0jS5tSkcR4WNPvOe2en8q7bTtAtrSGMmFXmHO9uTk1D4URYtCjZQA5JZuOuTx+mK6WzPmM2OBjGT2r4LOM2qzrSoxlaKdtOtj9EyXKKNGhCtKN5tJ3fS+uhSht2Fwq+WpTI5HGP8KtkRFtrdsrnvViSJA69c+v8AWpBaRnDMDtHBJr57nbZ9DZJCW6rgC3Ukr7dfQ1W1BppEYlfm7setXXkS2BWHcRnAJFIsUk0TMeSx3UpTuJKxipCJruBWVcj5SfWr0FuwU+UGLMwUgDj2x60+1jVbyNlHOecj9KsRxxrO5kXbtJIwD1H+etTztlNJFXVtNhurBobm3BBzy3UH1FeU63pp0y8eHzUlUHAZDkGvWru4NwzOCSzc8nNcj4h0ZL9DIqSrcL90r0PtXu5PmksJO0neD3X6o8TN8qjjqXuq01s/0fkcHRXRy+G3+ymRGKyKOUYdf8KwJ4ZIJWjmRkcdQa+4wmPoYtXpS+XU+CxuXYjBO1aOnfoR0UUV2HCFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAeAT2Fbeg6W9z5dw/wDqMjnbkMfT6j0rm7GF9d1COKGcpYW0paXaMGWRei567Rzkd69Z0WymaGL7RJIYo/mjUnCJxjgdP/1V8TxBmrnJ4Wm9FvY+74cylU4rF1Vq9r9DW07S2lt1URAhUO3H8PHT8a0ZNLMUKzsQ6qi7Qoxy2f0GCPrir+h3FvHPGoBxkZOc7j6k/XtXQeTbFW3DKBCR+Jzj2r5VR5kfTSquMjjEVpBtQBeep6UsuVKqF45+cng57Vt3iREcoqjjGB1NVdi7zvUFemKw0WjZfPfUzPLYQFsYP8Q78ds025tWS5T92d6Al1Xkjj/64rVSOIuZI3WFI/nJBHPPoeKr30tuisttuaY8yOx557E9/erirasly6HKXczsqRbQq5CnBzuOf/11t2luAmyThJF4PoaoJbNLOsxcYDE47DHSti4deMnahHA9qcpdR26ElnF5Ee2IAp16foasRRsW3YwD17VSjmIcbVwT3z0+tSebJLuU/e7gDgGp5x8rMzW0Ms5AYYAxlfT696gitsxksMBh36kVo3EBA5I3d6kaEuBuAVeMk9F+tJO7NL2jYyEcJdAsinHAwO1N1mCO9snjfBjYbSewP/1q0Vgtop90gkmXPXoP/r1HJJFIkodAinJC46j1ralNwkpJ6omaU001dHi8jCO8ntnIE0LlGX6dxRWV8QhFba1cXS3RguYl811UoS8YxlwrMuTz93OTiuJsPiVIkO2+sRJIOjRPtzx3Bz3r73Lc+pVqdq7s11Pg804cqUqnNhVeL6X1R9I+DLiJLGPzUSQAfLuPCn1x36Gt1JRGPkTjnBxyc/hXmnw511dW8H2908ZjlkaRR82dv7w4+vGP1r1bRoDNpLzO4+UqPUsx/wAmvh8VNVK87d3+Z9vhoOnRgpdkvwEtXMhBPUnp/wDWqxcFmjHU7j901IGaJdqrlScbXHB+n/1qJG/jaDaQcEKx4rlubblN4w7/ADH7tXbRSUWNCMkd1yRzTljje3cnbuIJJHWpLV0t0UtJ+9wB0+4MfzzjHpUpu4N6EUlqFbJiz84OQegGc8VWu0MjgIdrNwvapnuy02yJcnIUZqW2thcKzs+GHB549Pwp37AtFeRhLE4l2BSpX73GAPernk/6OxT5mzjAHQVf1JN5A+YqOvuayJm2Btsrr6AKRmhSaHbmC8i8uIBo+MdcY4rnL61tr1HiuBHjGEfow+hroLrU1lRY3HQAbpB/nisua0juXZ3YDuo3Z/GuuhiZUpKUHZoiph41YuFRaM891GxksZyj/Mv8LjoaqV6XPpcdxCFliDDGOvGP6Vy+qeF7m2jMtqGljHLDjKj+tfeZbntHEpU6rtP8GfAZrw7VwzdTDrmh+K/z/q5zlFKQQcHrSV758yFFFFABRRRQAUUUUAFFFFABRRRQAVHqdrJJot1Il0lmSrJHK/OW2k7QOuTjAPQHr6VMil3VVGSxwB611PhPTV8Ratay3doUsLADygW5O1iSG4GSXGc9goHPWvIzjGvC0fd3Z6+TYL61W12RP8OPBjafoFs+pDydwDrAq4b6t7n0rsIkuIpXjVkeI4KKeMCtzywWAcgDOcDpSXtmsbrtyQRwSpAzxx+FfmdSbk3Jn6XTSilErW8Egiz5mxm4yo4qzbXs0BWKctuzw4PX2qS0jUkKxVQ3G5jwKq3sDMpMbY2jd9ay5mi7J6M1TIk8ZBkO45ypPWqqQuwBEj4Jxgjp7VXMiNbxlchtuQAas6fJ+6Ko5IX0B/I1Zm9NhklpIuSrbWPPHr2yagS0KllkkUA8gk5J9615nHV0bCjGAMn86oXUJbJjO5W5+U55qiFJvcrzW0cVqEQFyUwc9wev0qrZQGSCOKRfLaMDBx8sij09D7flWpJGWlCMpGDjI6gAVAMRzgH5Y2GQ5zg+319qhs1i9BGtWMrCQgdBgU5LRgzFGVVY7chuuKneRPIfYuJAMqTnoPXHc1RkuHOGUbiRnGc4zWeiepaux9w/2YkPkvxzj5T+PeqQv3mkKKY9o5KMMDirImdVJIADDAyOn+FZ8xK7tiAk9zxmrTVw5S2zLOVBU+Wo5I7+lZ+rTLHBgAd8k+lWtFd2Bt5VBnYFlO7AOOo59qzPG5Ww0eW4LptOUHrn1qJz5U5G1NaqJ8//ALQVgUj0fUFHEitA5x3HI5+h/SvGa9p+OWoxy6Ra2ju/nCcSKhBxjZgke1eLV6eWz56Cfqc2Ojy1Ffsey/A7VC2mXumlyGjkMyZP8LAA49+K+lNALNb6bbecqiVd79Ww3QE+p4z7V8jfBOdE8axQTb/JmjYOFYAkAE45719geDrcNFE7sfNRvvEZwAvAHoM5z+FcdeHJiJPvY0jJOkjaFiUgLSSsxIO0qCRgHnGfz/Csu6udsT5Qf3gQME+1bVy6WhEcJaR2TcCDjaDjkj3/AK1kXMUc2X2kyYOQp68VnPexMO7IrOdprddoVdxyARkj6mrMPltKc7sMDhgM4PPHNUw6wRIkJBkVNq4HI4xk1PaFASXUgDjC89PalG5cl1Rq2OmQrgyAEnklc+lNmCxkmBflY5z2wOmKrahrJt1giXALk7tvdcHj+VVGv5LtQWDCIAYOcZx3quaKVjNQnLVkjwT3DkxnYpPPzEZNU7jTnZmLDGPfOa17C5jaJg21wvIIbkGp2uIXhKqVDHoG7+tLS1x80k7WOYazOVKr5gJwSR932NMjttx4AAJ6DvXUGBGik8odBkkf0rPuogpCoMJgAc5qTSM76GVHaiPc6sQfRulOMjSOY02KoA3ORg8+lXGg54PHcVD5JMpwMK5wSK0jIHqc54q8IxXVrJdaamLpfmKjpL6/jXmrqyOyOpV1OCpGCD6V7zCNi7MnivP/AIl+HzbSrq1qn7iYhZgB91+zfj/Me9facP5vKclhqzv2f6f5fcfFcRZRFReKoq1t1+v+f3nCUUUV9ifFhRRRQAUUUUAFFFFABRRRQBPZIJLqJWcICfvEkAfiAa9r0e0t7PTrdbdFMtwPOdVGNvbB9Oc14pYK73sCRsVdnCgjtnivo63sYoIFkDR5lgCsOzYHQf3Tx9DXx3FMmnBX7n2PCyXLUduqMvA4zkk9APWllUyTlnwDnGM+lTGNtwBdQxAAGePxqLe5mB53A9upr4htn2aGSh1RQpBXPQ+n+NISF3AAkdz61ag8omXzSWO35QvTOajkjMksrjAi6A7uevYVPQafcpugWLavrinWMwgyrAeW33RnkH0pJRkhehBwDmo7ePfPLlwrKvycfeOelJNjaTRcF0CdqyEHpzwTSvbu0mRIY1YAE/zP69agKSqiOzfNzn2H1pYpfIVWUkooJw1XGdiHC+xZuYlEOyIoAqhV7fp2+lUAxnSTBJc/eQ9iP61amkhnZnUtldpZc/r+lUrqKJ7uciTaSw2up74pyabCCsMW4JleNTtldcA5wDmnxLHHCr4IPQ59az7sPaYeX95GzAZxgjNaTJLH8rQM6H+Jh8pz71G6NXoSIsc38IQdeTiq0+95SixiRSuGJ9ffFPgmhD7XUwHJBWQEqfofSpjZl5EJI2Mc5XoTR5oLpPULXTVdRK4yUYOFzjHtWF41h+3xNbW/lytzHsJG3Cje2CfYGutW3G07XKqmWck5VsDge3NcD8SrjySZE8pVMobdnCn5eCfas6zSptlUbuR8t/FTVPt+r28GHBtkKkN15OR9eMc+mK4iut8cGHVNTvdSsQxQSlG91HAb3Jwc1yVe3gYqNCMV0MMepKs21va3odv8F2QfE7QVlDGN5irBcZI2njnivuizVbO1jhngWHK8fJ8pAOACf4j7+3evhX4MSLF8UPDzPKkQ+0EeY67gvytyR3r7gs5WazeATNMDISrSn52OR69O568A1z4t2qfL/MxhrGxYmLmaT955TXCjdgA7h02j271jTTM0LquA7fICWGavwPH9riN5mSMEmTb0Hpj6/wBah16WHylWFQGxuyG65/8A1Vxu1rnTF2djISOQStHF853bSfT/AD6VbhIUFGAYZABPGeP6U618mFF+bdGVKttOCSeadBtxtKc7sg55+n9ai9jRu5HcWEd0hICiRVLBue3P+RUdpBIQIW3NGfmGKu+YnzAHO7g8/wCfSpFlEZymByMDgdqm6eoc0krEkKqsEiKoy3OcCoJWPmt3AHOT0psty6zeUjbsE5bOR6fjTm5BLNk45wOvvSm9CVpqSW9zIAwyVQ9AeppLpeMqcEDr/hUUjYwVyVOBg8596ha5zKcKwI9T1HtQthpa3A/KTk85/OhpAY3VMjnrmq9zdoJMyBgCOvUZqWDDMowQT79KpOxbWl2WIVfbwcketU/GsyHwXqqY++iDGD1Ein+la8J2gDHTjGetUvGAEngzVi2Niw8c453Kf5gV6WWStiqX+JfmjzcyXNhaq/uv8jwiiiiv1k/JQopehpKACiiigAooooAKKKKALOmDOo2oJwDKoJH1FfRs2I9JtlYI2wCNJsjJAGf1r530II2s2IkOE85SePevftNmin0Nlnb5VjUp2yQBtYA/T618XxX8UF5M+04WT9nN+aKrDbJjcSc8062kVJh5ke9Dwwzg49iKLrzCFkOR5xLcjqQecetP8gHbEzjzVyz+nQYr4h6bH2V9NRqBd8YOSu4Z29amnYLCwydqnPTGcVGIyMl8Kp6A0yf5028gg4yeBUO/QW7KMh3yhojnIH60tp5hldSeg+Xj7vsac8TqCq5U4G0gZ/KpLdQiEMrKerFj1NUlYbZamLNYWhcfMYyGPGSwPP8Aj+NUfNkiEoTC7lKe/JHQ+tXI5Ip4jG0kaZO5VHODjH68VA8aLNsdlP8AFz3HtVS3uhQfRkO1jCoIO0fhVqzWIpJ52fl3bSemcZGfxqOOM3E8gaUsgPygDHYVPboI5y8udvQg0r2Y29DOuYkKSggyMynCDuT3/DrV5I82kZdzk4RQDhVx13Z6nvVu6tkClwdqdTk1l3RZ3BjVnUcvnt2z79qcWoqwr81gdVU8ZbuCT0+ntUltI7XPklRgAlcnAGKW2URW0kp+9uGFbocim2UG58MMBiSoA+8Pr3qXcrQv3DpFaOSdoZTjPfP+f0rw743pLL4ZWKwEoSSaOCWduMO5Pv6ADivcL8ILUhsAhsgnrjA4/nXzz4oubiXV5ILkj7HaT+aoKnJ7A+x71E5qmk3qa4dNvQx/CWi6f9osLCPa1zFiNkYFRMvpIP7pJHv+VeG6kkUeoXSW+7yVlYJuGDtycZ969Xhu2s7q8kncO+SVlBGQMkj9D+h7V5LcsZppZiR8zk9eecmu/K1Lmm277FZnDkUdfQ7n4Dxh/ix4eJDFkmZ0CnHzBGI5+or7R0J1n1C+aORUgEhVFZsgA/eIHfPAHtXyN+zdpbX/AI9muFiaUWVlJKFQjJZsIMDv978s9K+sdFi/s6zhu4lKfaNjb3AJxj07gYJ47Vpi3+89Dz6a90vavA0MwDMQ8gYkDgHB7D06HmsuV2eReFZtu75FGSOB8x68f41clV2uDIx3DYAroAo3NnBPqOKZbiSK9FxGmPIYM5B6ZPf6kVwt3eh0x0RFb25RAzKvPzDGMjnH86nSJwp2HBHTIxzS7cNu+/GZM4zgkZ/Q1NdzJ9okAk3nP3v71Tcd2ZE7EPtYhT/C2CA/rgnn1FWrS1MrLhs7yQwP8IwOf1/Sn6ldNHBbwyKJHgkZlB5ChhwP8+tVnubhiCriMbcAIMHNForcLya0L9wYopDtxkDbkDoB0FV2OdvzcCqSzsVGcjHrgg0sMksjbHPTtiok02OMbInubgiN1jYcjjmmxIzIQ3TGCeOnBwPToKltrcM7JI2MjGdvH1NSzRiFAobBHPPIH/1qpJ2uO6WiKFzAGzuOV4IpkbBnHlPhc+nWkuZCQyFR6dfbtUC3vkO5lTcq/KWUeg9KEzRXsbAkzGCWxnkVQ8bv5XgLUwg4fy19x+8U/wBKs2T/AGhUbftRsEggcUnxHQQeAL5ON5eHcRyDls8flXqZRG+NpP8AvL8zy82dsHVX91/keGUUUV+sn5KFFFFABRRRQAUUUUAFFFFAFjTmVdQtmY4USqSfbIr3rTos6XCuGESLg7V3EYPX0HA/Svn5SVYEHkHIr6B0VnvPDzANzsV1yMEpgFT+PNfH8WQ92nP1/Q+x4Un/ABIej/MjimGdzuxbaNhPRRnpVqVS0oZ1CuwHycAjP+c1TuGgV41RSsbIGI3fd6/1qWM5fKNheMnrjivg5dj7VrqW0DbUyCVHTvUVyPLcERrJIykEHoB61asJluTIDlYbdQSAeT7D3NQyx72dwCFbtnoKbXKrkJ62ZnLE+0nkgnnHGKa0ZlUIzMAM7gDzWqiAJgDAIzVCVU+0ybV2BcLgdzjk0tepadzMlS3Uk5wo7t2p2827IhBkXPpkgH0qa5UMygJ0IJPGD9ahjQSzLtAAye2Kk0Ny1gXaXjc4IwM/zprsxTaCCAOh5qA7olTfhguB15IokZmmQoedmeR2zVPUxS1Hxu0sZQncFG7HtSBCzYX7xJHFNt5RF/pUJUsjYK+uePxHWnC4Bl3HKt2wMcVFl1L9CC1uGdRERvXurHr2NOtnMVx3K9s9QKS2Uw3G8scc5CnB56DP9KaCDcMABkDmnqtytCDV52kiUbjtXJHHYDPX8ea8Q8bJ58mqSWls0Nwy5CxuWDsFGCOeD3PufTivWvEk7xeWIhnKHbz3JA/mK8f1rfLBLNctutgxZ2BwQpbofXsOKwrytaPXQ3oKzTPI/Fl4LOMWMccSyFArsoyenOT3PWsJNMB8NzarJcRRkXS20UDBt8vyszspxjC/ID3+dfXlNduDfatcyDG3eQvbjNVbyOa3dYZg6YAkVG4wGAIOPcYP5V9Jh6fJTS69Tkx1Z1qrb2WiPYf2X79LTxHrMDYV57RdkvAK7XBI+hGc819O2SGW5tUdTiOBQVZ8hvlzwRwAfbpXx58Er23tfE10lxIVM9sURSu5XYOpweRjp17c19gaTK1nYGSbyZ5LoBjtX/VMOQvX5fTA9q4MU/3zT8jOkrRuiwkkdnc3OGBjTIAwM8dPYn3qGDzZBcbR+9YeZkjCshOCffBAH50alZeVGkRZJZHUMCDxyM/hWdElzbCSOHJRsd8qvcjnp/nNcmq0N0r6l23MpuoohnBkAcg9R7CpXhBjVi6hiTjcfSsYy3EYCzoQN2VeNhlPr3rYt5ZJUm2j5UALNtzgevtRHVDd0PiiXDFgzHHUnkmq5xzEx3GM4fHNXYgHVkZsnoD61RG1b6cZ5fnp17cVOu4LcaEK/KV4P5Vct0BXg4GfTrUcqLvQAlnI27Y+TnHH4f8A16oR3JOSisq7sBc5qdg3NmWMPGyDO8qSCeOnoaynEybRgjdwQfSrZdpUYdVUHOVqncHIx5wBKnYhz2GT+n8qtLQFoQ3McqROUCCTqCRn8hVOCR5VWOfBDEAkDjrxipzNLgeYrYZRt9xU+mLHLOnmv5SHjcVyF9yBUdUbp2Rs2ejyRmCSNB5L87M52/X261V+JrRy+D50EyeYcOYiwXOP4h+XTrz6mtTTb47o0JK4jKgg428YB/AZNeX/ABE1CS9uLgwnfaRy+WHHA6nb+YXNe3lFP2mKpqPdfhqeLms3DC1ZT6Rf46HC0UUV+qH5SFFFFABRRRQAUUUUAFFFFABXungW7W58Pae/yiMQCN2CkYKHbz68fnXhZIAy3AHJr2r4cppt94Vj/sy4aXKxk7hjZKVBaPJ4JB59Pm9q+Z4nlH6vGPW//Dn0/C91Xm+lv1NOazlS3LzEBSxwSBzk8/QVBa3JSaaAIG2jO4HoO2a0dR1Z/LW1S3VpiNqE/wAWDj+nIqpdRC0itYgURgp3kDG5zzuJr87aV9D9BTbXvI0IFNraJEGRg2JGbHXn9R0/Kgv8yjPXjGM02zuoriBd7JEkaBTv+8xA7DHTNRPcAxsCACBjjqDUyab0M0n1Jpm8tyxzs9aovJuTcx+Zstj6/wCRUvnuYwpUEn7wz0qF1hKkmNdy46+p70kyloU2ZpX8tPmd+Bj0q1aoH2vGQyDv6VTuYyEO5h83Gccj2qe1YIBHknA644+hpXLd7GpJCggeSXOd2VAHtisnVZpYbiBUAJ2neW/unp+tazyqbZRjDyZPIxnA/wDrZrIvgt5evPbqvk5GNzfe2jHNXJaaGcN9SWwtzKFBf92RuYDjAHWrWowrFNiFQIGG6PaT0/HvUdo2GL/KAq55B5qx/wAfm0AHCJuPPT2/lU3VuVbl6p36GVI8qXCHeSHGOegx/wDqNMmlkDGdQfLQYfA6HnFXLyNTbblQFl5U9T0xVSCdTp7xleWcNg9hjpUlo5jxvKXvEj8wxhrYqykfxhuv696+f/Eupk6C9xFc+cisdrH5d/OFO3vg44/SvbfHNyMqySncsRI3nbtO8kj3JAr5r8ca2l1K1hYJDFaRt+9MP3ZHGcH8KMLSdfEbbWNfaexpt9ehyYdtxbJye9LLLJNIZJnaRz1Zjkmo6K+nsePdnX/CkRHxxp/nxrIg3PtbuVUsP5V9jMnm61LZzr5ShxtbaQsUQGQMdc8/Xr1zXxp8MLlbXxzpbuAQ7mP/AL6Uj+tfZXh5vtN2ryKsTJBGuWBYE8H+Zz+eK8fG/wAe3kv1Oul8F/X9DpJ5IEtHmdRHMI9sJk52jp+fPX0qtqUK+VGybBEUXeFGcED1+vfn9K3ruFTYsJVIZG3tnkDjp689APeuadGX92WaIgsjZJKA57Y7YNc87rRhT11MlTm4yTkkNlX6+gz9auWzSw2kcas2/aQEHVhjkH1HU1ScCC5AB38dOeOfunPf/Gr4t5ROY2BWY/Lx245x+tZJ22N2ioiySFo9zqW4GDU5s1Z15beSMfMc5qYILa4LDG3bjaT19/qKnciTGFOT1JGOPaosO5QImSMsj7lYjqp6dRz9algjXfK6J+76YfsSP8au6hCiWduquQXbcWz90Aen41UvbnakCglZvNBK4z+7wckfj/KtHoiN9hsjyxJIokyj8cDryD/Os6dw5XDKsgwUwOd2emO5PvU0l2xLxp/rSRgA/wAPTOKZplpN5/nCQpIjb/MYdMc9O4qObWxcVZXZKkE8o82eVSqgIeQdoxxhfQAUpVxM0aPH5akDdxlvf6VevDJbQ3ML4WVCGzFwu1uG29zgHGOwrIv7r7FeeY25SyoyKY8q+AAMD04/GtehcE29CLxB4kjtrG7EMNxDPCWhxPEY2ZgBucA/w84Brza9vJnskgl4LP5rY79cfzP5VqeIrubWNRuJbgsUDFyXOPMxySP9nPA+lc47F3LN1NfWcMYH21b6y3pD8W/6/I+V4pxv1egsMt5/gl/mNooor74/OwooooAKKKKACiiigAooqxY2c19ceRbLvlKsyqASWwCcDHfipnOMIuUtkVCEqklCKu2V/FNosfhaCazuJPtVwGEoUDcgDgYRc5YkH9Tjpmtj4E65Np0mo6bcQzvbmL5A6ZVXHzsScdSN3vwR2riLC+uE8eQ2niSW60VEnSOKVx5bRRFipdGI75xv6DNa0ep2eh/FyyeO9gtrWzl2lPMDoyj5Buxjfkn0zzzX5tmuLnXxEm3dX09D9EyzCww9KKSs7K/qfRkbR6hcia3XMgQYB5B3DnOPUZ5FGpxhLwPcKswZdqAnb5ZOOcd8CsvRSsGoW0UHm5jmYFMEARsdwU/TPH0rZ1kKNSBIDK4Emc9BjoPzrwakbLQ+gjul5FEwb5QsbBfMGAc9D2qqhkUDzycj+EdGatIxKxH3dp9KbPAkdyZd2VyTgnOfaue13c0UuhDGFYDnk96ZLKEcsRuRQRmolV3k3Ana3GCKfLH8udxVSQM9QAeuKtMVis5MixryHaQL1456VYlVIcLjHqTUkkCGNRtyw6NjH41BhQ6xE5YcChvoBPcvnT3OQcDPJ9O9ZsYCmCNQHAdWYY4IPcjpmrd1IJk8hOGcc4/hWobOFw+HA3A9TwAPWga2Na0jdotsibHY7tuOQvb9KsFBAN2Cd2T7fWnaWPNmDuFSM/uyznIJAGefTFMuDIZWZiCiE4B46eoqktOYyvrYrsXfd8oBY/dJyKxwxZkjZ18wuEzk8dsjH+elaFxkxvJI+3hjnnnANYF0WjtlMRxImBkdd1Zt6XN4LU8y+Mpnn0a+eBWjhYeVGxYblO8HHuQucn614/4V0yzgi1LWLrUIbVNFiWdEW4VLi5uWJEKxAhsgON5+U8LzjOR7/wCNdPsZ9Ka41rUBp6ncPPfBRW8slPl7bmAGeg718lEvNLliWZjyfeu/LINxlfa9xYipFQUEveIySTk9aSr93beXbKQuAvVsc/Q1Qr14yUldHBVpOlLlkbvgaVYfGGju4+UXSA5HTJxmvtLw15STxB5gsVxHgjkhWX5eR69xnjivha1cx3EbqcMrAqc4wexr7N8AajcagI4ll/dSCKTcCf3atyQcdBnn615eOVq0X3X5f8ObUdab9T0y1vzNamBx84UxllPytj+IHv7msmSPLSS7yFG0AAE5c9vqOuT6fSp5LgWt5HBCWaCMnajEjCnJx69yD9KvQwboDNaou4yHcGOBGpBPPvjoa5mud27DXua9zmb2MiYs3zvnp3Pv9c1rWrxPNE6RkkMQVc9STgCqlzIhZQrAvn73TFVJ3KFpAMkg5559j9awTsbtcxo3cO24kjlA+VipJ4yRTJ0ZVR0fC424yc+5+lQPffaJ2kUBQyhtud3Jx3NMe6JlKjaEPBLflgUrjSdi5deb9kQODlCDjZ0BGACc++cVXvkV9QeTy2RdioS3IJCjp6DmrWYViVI2Yg4PIxwM/pk0if8AHwjyIGXbjr1H+TVNkrQTU7SI3UDpwggVFdUxkD/J570tt5UVwfLY8EBXPHJxnHXjrTDIYm2EncOmTyOvGO9VbZA9y/nhuTuAU4znkH29fwpPe5UVpqbOqQm50tUhA3bgzjgnBJ544GSMe+Dx3rjPFeLSyaPzpJ7p5PlL8yRrggJnvxjjtiu3vbWP7EqROkCiADfnhmzyeOf4s8+leZeML9LgiJIN7RwsApb5gSpEeEPLZwST7gcVs3y6v0Clrojj7yfzAGUgArgAZyAcf0A/OqVdCmnxXHhBblLuyluY3LyQQhi0BO4lc4xsK7GGTngj1xz1fovCypxwCUN7vm9f+GsfnPFbqPHtz2sren/D3Ciiivoz5oKKKKACiiigAooooAKs6c9zHew/YZGjuWYIjK20gnjr2+tVqu6YII3kuryETWtuu90aQxh/9kuOV4yc+1Y4icYUpSltY2w8JTqxjHe5zvxL8La34n8SW9rp1zDfaPY3JtTczOkUUTHBJeXrhsE5PQkevPkui6ZJq/iIRaVDLMfPH2e2Vt80gL4VVC/eIHJx2BNes+MtI0228KWKz3WoxwXWpG6e1KLJdi3CDnGdoBJB5+XIwSSteY+E7fUoviNp1tpt1aLqhvRGk3njyS5ODl0yChyQSMggntX53PSLSP0ei3Jan2T4fvTdrNLqGRPsjSWNXCtLKBtDY68nn2zV+zuoNRtWt3cx3NmQo3Hlh0IPuOn4VymgNBfebZyR7ppn3xLAoZiwGSinIIXGTxgnAqt4c1B7bxErzoGQsbcM+fLJ7ZI64yD+NfO16luWK2Z7tKOjO4iuAkeJZF8xCcptOQvGD75qi1yLy5dNsgUA8EEceo9uahgnktLy9hdwpdtkgZcZAPTJHTPp1qC+bEhAb5uvB6+oFYykbcmprWsuFWNypPIGOMip3KshRj8rD171laRGSi7mLBexbPHpmrkUbsN0pGdxGAevvVrXUylFJk6ziJQh4IGM/wB739u1VXKyTHZ0HJ5xkf4Vn6o0iSLu3ZJwu0ZUAdSaQQXcloksDhSwLqSeCM4Ax+B/OhgkaekKrTyyMwLt156U63kV72dIyGUnG4HIBOOKW3tYYmaSMuUY5G/hsdh7VBbyRQSzbCImVllUg4HXGMfXmmuxL7o6i9iW1VIRjzVUlgnc9AT+B/nWXNfCFxFKFZmGBn27mqv9qRrBd+c8k85ZcBULMNxJ3Z6DpjFVGmiYO9yGckYAHIH1xQ566ChDTUj1C6DoQrGNAQGdST8m4DAFQySbbuJw+3bufgDljnp26modVu0McUUSjBkG9+QOOcD16j86x73XHS+kS1lVWWNw7noBg5/DGaznUUFeRtGLex5v+0Jrduuj2nh5bOJryZhK8u8h4Qp4XA4wff0rxaHTZktmliPKr8+0blHYZ9Oa3fGevL4j8WXN5EweGNRCjqAoYDjIA7dcVlRxiPLkhUA4LHrXqUOanSUdnv8A18jvw+GhL3395m6reRSWNvbrZpDcoXM06yOWmyRgFSSo28424znmsir+rkvMsm0gMM81Qr0qStFHhYy/tpJhX0r8CtfXU5rZbmVokFuIZXVMksuRyAeRyp//AFV81V6x+znro07xuljIf+PpT5BLYCyjkH8h/wCOiubHUueCkt4v/hyaE+VuL6n0teXaoyAM4ZSB8+dwPqc+9bEt615BdSRXG8kIjsRjzMYycHk4I61m3l3HdWm14ArxYVpWyxbI7n656Dj3qTTp4Ps0MYiKOgaMl5NyucA7vY4PT6V46TTep1vZaE8FtHPaxyucsp+XaSe3JJqreW0oJaH5toPynvWlDJbpaeQgCPG2FA43Bskk/iAP8moFB3SfMSM5APSk0OLZh6feJcwyKoyGG4HptqWESAjzF3A5IK8A47VauLLY53KeW5ZeufSpCI5LREcpvjYYAPJB4P8ASojF7M1bW6JoiyqCccjn2q1C4CuDyQOvpVUxbnypO30zkU6IjafQdhTJauF3KomQqNzMQmQec4GSR6f4U6V5oZkIIKMilZsdSO/qOneqdu/7yRgyMu9QyE8yc5AGOw6mr2nNFHqCGdQ3lZcgjgAZ6+vX8elNe8NrlMjxbr80GltbIqxJLH5RwcMQWywJ/nXkF9qBuPEogubqVWhHlmcxFFjO4DDMTzwycnGM45r0rUrqDUNR1CFZ1hjuLWS18wx5TzWIPXa2BxjIwRxzXndqY7fwrqd9dRtOPsrpdSSOVYvxGAHYNhzuBwQAQCM5xWNS1Sdr6beh1ULRi7LX/MtQ6Rq/g+ec2uoCfT9QWRL633BRJIkhVuhOSCOSMdcjg1Hqdr9h1C5tRIsohkZBIvRsHqK5DwOlrD4Z1a5kaee9hnihhgLbYlR87pHPoMY7dc12OrXek2+lWd7eXkNvJ5EsEsVrEZyLiEZYMFJIyoLFwNv64+04azCGGqyo1HZP81+R8rxflVWvCNSC5pRdnpbRq/8AX4FOisB/F+iixkukvY3CDPljh2+inBrkdN8QeJPFPiq3svDsTNJIxEUCpuGzqzP14AGSe3OK+yxGZUKCV3e/Y+Ew2UYnEN+7y276HptFVtBvLXV9NnltLsXVzbLE06RQOoRHUHeSwGBuIX3P4Zs110q0K0eeDujhrUJ0J8lRWYUUUVoZBRRRQAVpXt9HYeAbuaW3vbq1S7H2mOIApkqFhJHXO8t69BxVBZbe3gubm9DNBbwPKyrIELEKcAEg98duelc747uX0/wtalpJIbOZ/LmSd1WZyW8wFYsksQDjccKu0LkkkHws6xUI0/Y9XZ/19x7uS4WcqntumqNH4r+KVTwfN/Yk0UEGri1W+haIFyBHkRKy/wCrX5Vdk77gc5LCvPvA3h628Q+KY5tLk2WtoIZDDcIS7vj5l4IHVWOc5wQQpwQOY13xBf6zbafa3c7vbWERggQk/dLu+TzycuRn0xXpfww8Yatq+t3UdzNEiJp9vBIkNuiK8UJEas2ADuUPjI6jg9BXxdf93TlJH21Gm3ZM9l0rypbsxpAz3lwfItkRhGqMwYbieo2n+WK5/W9dOkn+wp5fk89pisibWM23aQvGdpAXg47E12vh6/07VdU1aW8AaSZRFEiyiPzZvlUYYAbctyOOCec4rE+IvhvTfI0u+gmubm4u4XeWW4cM/mqQGOcdQcjPPTvXz9eH7v2l9P0Z7NGUefkmjS8GeJ7fxRpmJdv26zUJIWAzIv8AC/1x1/Cr8okuZPKAOcFgB1P0Pr1rw6CxvvDWnz6/pd9N9ot7lY2R4P3LxlScFuhJIPy44HOa9d8MeJNL13TlurGVtsm0yoWOY37IfTBzg85zSsnFO90dlSkoXcNUdBprSQSRceZGGBZG4yO4z71pS3C4PYckLjpVWx8twHjOVPcHvV5okX5ic4HOOf0qkrKxySauZkiKyzSFyZxkk9BjHA/nV/TfLCIuHUoAwywPy7c5PuSc+1F5YRrC/nhxKR8yhsFc9BnntiqGiW6x20AeQeYA275s4YOf6Y/HNWZuzRtTAxLtdeTg4z6//WrMIH2guVJP3QQK1rJ4p4AQhkvJGIBJ++B6DpnioXJkTcFI+bnd2PXFS1YIvoYL+bJcCNJBEjHe4XgnHYnv29KswXIhuVgMeBt3ZU8VLqczyN86CMSDcNp6H69elZur6lHYWZ8sF7mRQAvTPufSs5SUVds0SuZXifVn/tGG2Qs1vACwRenmHqSfXGK8h1zUrTVLuW3XVHkgEp+3PAF3KpICrEMjdg8HHYZPHXB+LfiwTyf2bY3UjzLlLhojiIf7I9enJrK+G+heejXtzFuBysY69ucj0waqNC1J4qs7Lov6/rqb0XaooR6b+X/BM/U9Du9J1HJKtFOpm3DC7Txke/XoPyqhOvnAISTFty2Op5/+tXpHxVtUs/CGnXLwy+bJd5jlC/uyoBBAP1BH4fWvNbKQs7Qg85645PtXoYSrOtRVWW/9anXRnB3pdH/Vvwf5GXqEisyqAfl6ZPQVSq5fQFZpmzkKR19D2qoBk4HJr1oW5dD5/Fc3tXzf10DtV/QNUm0TXLDVLUAz2c6ToG6EqQcH2OKoujIxV1KsOCDwRTappNWZzp2Ptmx1y21fRLbWNMkaazuwJE80gsrYAfOPRsjHtV/TQklhOQcFrj5mAxzs49ugPHtmvk74e+PbjwqJ7WeOS50y4O5olfaUbuy+5HGPp6V754b8baHrOl266VfJvyvmW8xCSKwBGcenP06187Xo1MPNuXw9/wCv67Ho05qpFJbnoUO/YVnnZkUZjGzPJbnJ/X8KswSiNWR8MpwQx6jFY1lPIxO6NiuB8+Rgn/8AVUrXjxDkLI/qWxgY4/Csm7as0SvojXa7CkSBgCOQc8g8dPeqNmoup5im4wxE8nuT0qlp376eSSUKh6E5+97Y9BWhaXC2s/lxsSsnzuMDAI4HP4n06VV9L9A20W5OAxLBXG08U9IYpAQ3yEZO9m4xjoapTyiK4MrMArdTnvUwv4lBwrM2OMcAnsf0qE9S7O2hWQSJcvHABDC06sqk5Kkg4Bb6fnVPxxrNr4b0ee8uLgbySiP1Il5DNjHIxkDPU8itPdI8FxdXU21+vJ4POTj6V4z8eNWh1HS47aSd0n8zz3ijl+UIF2xLgHBIyzHPIzjirilflely4xdSSSIvhX4yijvkM8cvnpkicShcAZ3HBBBZhwM8A889sLxm0Bha2sGvclo5GUoVj2MgZt5zlm3AdscE+lJ8O9Isxf6XcyzPLZgAXESfK2COdpwen06Cul+INnHpmqzzR3An06aZhbXSsXEijbwH7lQVyO1Yy5Yy/dq6T27M9KPJDEqy1a/E574caU19NKrQPJZyKFuHC58qIkAsCemDjJ9M1X+JGnwaZodxHJqBt5jqrR+bByHRopRJgDBKkhR6Yb8K7HwVrFzYXNxfWSRb4XKeXIu5HTbgqy9wQSO39a5H4zajPD4ZsXjmltTqc82YoNuyaJdpKud25QrFcLgq2TzlBXTgKvtMQu+pw5rUlLmvotDyW1v4bXSbu3jtx9suD5bzOFkXysg7VBB2tuUHepzjjoTnbs4YNGiaCLxKlrNfRNBffZ4jIiw7Y5owJFJ3bnCqwABVk5yM0upeHGi8NTXZW0820uYbdJY3dGu/MVywWNl+coybSy4x6MCCMTXtHvNC1280e78p7u3k8lxA4kVj/skde1fSp9D5zSSOw8B6lr2m6VfQLMlnoMN/bpqKNa5kDS5UHIAZsCMsELAZGQM5r0+aIwylGeJyP4opFkQ+4ZSQR9K8Y1G+l8V30VhpNhb2thBLcXVtZRRKphRzvdWlA3SBQoAZ+gHAA4r0rwTFHF4P0ooZdzo7NvXA/wBY2NvqMYr6PJKsrum9nqfMcRYeDgq32lp8jZooor6M+TCiiigDb8IWMF/rIjvFR7aOGSeRHXcGCIWA298kDiuY8VeGbTxNdC/vXuJbzaFDTSkKq5JCBewGT0wK6vwu5h+0Pbyql0UKcjOFOB075z+lReKNMW1muFjYqkEKt8584jcAeW44zz6jOO1fn3FWKlGtaN1ZW/U/QOGcMlhuaXV3/Q8G8UaPa22srpekx+bdyckBs7RjOM9M45NSaHp2peHfFNoqyRLK67Jck7VR/lOcA+vp6GuwuNGluPFMEtuBCrIZluI2B3MpHGeeCCcg/X2qHxTaRWtj9mtocNK/nS8jeyjkkMec5Hv1/CvmljuZRpb3Wp9TDDRUr9T1G2Edv4bWXyzHcSkM5dtpiZDhgw75GB65FWdW1Ca4gsUvIFgS1iNsvlKPmJJZS3OOrdfQ1yXw319Nd09rO5tn8zcWBYBxIF4z689wa7bx6kdlY+HrcQpIjQKjykoHySOpHZcgc84BrgrwkoSv0srfM3pq8kurPNPHOm339lR38MsS2TyPHJEJfnJBXJK9AOQAe/NcV4S8QX/hfUTNaspRjtkikztmX+6f6HtXoMt0t40trNbOkZcQu0uF+XPB/wBrjv6HiuT8ZaYkXiS5EccVvbyASxoHyNpOMDPXnPvV4KtFR9jNf1oezRgpL2c9/wDhj3Hwh4ts9cs1ks/OtpVzmOUZA+hHX/PFdba6ofMjWYqiFhlwM457V896RqmqbNG07UJp7TRYZ8IVhJ8hWPzuqg5Zuhx+Heu217xHp2kahp1vZalIbSQhZLuSzZQg3fMxQZJAGDxk0nNqVlr/AF2OGrhJKfKle9/P8f0PXLy7nnWVkMW/q7H5gPfArJ0mxN9cIZ3eWSeXLEALg5JO0HtjHWvM/CfxDt72+mgvZblbMb8mBN7KoPDleu3GMke/Ars4dd01VhcazZyWzgGP94ihu3GTntipnWSa9omc7w86fu2Ove4SBgm8hV6rn8jVKe824EDSAOxZtyjj1rKXUbzVNT+y6FFB5gHmSNnCRjIHbqckcc9aytYvJ4pdl/fZk2/8sccHOMHj0Hb1FZVcVGKva4o01fUm8SeIvsFoxJO/oojXcfwHUnpXIRa5ZrdS3mpzwzRLE3mwTIH2AjCtg9SGK+386dLe2rzt5IlIBzvkX+vpWXdOk9w0yW5E2CqzY2sARggH0IJB+tcUcRKc1Kaeht7NW5bHmnj29ltPDtpokUWnmyurr7fFJF80qhVMYGc4VSWclepIB47+jeDNJe08IxSFkS5SPK/LnaW/vDvXmfiHwY+m3c97F9misYU88Ce4VdwBGUQEgs3OQBzxXpeieJPsuiRajZ2do62sYnltJmXY0eccBsB+Odo5OD6GvVzCXtcPShRd1fV+ZFOnOLnJ7tr+vmcx8U7lhoH2OW/yks4NvZeWGGUADz7v4Bj5RjOctwOtcdDaSRadZ3ZGIpw22X0I6/iP610HxCv9Yg1r/hGtUitRLp0jXbJEVfY8scZ2Fx1wAARwA27rwawrKQz6e1o0jARL5kUZ+6AcZx79K76MJUaEIPpv8/6R25fFSm6i66fdsc/qDq6q067JAMjb0c+vtVfTXs0a4+3xyyK0DiPy+okx8pzngZ68HjIxk5Gqmt3mki8FhKqG/tHs5soGzE5UtjPQnaBnqO1QRa5OPFFprF5bWFxPBLFI8M8AMExTA/eIuNwO35sYzk+terSvY8LMHeqzMvnSS9meN5ZI2clWlOXK9tx9cdaiijeaVIoUZ5HIVUUZLE9AB3Nb/jye1ufEc81u8r3L5N6WuFuI/tG4hvJlBO+LgFSSSAcZbG40vD32RbyaS71G4054raWS3mgQsxnCExocEFQxwu7tn0zWielzhLei3tppWn3kjRw3V3dWxijiubYssbGQYkjcONrgK3zEcZxg5yMWOR/tSy+YY337t68FTnqMV0U9hr+jx6d4nuUaJGk/0GechWlMLGPKLnP7sooI6r8vbmsLTrK71S+t7LT7aa6u5m2RQwoWdyewA5JoVtWB6boHxg1XTS9nqG3VbZCUjnCmORxnAP5Z6jPSvU/Dnjy0u7qe11aynsr5I45o4bgBJVRlDKdufmBUg5HIzyK8Z+G+n2lj4i8NanNeM15DrkETWUcDCSAbsebI+0qMOF2pyW+b7tUvi94sufGHxG1LU9UW3HlyC2CWc/mxbIzt/dueCDgnIGDnOK82pgqdSX7vT8vu/wAjqjiZR0lqfS1h4p0oSM4uYxNu+eMKSyk9OOvSpJdbhuZg0COsfTc0ZGfqDz/KvmbxJ5Ok6jJp1i00mmosdxazS7jIkcyCWMOdqjdtZc4GODjI5qGPxDq+lKi6ffXEeSDh5N6kH2ORXFPBVmrRkvu/4c9aNOlKHtIyv5H1RHqFmoEjXHmSehQ/pVbUPEltahWhdWdjw3XZ3B/SvANF1bxJ4isZ5Yr4ySI+wxo4jkbjPCjGeKo2msSNFcWsKSTFRukLZOztz9a5fYVleN1db26fedlHBwqRUuffoez+LvGsVhojsJ1eWVvKhRWGVbA+bb9D19eK8ftLV/ElzPkyRxRr94v0Pqc9Sf6VlX19LfiN3CxIg4CjGfr710XhO9b7LPb6dZTXFyFyy28bSSMM46DsM4+prX2NSlT5lrP8jqjSjRpvlLehaPc6F4qu9FurlGurZ1aElQRIjKGDYB6lSO+Rmu7udDttZiui8BV0cNFCHGVdj1TPUcYK45GPQV5F4l12HVdblu7Sye0ZvLRYnnLlNqKv3jzklScds47Vtad4idorP7RcSi7ijYv5q8REHgrg5JxnJNRiMPVc1WXbb5GDpynGLjLVL+tf+CdLpLXtxpohtrmC3NosqrHLDnOXGQMAEnPc9MEdhXn3xTjaxuobHU4QNajYStPG4KtEUVQre4ZDjpgE+tegal4kvL63huVkjliiSQyzMcCJVAJbgdwM4yctnqTzx2p3mmPeXGoR6ra2Op3YAjBhF3GFjjDgMZEDR73WIKwGMSOrcK27ryyL9rKf9eh5GZzfLyySu3scz4kudWs9G07R9X0prILEk0MkqurSKS7LIuTt+ZZACQOQidxRpT2mkaCbqJTP4gu3X7C0Uk0M+nMkisJlwAsm8BlGGypGetbHhfSdV8VaRq+lPr0MOhaXKt5IZQZRuwY1cYG/YF3c9BkcZata7tr/AMLeOvFmiactpFbBG0v+z764BM0LqTG6uegUhZshlwQPXFe+tXY8JuyJPhBreneG/DHiPUUuXi8U3rR2OmtAwaSNScyFlJ4U/KM8812kDzLpthaTSF0s4RDGD/CNxY/+PMx/Gq2lDQRo2h6fpFlI0emW0jXN1LaxRyteSkn5mXO7C4A5OAAM1Zr6jI6S5HVt6M+T4jrWnGkn5tfkFFFFe+fMhRRRQBLbTyW06yxHDL+tX73Uxd285kcxyurAk5x09uvTv61l0V5uY5Vh8wjaqte63PSy/Na+Af7p3T6PY4zxHINOtbK6sQbPUIwFUugAwRhhjoR0H41xmoeIJ7zxAt60USTlCjHlkcHpwe1ew3FvDcxNHcRJLG3BV1BBqGTTbGRGV7O3KsNpBjHSvF/1VpRb9nL7z3IcVTaXtIa+QeDrq1ZbW7s1WDZjdngI3G4evcmu019luoVBQg9VIwec8/ga4UWktnbyLZs8iAEpGWweudue44xz+ddNaXUt1beSx8ltg8tmUMM46Y9q+RzHI62EjKFRaN6PofV5ZnFHGWlB6rddShoj29pcal9qWOeaOASRNIuTEd4OQP8Ad3Dn1PevPvESah4h1uWPT1zFbRPcx4IXEaDc53HHYZx+XJo8Qajf6BqjefKsisMSrt2+YufXocf1revtGd9CsdR0h/tNvM/ny7M/K55AHQgdemecV5NKjLDyVSSv/Wv9dj6fnipPXV7HZabHYXPgmE3MQuZNwmjlLsJIiCQUOevQHH61Z1eTw14mt9N/sqzeK+tdoudOmTyzMgyGIcjG9gvBwM8cZrynUfGN/pDeTc2ssFvLJg7YirKRjcozxuwRn61hWXirUIb21vLJi3kyL5s0kh/euzMUDZOFA5x0AC5+utLB1ZapaW/p3/r7jgq140W7yd76W8/66DfiGG0zxfPe6PBPpsay7kjVyRAx+ZVDd/lx1681HFqT+KL22ktbGCPxHbnz08qIFLwp8xBjIxuwM46NjGMnBn8X3sXiy83aPpeorOpMk8rTyXAnc4+6u0BQOce2M10Xw+8Cy2UM2sX8wh1G3Tfa26uwdXDDBJXnOA3Tpx68d75KVKLqP30v6+X9bmHtZzm2k1CW9/63vqdXofiBtT+Hdja2l41jdeaJHjjKxfKmfNYH744wuB1zzwK4HxD4gmuLtBayXVqEyMFiCT/te+a27u01q28QWuuSaU2paZHvmexebDKjjc4wpBAJJOF7jNcR421PTrm/+06I3lxXILy2wJYW8hOdqMeWXBGM8g7hzgM3HhsNCpNSjqvvt5P5HoQxNOgpOpv/AF/XkemeE9dsbmzRLh4YblfvqzYDf7Qz/L60a54tsLK4jjt5Y5pG/iTkKOv414b9ouJCoDuSOmK9w0v4f2Ph/W9Onlu4tXuYYWd7aVQ8TSAcvg4zENwAB5ZkboOayr5VQoydSpLTsYRxVOrJyjFnC+OPENtrNlGDnzVXAXPGc9cevFbXwZsZvEtvqmgssqJIke2aOEyhSZkJMiDJZfl5wMAA5IGa6HUfAE2t39zqM76fpqzPlYbK0CxqMYG1eAK5u88G+JvDM8114d1iUTmNomNuzQSMjdVBB7/UVpRxWDcPq8ZW1ur3/O1h4iMm1Onva1vx67nBW9/LLrNzeyIgNw0jv5cQVQScnao4Ayeg4FXpPJ8zz4LpHlCYGDj9KwJoprSV45kaNxlSrDFRnoAeOK9mVFSfMmc9DHyw8PZSjezvrdWZc1O581wEKbCA3y9RnqD+NUKlht5p1laGKSRYk8yQopIRcgbj6DJAz6kVYubE21jY3bXFpKLoOwhjlDSRhW2/vFH3c4JAPJHPQjO0YqKsjz61aVabnLqXZntLbwrBBGbWa+vJzPM3lkyW8cYKogY9N5Z2ZRnhYzntWNU8UkRlZrtHkUoVAjYKVOPlPQ8ZxkemenWoKa0MhzOzKqszFVztBPAz1xXf/CHxfoHg671W517Qn1aa5gWGAicxiJd26ToMhmAUBh05HQmvPaeqghsuq4GQDn5vYf8A1/SiUeZWA63x34pufFV3fXVraW2l6IbvfFptsypHGxDBW2DGW2rgsFA4GcZ54+irOnTQW+oWs15bC7to5VeW3LlBKgIJTcORkZGRyM0JWVkBueJvFF94h03T7a+Zni09Fhtmdk3iMRqgU7VXfjyxgkZHQkk5rON5PfX73c6xlnPKxqEUHHZRwOlbN5Y2k/w7s9Sju7YXVvePbvar5jz7GAZWck7FjBDbQBnLMSTnC8whlij8xQwRyVD4IBIwTg+oyPz96lxTVkaUKihNS7G5ptz5DQuLho1xjcD/ABZ9fWo21aex1SV9Nuym/wCRpduMjpmsWSVnyCflJzgdM+tMycVl9Xi23LqehVzKbpqnDS3XX0Oqi1s2Gmz6d9pEtrcSLJMiYbcyggMD26n/AL6NJpfjLUtBvXuvD1y9nOU2iUKNw+YHKnt0x9CR3rlac6sjsjqVZTgqRgg+hoWGhu1cirmVWpB00kk/63HzuXkLl9xb5j14PpRFK8UqyI7K6nIZTgioqK3srWODmd+a+po32q3FxB9ljkljsgRiEvndjoWxgMffFUnYsilm3EfKASSQB/SmqxVgw6g5HFDMWcscZJyaIxUVZBOcqj5pO7Pevgp4hsLHwRHZ6xPcWcdlqT6lEscS7LkNEYt0hfh412uGxz2AJxjnru2GoeKF0GVXmFleLYo0bbi9nHEMAynBZMRBwCgxk9CcV5299FfaZbWdykUD2iFYHt7ZAZiWZj5rZBJyQAxzgDHYV674YvLnWfileatr1pbaJc3ulx3kMMMYjinXEYygOcB0DN15/Stqa1duxyTjrdm42nNpE9zZNvVllJkVm3YccHJ7njrSVPfz/ab64n/56yM/THU5qCvvcPT9nSjDskfnOKq+2rTqXvdsKKKK2OcKKKKACiiigAooooAKORgjqDuH1oorOrShWi4VFdM1o1p0JqpTdmi35en6np0iatb28k8Q3AyJuUjnOM//AK6zbzXpvCPhy2XTrZHt7dpDB829VLHOOckYzwcHGB0wKddq0tpJGoRsjhXGQfb/AOvWv5Npa+HNXk1JII7KSyWKOORvu5YMWJyOQAfzr80zjLJ4GtprTev629f68j9MyfM6ePopy+NaP/P0PF3k8ReP4ri106ET2un+ZqMke5YxGXKIzZY/MxOxQBkn0r1P4VeGoYdCgt5YYr+ZpnYAW5LRycAoQRkMCCOmeK860fx/F4WXW7TR9OtZmvrjBvFJQ/ZwrKY0O0MoYlWzkHjBBrX0bVLXwro9vrtjqMpt9VjlUWkRYvZzJtVDI5OSpw2O4BHXBrCdK9NQSsux2Oq/aXvfzPWIJrbS7sTTGNI4X/eJIMK/P3XXjIJ4xTNDMWpSyppu2RJGKJI7BIxjqxc8DHr7d68g+J94f+EhsprfXG13SZljea3gnOy2kcH9yzjjfwTnnoeuDXvXw7t92nG1sryG4ngjcNbzur7tg+4rHG45DZOBjHvivNeEcOVSejudKrRkm47nLaxAZ7IQG/ljvZS6pDEoj8oLg72lbglucKMH8a4L4v8Aw0htLeXXfCkazaZbKkV20Qby3fZuaRC2M5wxKr90DPQ17ZdWFrb69YRaxYR3CNLk5OSVKgHC/e4JJyevGOOrPE+umB5NOjP2ayTebaZI/wB3NuKjDE4+XauM45IOc5zWdOr9Wbkntp6+v9eljSSdRKPQ+R/DcE97fi1thhpV2uwAzt719L/D/Ro3028eKXOnWMKB2diQ7k4VRnnP3voAa8xfStI8MfEezuY5I4dEvLctNcrG8iWLkhSwUYIQOVXLZ4YnGcCvY/CEEDeAbq/tLlZY3vUMkKNuVRhjuyOCOW/KlmM3W5Zpe7Zv5pP8v8y6c+Wn7N7p/n/X9aFsoDAQxGBx7Vw/ie+W1huZFVneJSygDIz0x+ZH6+hrrboyeTMrH5egIOK4nxDJbNaqZYw4XPnRuD02kdARgg8jtkd6+Zw0VKouY7oJXVzxPW7mK8u3knI8xjk7hyT6D26VrfDrwrYeK9bns9X1iPTLeO3eSNiMvI4BKxIO5JPTv0HOKoeLdKuI4kvrWyuv7KWQW4ujEfKMpXds39C+OcZziqmn3s1ppM9xZJIl4syFrxHIZAMkAenIU565X3r76n/CThocuIkqlaUWtv8AL9CbxL4S1zwmlk2sWxtHvRIUt3YeaFRgD5kX3lGeRuHOMjOK5s8mrurape6vfS3up3U11dynMk8zl3c9MljyeOKo11xvbXc8edr+7sFFFFUSFaOkatdaT9sNiYkkurZ7R5GjV2WNxhwpIO0lcqSOcEjOCazqKACp7OQRT5MUUu5WQLJ90FlKhvqCcj3AqCigCxeQzWk81nORvhkZWVJA67gcEgqSCOOoJB7VJZxQFTLeM4t/mX90yl9+wlflJzt3bcn0z34qCKGSWOZ41ysKb3OQMDcFz+bCmkp5agA78nJzxjjHH50AMoqee2mgSB5oyizx+ZGT/Eu4rn81P5VBQB1iQ2mny6c2kzrdQalZpLepJGZfsoWRhIjheoBiEvQELt+p5e4ZHnkeONY0ZiVRc4UZ4AySfzJqzY3UkFvdxxzRQiROSYgZG7bUfBK5DHOCARkHPApt1aeTDFNFKssEhKhgCCGABKkHuNw6ZHPBPNFhLRlSiiigYU7jbnPOelNp3BB7HsKAHIxCFQFIJBOQM8e/brX0P4R0m31e3n8Y2OjS6fbXsrx7i48mNS+FijHHyrtC8D0GBnFeS+A9KttYl1W0vWW3tJLV5EkcpuWVBuQBmGeSCvy8nOK9T8M29xbR2qyq4iihMbQ+YZIFzL5m6JWyIiTjOzA46cmsKuJjTVk7M0hQlJptaeZ0XijTk0zU1iiQxpJBHMI2fcV3KDycDr1+hFZFaGtQyrq9yrh8/Kw3/ewVDD8OePbFVLq3ltZ3hnTZKnUZz2zX3+XYqnXoxUZ80klfufm+aYOph60pShyxbdu39eRFRRRXoHmBRRRQAUUUUAFFFFABRRRQAVU1bTbXVrb7PfxmWLqF3EYP4GrdFROnGatNXLhUnTd4Np+R4b4t0SXRNWkjZT9ncloX65X0z6ivbPBvhb4aeL7Wz8P6Zp7p4imhhlW4OoT7bg7Q0qISuA6/NkFCAF43c1neJNEh1qyZHVBcID5UhGdpI/lXjd/Ff6VfC1uZponti2wqzYGepXpwfWvkczy/6vPnh8L/AAPuMrzD67TUW/fjv5+Ze1mz07Ttc1C1Nzbz29lOI9tlcNJHdgNgtHKVIAxk7iO/AruvBfjiUtFBqkkAtpiIUneQ+cpLqqmUkbW+U9Rt4jYnnr5MCu8FgSueQODTK8StRhWjyzVz24XhZxZ9f+IPEmm6U9kkl9Fbq0RiihfltwHzBB3Ge/v2rLnke+0x72W7twIGSFIXYiTbj+FcHAA7kj2zXgPgHVrfTfEenz+IBPJort5cmFBxtBKYJHAVyrEDt69K6fxT4xvbTxZJptgQmnJODEIm80uGGevfJPbr9MV4GMy2cp8sXfRvsv6/rY9PDVoyWump32oeE5fFenWf2dtM/tEXapDFfKduJFdSXIGdowrZ7HHB6Vyfw58RSeAZ5ND1q9tjb36FwYplkS3bJBWTB+Q5XOCO4PRs11PwqvbiG6k1CTet88xkRJFIUeXtIGD6HjjqAa4/4ieGZdZ1q7uBDBaXsj+au3KxOpJOF9h+OB+rpShTpLD1tFrr2f8ATNnhpVZylTeq/Hy/4J6lJqiPHlXVlPRgwIxXI+JL+OaC5eJ0a0V0imcjduDA52+vbn8K8RsNY1XR2eG1upoACQ8Lcrn3U8fpVuTxPdXOm3NvfA3EzbPIn3lPIIPzEKuASwwMnOAOKyp5DKFTm5k1/X9bihjqcPiTue46e2ia34X0vw14ctpbnVJ3maXT4ZAq3JSN5Y5w7A7HRgoIH3gMdDivPPDPw+1bVtLeOwvNNCXcdxLcQySsZdPW3yS1wqr8gbGFPOSe1c9pOp2GleLob+1Oo3+mWqLMyLcfZZnJjAdfMXlBuYjIycD3zXSfDOPVfEOr6rofgyGxS4vNJmtJWvpXR7pDKG8z75Cy42LtBK8E8nJr140Z0oct77f1/W5zutBycoNpu+/nuQaD4F0u8N3JqtxdWjBRcQWcE0cssiyRy+RbLj52uGkVF2+WAF3EkEqD52jmBpFaNd2ChDrnHbv0NeyeJ/B/iDRvEGkeLPEWtS6nrN5P5ko0h0e7gdUxG4X+La6EMAAMKBuBYY8s8Q3K6jr2pTjUJL1ZriWf7XcQCKSdmJYuyqW2kntkgE9ua7YNtXZ573aMntikpcVsP4Z1lbw2p064Mo54XK/99dP1reFKdT4It+hE6sKfxyS9TGorp7HwPrl03zWy265+9M4H6DJrH1vTZtI1OeyuCC8Z4YDhgeQRWlTC1qUOecWl5mdPF0Ks/Z05pvyZQooornOgtXN9c3VwJ7iZ5JvLWHex52KgQD8FAH0FVjSUUASNK7QrEWyisWA9zjP/AKCKjoooAK1b6502XSYEtbe5hvklO/Lo0Rj2rjooYtv8w8nAUqOxJyqKBWCirV/cpdSxvHawWoSJIysO7DlVALncT8zYycYGScAV2nw6/wCENtoFvfGqy3Ia6SBLS2yX8nBMsjAEEH5owpyOknGQKmUuVXGcERit3R/Dd9qaWUqwtFazyNH9oYfLxjP4j0rQ8VXOj6tqNpZeHrK3sLC1LwpeTI6SXCGQkPNgsMqp6gA4BznAFa0F/qi+ImsND3poqS/Z4c220Kg/iOeQT94knknPHbmr15xheGj316f8E6cPRU5Wkv6/yOoi0Sy8P6ndaZavb3yh1Uz2rHy5OOqnqRzj88cV63pflQ+F9Rs7aaK7ie1gu9pjIa0m3qjKCRydpIzxwfz8p8PLHFfTvNM8shVS0rYVWYnAAHrx0rttCnAefy32MVAAUdcnnntgV8/9ccarT69fl/X/AA56lehovI1odFu7ye4ZAsxhiM7SIdoWMcnOevXt61RvrGGSJnxILhUIODkMw6fp/StmIFlIUHAXILc89ak1OxWxeErdw3IkUSERt93j7rAfjxnp6V7uX4+eHqKpF27+h42PwUMTSdOav29TgqK0dehhi1GRrOF4bSX95CjNuwp7Bu4ByM+1Z1fqdKpGrBTjs9T8orUpUakqc907BRRRVmYUUUUAFFFFABRRRQAUUUUAFee/FNFW80h1UB3EqswHJGF4PtyfzoorhzH+B81+aPWyT/e16P8AI8zbqaSiivhmfoIvalVirBlJDA5BB6UUUnsC3PqD4fos3w00iaVQ8yWMkiuwyyt9pQbgexwSM+5qHxWiyeFL4yKHMTFo9wzsPqPSiivnMf8AxI/L9D2sv+Nev6nzz4kJa/Vm5ZkyxPUnJ61k0UV71D+HH0OHMP8AeanqwrvfhciC08S3IVRc21tbPBLj54mN5ACVPVTgkZHYmiiqqfCzilsbXxM8S67Z+OLy4tNa1OCeOwWJJIrqRWVC6kqCDkAkA46VT8dTS3Hwb+HDTyPKyTalEpdixVFaDCjPQDJwKKKin/l+pnHc5OKWSa68MRzSPJHGioiuSQqm5kJAHYZYnHqT617hRRX13D/8OfqfK8TfHT9H+gV5h8XkUX+nOFUO0bAtjkgEY/mfzoortzj/AHSXy/NHDkH++x9H+R5/RRRXxR96FFFFABRRRQAUUUUAKOhqaEfIvu+KKKUtiobnq+rQxp4E1NUjRVWFNoCgY+ZelP8ACMaDwzCwRd3kqc45zzzRRXzE/wCBL/H+iPoaf8WXovzNHSoo2yhjQoEicKVGN2SM/XFd7pqKkkYRVUHHQY7UUVxVP4i9f8jWuet6dbQRan4WaKGJGeW43FUALYbjPrisXxfbwx+FtJkjijV2kugzKoBOJDjJoor347f15Hiv4v68zzjxL9zSP+vIf+jJKxaKK/Uct/3Wn6I/K82/32r6sKKKK7Tzj//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen shows a well- circumscribed, solid mass with a tan-ivory and lobulated cut surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26801=[""].join("\n");
var outline_f26_11_26801=null;
var title_f26_11_26802="Cetylpyridinium: Drug information";
var content_f26_11_26802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cetylpyridinium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cepacol&reg; [OTC];",
"     </li>",
"     <li>",
"      DiabetAid Therapeutic Gingivitis Mouth Rinse [OTC] [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiseptic, Oral Mouthwash",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antiseptic (OTC labeling):",
"     </b>",
"     Oral:  Swish 20 mL thoroughly between teeth for 30 seconds then spit; use twice daily; may be used before or after brushing; do not swallow.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antiseptic (OTC labeling):",
"     </b>",
"     Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as chloride [mouthwash/gargle]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepacol&reg;: 0.05% (710 mL) [contains ethanol 14%, menthol, tartrazine; original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepacol&reg;: 0.05% (360 mL [DSC]) [contains ethanol 14%, tartrazine; original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DiabetAid Therapeutic Gingivitis Mouth Rinse: 0.1% (480 mL [DSC]) [sugar free; contains ethanol, tartrazine]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14325847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vigorously swish between teeth; do not swallow.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiseptic to aid in the prevention and reduction of plaque and gingivitis, and to freshen breath",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Gastrointestinal: Tooth and tongue staining, oral irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cetylpyridinium or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Accidental ingestion: If an amount greater than used for rinsing is swallowed, seek professional assistance or contact a poison control center immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Stop use and consult a healthcare professional if symptoms or condition worsening or persists; if gingivitis, bleeding, or redness persists for more than 2 weeks; if gums are painful and swollen; if pus from the gum line, loose teeth, or increased spacing between the teeth occurs. Avoid contact with eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Cetylpyridinium chloride mouthwash (alcohol free) has been associated with a reduction in preterm births in pregnant women with periodontal disease (Jeffcoat, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Cepacol Mouthwash/Gargle Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (710 mL): $3.59",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Algol (IT);",
"     </li>",
"     <li>",
"      Alsol (IT);",
"     </li>",
"     <li>",
"      Angifonil (ES);",
"     </li>",
"     <li>",
"      Bat Zeta (IT);",
"     </li>",
"     <li>",
"      Borocaina (IT);",
"     </li>",
"     <li>",
"      Bronchenolo Gola (IT);",
"     </li>",
"     <li>",
"      Cepacol (BR, CO, HK, NZ, SG, ZA);",
"     </li>",
"     <li>",
"      Cetilsan (IT);",
"     </li>",
"     <li>",
"      Cleanthroat (TW);",
"     </li>",
"     <li>",
"      Curisol (ES);",
"     </li>",
"     <li>",
"      Dobendan (AT, DE);",
"     </li>",
"     <li>",
"      Farin Gola (IT);",
"     </li>",
"     <li>",
"      Geyderm Sepsi (IT);",
"     </li>",
"     <li>",
"      Golacetin (IT);",
"     </li>",
"     <li>",
"      Halset (AT, PL);",
"     </li>",
"     <li>",
"      Herbagola (IT);",
"     </li>",
"     <li>",
"      Menthosept (PL);",
"     </li>",
"     <li>",
"      Merocets (GB, IE);",
"     </li>",
"     <li>",
"      Neo Cepacol (IT);",
"     </li>",
"     <li>",
"      Neo Coricidin (IT);",
"     </li>",
"     <li>",
"      Neo Formitrol (IT);",
"     </li>",
"     <li>",
"      Novoptine (CH, FR);",
"     </li>",
"     <li>",
"      Pronto G (IT);",
"     </li>",
"     <li>",
"      Pyrisept (NO);",
"     </li>",
"     <li>",
"      Tirocetil (ES)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Jeffcoat M, Parry S, Gerlach RW, et al, \"Use of Alcohol-Free Antimicrobial Mouth Rinse Is Associated With Decreased Incidence of Preterm Birth in a High-Risk Population,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2011, 205(4):382.e1-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/11/26802/abstract-text/22083060/pubmed\" id=\"22083060\" target=\"_blank\">",
"        22083060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8853 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26802=[""].join("\n");
var outline_f26_11_26802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149060\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149079\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149061\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149072\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149062\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149054\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149045\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14325847\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149055\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149077\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149057\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149048\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299007\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219069\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206270\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323055\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149058\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8853\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8853|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_11_26803="Aneurysmal bone cyst sites";
var content_f26_11_26803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skeletal distribution of aneurysmal bone cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 605px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26803=[""].join("\n");
var outline_f26_11_26803=null;
var title_f26_11_26804="Myositis";
var content_f26_11_26804=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Myositis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/11/26804/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26804/contributors\" id=\"au2018\">",
"       Basil T Darras, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/11/26804/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26804/contributors\" id=\"se173\">",
"       Ira N Targoff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?26/11/26804/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26804/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?26/11/26804?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      MYOSITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Myositis is the word used to describe a group of muscle diseases characterized by inflammation in the muscle tissues.",
"    </p>",
"    <p>",
"     Normally, a conscious desire to move some part of the body is conveyed by electrical signals that travel from the brain through the spinal cord and, using chemical signals (neurotransmitters), into peripheral nerves. From there, the electrical nerve signals are transmitted into muscles, again using a chemical transmitter. There the signals stimulate the muscle tissue to contract. Along the way, the nerves must be in good working order, and the muscles must be able to accept the impulses and to generate a response.",
"    </p>",
"    <p>",
"     Problems can occur anywhere along this route. If the brain, spinal cord, or nerves are damaged or diseased, the electrical signal may not be generated, or it may not reach the muscle. If muscles are inflamed or abnormal, they may not be able to respond properly to a nerve impulse.",
"    </p>",
"    <p>",
"     In people with muscle disease, nerve impulses are usually able to reach the muscles without a problem, but the muscles are unable to respond in a normal way. Many things can cause muscle disease, a few of which include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Inherited conditions, especially muscular dystrophies",
"      </li>",
"      <li>",
"       Problems with certain hormones that affect muscle function",
"      </li>",
"      <li>",
"       Chemical imbalances in the body",
"      </li>",
"      <li>",
"       Drugs and toxic substances",
"      </li>",
"      <li>",
"       Infections",
"      </li>",
"      <li>",
"       Inflammation of the muscles",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This topic review will focus on inflammatory forms of muscle disease. Dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM) are three types of myositis. Muscle weakness is a shared feature of all three, but each disorder has unique characteristics.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DERMATOMYOSITIS AND POLYMYOSITIS",
"     </span>",
"    </p>",
"    <p>",
"     Dermatomyositis and polymyositis cause inflammation of the muscles. These are rare disorders, together affecting only about one in 100,000 people per year. More women than men are affected. Although the peak age of onset is in the 50s, the disorders can occur at any age. Dermatomyositis and polymyositis have similar symptoms, although there are different mechanisms that cause the muscle inflammation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Dermatomyositis and polymyositis symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common symptom of dermatomyositis and polymyositis is muscle weakness. People with dermatomyositis also have a skin rash, although it can sometimes be very mild. More detailed information about dermatomyositis and polymyositis symptoms is available separately. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"      \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Muscle weakness",
"     </span>",
"     &nbsp;&mdash;&nbsp;A person with dermatomyositis or polymyositis may notice muscle weakness that worsens over several months, although, in some cases, symptoms develop more rapidly. The affected muscles are typically close to the trunk (as opposed to the wrists or feet), involving the hip, shoulder, or neck muscles. Muscles on both sides of the body are equally affected. In some cases, muscles are sore or tender. There may be a loss of muscle in more advanced disease.",
"    </p>",
"    <p>",
"     Some people with dermatomyositis or polymyositis have involvement of the muscles of the pharynx (throat) or the esophagus (the tube leading from the throat to the stomach) (",
"     <a class=\"graphic graphic_figure graphicRef55616 \" href=\"UTD.htm?28/22/29024\">",
"      figure 1",
"     </a>",
"     ), causing problems with swallowing. In some cases, the muscle weakness allows food to be misdirected to the lungs, which can lead to pneumonia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Skin changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with dermatomyositis often develop a rash or other changes in the skin. Sometimes the rash develops before muscle problems occur. In some cases, the rash of dermatomyositis appears, but myopathy never develops. Several types of rash may occur:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gottron&rsquo;s sign &mdash; Gottron&rsquo;s sign is a reddened, often scaly rash that develops on the finger joints, although it can spread from there (",
"       <a class=\"graphic graphic_picture graphicRef77884 graphicRef57889 \" href=\"UTD.htm?5/39/5751\">",
"        picture 1A-B",
"       </a>",
"       ). Similar lesions can be seen over the front of the knees or outer arms, similar to psoriasis.",
"      </li>",
"      <li>",
"       Shawl sign &mdash; The shawl sign is a widespread, flat, reddened area that is seen over the upper back, shoulders, and back of the neck. This can be worsened by exposure to ultraviolet light.",
"      </li>",
"      <li>",
"       V sign &mdash; The V sign has an appearance similar to that of the shawl sign but occurs over the front of the chest in the area of skin exposed by a V-necked sweater.",
"      </li>",
"      <li>",
"       Heliotrope rash &mdash; The heliotrope rash is located on the upper eyelids and is often accompanied by eyelid swelling (",
"       <a class=\"graphic graphic_picture graphicRef60243 \" href=\"UTD.htm?43/40/44673\">",
"        picture 2",
"       </a>",
"       ). The heliotrope sign is named for the heliotrope flower, which is violet colored.",
"      </li>",
"      <li>",
"       Nail abnormalities &mdash; The nailfolds (the skin around the fingernails) may become reddened (",
"       <a class=\"graphic graphic_picture graphicRef75841 \" href=\"UTD.htm?42/57/43935\">",
"        picture 3",
"       </a>",
"       ) and may develop changes in the blood vessels (",
"       <a class=\"graphic graphic_picture graphicRef61209 \" href=\"UTD.htm?18/21/18783\">",
"        picture 4",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Mechanic's hands &mdash; People with dermatomyositis or polymyositis may develop &ldquo;mechanic's hands,&rdquo; a roughening and cracking of the skin of the tips and sides of the fingers, resulting in irregular, dirty-appearing lines that resemble those of a manual laborer (",
"       <a class=\"graphic graphic_picture graphicRef78682 \" href=\"UTD.htm?41/46/42720\">",
"        picture 5",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Scalp &mdash; Changes in the scalp resembling psoriasis often occur in people with dermatomyositis.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Dermatomyositis and polymyositis diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to a careful history and physical exam, a number of tests are useful in diagnosing dermatomyositis and polymyositis. Blood tests typically show evidence of muscle damage",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     characteristic antibodies. An electromyogram (EMG) often shows abnormal muscle electrical activity.",
"    </p>",
"    <p>",
"     Muscle biopsy is the most accurate test to definitively diagnose dermatomyositis or polymyositis. Careful analysis of the muscle cells with a microscope will reveal the typical inflammation seen in each disorder. However, in patients with typical dermatomyositis, EMG and muscle biopsy are not always required to make the diagnosis. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"      \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Electromyography",
"     </span>",
"     &nbsp;&mdash;&nbsp;Electromyography (EMG) is a test that evaluates the health of muscles and the nerves associated with the muscles by measuring the electrical activity. It is used to aid in the diagnosis of most types of myositis.",
"    </p>",
"    <p>",
"     A small needle is inserted through the skin into a muscle in several locations (usually the arms and legs). The needle is connected to a recording device that displays the muscle's electrical activity at rest and in response to contraction. The electrical activity may also be heard as a static-type noise through a speaker.",
"    </p>",
"    <p>",
"     The size and pattern of electrical activity recorded from different muscles is analyzed to determine whether the muscles and nerves are affected. You may feel some discomfort as the needle is inserted, and the muscle may feel sore or bruised for several days. The test generally takes about 30 minutes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Muscle biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A muscle biopsy is a procedure that removes one or more small pieces of muscle in order for a pathologist to examine it with a microscope.",
"    </p>",
"    <p>",
"     Before the biopsy, the patient is given local anesthesia (numbing medicine) to prevent pain. The clinician then makes a small incision, usually in the thigh or shoulder, and removes a piece of muscle. The procedure usually takes between 15 and 30 minutes. The area will feel sore for several days after the biopsy. The biopsy results are usually available within two to three weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      MRI",
"     </span>",
"     &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) can be useful in evaluating patients with dermatomyositis or polymyositis because it can assess large areas of muscle and is not invasive (like biopsy and EMG). MRI cannot replace muscle biopsy to confirm the diagnosis, but it may be used to evaluate changes in the muscles over time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Dermatomyositis and polymyositis treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatments for dermatomyositis and polymyositis are intended to suppress the immune system, which is thought to be the cause of muscle inflammation. However, dermatomyositis and polymyositis are rare disorders, and the optimal treatment regimen is not known. Until more data are available, treatment is guided by the severity of an individual's symptoms and by treatment complications. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"      \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Glucocorticoids (steroids)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Glucocorticoids such as prednisone are typically used for treating people with dermatomyositis or polymyositis. Prednisone is usually started at a high dose, which is often continued for a number of weeks or sometimes longer before decreasing slowly to the lowest dose that is effective. The duration of therapy depends upon the person's response and other factors.",
"    </p>",
"    <p>",
"     Side effects of prednisone are common and can include skin changes (thinning, development of small red spots), cataracts, heart disease, gastrointestinal problems, and fluid retention, among others. The risk and severity of side effects are decreased by using the lowest necessary dose.",
"    </p>",
"    <p>",
"     Some people begin to see an improvement in muscle strength within several weeks of starting prednisone while others require up to three months to see improvement. To monitor improvement, the clinician will see the person periodically to measure strength. Blood testing may also be recommended, and the clinician will monitor for medication side effects or complications.",
"    </p>",
"    <p>",
"     If improvement is seen, the prednisone dose may be slowly decreased. If improvement is not seen, a second medication, such as methotrexate or azathioprine, may be added. Most people with inflammatory myopathies can improve with steroids alone. However, polymyositis may be more difficult to treat in some cases.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Methotrexate or azathioprine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people are given a second medication, such as azathioprine or methotrexate, to slow or stop the progression of their disease. Use of a second medication can help to reduce the dose of prednisone that is required to control muscle damage, which can reduce the risk of prednisone side effects and complications. These medications are usually well-tolerated, but side effects may sometimes occur:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Side effects of azathioprine &mdash; Flu-like reactions, including fever, develop in a small percentage of patients treated with azathioprine. This type of reaction requires that you stop azathioprine. Other side effects can include nausea and vomiting, low blood count, hair loss, inflammation of the pancreas (pancreatitis), and liver problems. Long-term side effects may include an increased risk of infection, cancer, or birth defects.",
"      </li>",
"      <li>",
"       Side effects of methotrexate &mdash; Common side effects of methotrexate include upset stomach and a sore mouth. Methotrexate can interfere with the bone marrow's production of blood cells; folic acid or folinic acid can reduce the risk of some side effects. Low blood cell counts can cause fever, infections, swollen lymph nodes, and easy bruisability and bleeding. Liver or lung damage can occur as a result of methotrexate, even with low doses; monitoring can reduce the risk of these problems.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Tapering treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;If dermatomyositis or polymyositis is well-controlled for a period of time, your clinician may consider slowly decreasing and then stopping your medication. You and your healthcare provider must watch closely for any signs of worsening muscle weakness during this time; if weakness develops or worsens, consult with your clinician to determine if additional evaluation or treatment is needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Treatment of resistant disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your dermatomyositis or polymyositis does not improve with glucocorticoids and a medicine such as methotrexate or azathioprine, you may need to try other options, including intravenous immune globulin or other medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Preventive measures",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to medications, people with dermatomyositis or polymyositis should take precautions to prevent complications related to the disease and its treatments. These precautions include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoporosis prevention &mdash; A calcium supplement with vitamin D and a prescription medication to prevent osteoporosis, such as one of the bisphosphonates, are often recommended. The potential benefits and possible side effects of such medications should be discussed with a healthcare provider. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"        \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"        \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Exercise &mdash; Physical therapy and rehabilitation should begin soon after the diagnosis of dermatomyositis or polymyositis to prevent contractures (shortening of the muscle that can limit joint movement).",
"      </li>",
"      <li>",
"       Avoidance of sunlight &ndash; People with dermatomyositis and rash, particularly during treatment with methotrexate or azathioprine, should protect themselves from the sun by using sunscreen or by sitting in a shaded area. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"        \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Aspiration prevention&mdash; If you have difficulty swallowing, you must take care to avoid inhaling (aspirating) foods and drinks. This may be done by elevating your head, by using thickened drinks, or, in severe cases, by having a feeding tube placed in the stomach.",
"      </li>",
"      <li>",
"       Pneumonia prevention &mdash; The medications used to treat dermatomyositis and polymyositis (glucocorticoids, azathioprine, and methotrexate) weaken the immune system. This can increase the risk of certain infections, including a type of pneumonia called pneumocystis. To decrease this risk, an antibiotic (eg trimethoprim-sulfamethoxazole) may be recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Pregnancy and myositis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Little information is available regarding the impact of pregnancy on myositis or the impact of myositis on pregnancy. The data that are available indicate that complications of pregnancy are less likely in women who have inactive disease. Complications may include a smaller than normal infant, stillbirth, or premature birth.",
"    </p>",
"    <p>",
"     Women with polymyositis or dermatomyositis who want to become pregnant should discuss their condition and current medications with a rheumatologist or maternal fetal medicine specialist before trying to conceive. Some medications, particularly methotrexate, are not safe for use during pregnancy due to a seriously increased risk of miscarriage and birth defects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Dermatomyositis and polymyositis prognosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The severity of disease in a person with dermatomyositis or polymyositis is highly variable, ranging from mild weakness that responds well to treatment to a rapid progression of symptoms that are unresponsive to all treatments. Less commonly, people with these conditions improve spontaneously without any treatment.",
"    </p>",
"    <p>",
"     People with dermatomyositis or polymyositis tend to have a better outcome if they are treated promptly, have mild muscle weakness, have no difficulty swallowing, and have no signs of disease in other organ systems such as the heart and lungs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      INCLUSION BODY MYOSITIS",
"     </span>",
"    </p>",
"    <p>",
"     Inclusion body myositis (IBM) differs in a number of ways from polymyositis and dermatomyositis. It affects more men than women, and the age of onset is almost always after age 60, although it can affect persons between 30 and 90 years.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Inclusion body myositis symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Typically, inclusion body myositis symptoms come on very slowly, over an average period of six years. The first area to be affected by weakness may be the hips and upper legs, but some people with inclusion body myositis have weakness in the hands or feet. Weakness is accompanied by muscle pain in 40 percent of patients. In 10 to 15 percent of cases, one side of the body is affected more than the other. Facial muscles may be involved, although the eye and mouth muscles are usually not affected. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"      \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Muscle atrophy often progresses along with the weakness. Some people have profound thinning of the muscles in the upper arms or upper legs. Between one-third and one-half of patients have difficulty swallowing due to weakness in the throat muscles.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Inclusion body myositis diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Diagnosis of inclusion body myositis is usually based upon signs and symptoms of progressive muscle weakness and results of a muscle biopsy.",
"    </p>",
"    <p>",
"     A muscle biopsy is done to determine if abnormal structures are present in the muscle cells. These features are seen in over 90 percent of people with inclusion body myositis. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Muscle biopsy'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     Blood tests may be done to look for signs of muscle damage, although the results may be normal or may be only mildly elevated. Electromyography (EMG) usually shows abnormal electrical activity, and MRI may reveal abnormalities in some cases. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Electromyography'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Inclusion body myositis treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Unlike dermatomyositis and polymyositis, inclusion body myositis often does not improve with treatments that suppress the immune system. Muscle strength usually improves minimally, if at all, with glucocorticoids and other treatments. Some of the same medications used for dermatomyositis or polymyositis may be tried. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28133?source=see_link\">",
"      \"Treatment and prognosis of inclusion body myositis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Preventive treatments are also important for people with inclusion body myositis. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'Preventive measures'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Inclusion body myositis prognosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with inclusion body myositis may become progressively weaker if they are not treated or if treatment is not successful. Progression is usually more rapid in older patients.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498533435\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5519406\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/63/5106?source=see_link\">",
"      Patient information: Dermatomyositis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/47/30450?source=see_link\">",
"      Patient information: Polymyositis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/8/30850?source=see_link\">",
"      Patient information: Antinuclear antibodies (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5519414\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=see_link\">",
"      Clinical manifestations of mixed connective tissue disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28133?source=see_link\">",
"      Treatment and prognosis of inclusion body myositis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31079?source=see_link\">",
"      Diagnosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"      Drug-induced myopathies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8313?source=see_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=see_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=see_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9879?source=see_link\">",
"      Viral myositis",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Family Physicians",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aafp.org/\">",
"        www.aafp.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"        www.niams.nih.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?26/11/26804/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?26/11/26804?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26804/abstract/1\">",
"      Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26804/abstract/2\">",
"      O'Connell MJ, Powell T, Brennan D, et al. Whole-body MR imaging in the diagnosis of polymyositis. AJR Am J Roentgenol 2002; 179:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26804/abstract/3\">",
"      Lundberg IE. Idiopathic inflammatory myopathies: why do the muscles become weak? Curr Opin Rheumatol 2001; 13:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26804/abstract/4\">",
"      Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009; 80:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26804/abstract/5\">",
"      Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol 2011; 13:119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f26_11_26804=[""].join("\n");
var outline_f26_11_26804=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           MYOSITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DERMATOMYOSITIS AND POLYMYOSITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           INCLUSION BODY MYOSITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\" title=\"figure 1\">",
"           Upper GI anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/24/30081\" title=\"picture 1A\">",
"           Gottrons sign 1 PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/4/40001\" title=\"picture 1B\">",
"           Gottrons sign 2 PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/40/44673\" title=\"picture 2\">",
"           Heliotrope rash in DM PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/57/43935\" title=\"picture 3\">",
"           Periungual erythema PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/21/18783\" title=\"picture 4\">",
"           Capillary loop PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/46/42720\" title=\"picture 5\">",
"           Mechanics hands PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f26_11_26805="Vitamin A: Pediatric drug information";
var content_f26_11_26805=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin A: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/59/24502?source=see_link\">",
"    see \"Vitamin A: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/34/11812?source=see_link\">",
"    see \"Vitamin A: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-25 [OTC];",
"     </li>",
"     <li>",
"      A-Natural [OTC];",
"     </li>",
"     <li>",
"      A-Natural-25 [OTC];",
"     </li>",
"     <li>",
"      Aquasol A&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Fat Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 unit vitamin A = 0.3 mcg retinol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate Intake (AI):",
"     </b>",
"     400 mcg (1330 units)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic lung disease, prevention in ELBW",
"     </b>",
"     : I.M.: 5000 units/dose 3 times weekly (ie, MWF) initiated within the first 96 hours of life and continued for 4 weeks was used in 405 neonates (mean GA: 26.8 weeks; mean birth weight: 770 g; range: 400-1000 g)  (Tyson, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/59/24502?source=see_link\">",
"      see \"Vitamin A: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 unit vitamin A = 0.3 mcg retinol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for vitamin A",
"     </b>",
"     (presented as retinol activity equivalent [RAE]) (IOM, 2000): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Adequate Intake (AI)",
"     </b>",
"     (IOM, 2000):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-6 months: 400 mcg/day (1330 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 months: 500 mcg/day (1670 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Recommended Daily Allowance (RDA)",
"     </b>",
"     (IOM, 2000): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 years: 300 mcg/day (1000 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-8 years: 400 mcg/day (1330 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-13 years: 600 mcg/day (2000 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;13 years and Adults: Female: 700 mcg/day (2330 units/day); Male: 900 mcg/day (3000 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     14-18 years: 750 mcg/day (2500 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;19 years: 770 mcg/day (2560 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactating females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     14-18 years: 1200 mcg/day (4000 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;19 years: 1300 mcg/day (4330 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Measles infection, supplementation",
"     </b>",
"     (WHO, 2004; WHO, 2010): Infants and Children: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;6 months: 50,000 units daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 6-11 months: 100,000 units daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 months to 5 years: 200,000 units daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note",
"     </b>",
"     : If severe malnutrition or ophthalmologic evidence of vitamin A deficiency is present, repeat a single dose 2-4 weeks after the second dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin A deficiency (varying recommendations available):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis for at-risk populations (eg, potential HIV infection, local prevalence of nightblindness &gt;1% in ages 24-59 months or prevalence of serum retinol &le;0.7 mmol/L is &ge; 20% in ages 6-59 months)  (WHO, 2008; WHO, 2010; WHO, 2011a; WHO, 2011b; WHO, 2011c; WHO, 2011d): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;6 months: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 6-12 months: 100,000 units; administer as a single dose; repeat every 4-6 months, but do not readminister within 30 days of previous dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents: 200,000 units; administer as a single dose; repeat every 4-6 months, but do not readminister within 30 days of previous dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 200,000 units/dose every 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant women: Maximum 10,000 units once daily or 25,000 units once weekly. Administer for a minimum of 12 weeks during pregnancy or until delivery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postpartum women: 200,000 units at delivery or within 8 weeks of delivery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.M.: 7500-15,000 units once daily for 10 days followed by oral supplementation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 5000-10,000 units daily for 2 months following I.M. dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-8 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.M.: 17,500-35,000 units once daily for 10 days followed by oral supplementation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 5000-10,000 units once daily for 2 months  following I.M. dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;8 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.M.: 100,000 units once daily for 3 days; then 50,000 units once daily for 14 days followed by oral supplementation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 10,000-20,000 units once daily for 2 months  following I.M. dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xerophthalmia (WHO, 1997; WHO, 2010): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;6 months: 50,000 units administered as a single dose; repeat the next day and again after at least 2 weeks for a total of 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 6-12 months: 100,000 units administered as a single dose; repeat the next day and again after at least 2 weeks for a total of 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents: 200,000 units administered as a single dose; repeat the next day and again after at least 2 weeks for a total of 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 200,000 units once daily for 2 days; repeat with single dose in 2 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Females of reproductive age with night blindness or Bitot&rsquo;s spots should receive 5000-10,000 units daily or &le;25,000 units once weekly; if severe xerophthalmia, females of reproductive age may receive high dose (ie, 200,000 unit regimen) regardless of pregnancy status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malabsorption syndrome (prophylaxis):",
"     </b>",
"     Children &gt;8 years and Adults: Oral: 10,000-50,000 units/day of water miscible product",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-25: 25,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 10,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Natural: 10,000 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Natural-25: 25,000 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aquasol A&reg;: 50,000 units/mL (2 mL) [contains polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10,000 units, 15,000 units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food or milk; for infants and children &lt;24 months of age, capsules may be cut open and contents squeezed into the mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"     <b>",
"      For I.M. use only",
"     </b>",
"     ; for neonatal patients, a 0.3 mL syringe and 29-gauge needle should be used for I.M. dose administration",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of vitamin A deficiency (injection: FDA approved in all ages; oral: FDA approved in adults); has also been used for prevention of vitamin A deficiency, supplementation in infants and children &le;5 years with measles, and prevention of chronic lung disease in premature neonates",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aquasol&reg; may be confused with Anusol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F234461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Miscellaneous: Allergic reactions (rare), anaphylactic shock (following I.V. administration)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vitamin A or any component; hypervitaminosis A; pregnancy (dose exceeding RDA); intravenous administration of Aquasol A&reg;",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients receiving &gt;25,000 units/day should be closely monitored for toxicity. Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May enhance the adverse/toxic effect of Vitamin A.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoid-like Compounds: Vitamin A may enhance the adverse/toxic effect of Retinoid-like Compounds.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F234431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. In humans, the critical period of exposure is the first trimester of pregnancy. Excess vitamin A during pregnancy may cause craniofacial malformations, as well as CNS, heart, and thymus abnormalities. Maternal vitamin A deficiency also causes adverse effects in the fetus, and vitamin A requirements are increased in pregnant women (IOM, 2000). The manufacturer notes that the safety of doses &gt;6000 units/day in pregnant women has not been established and doses greater than the RDA are contraindicated in pregnant women or those who may become pregnant. High doses are used in some areas of the world for supplementation where deficiency is a public health problem (eg, to prevent night blindness); however, single doses &gt;25,000 units should be avoided within 60 days of conception. High-dose supplementation is otherwise not recommended as part of routine antenatal care (WHO, 2011c).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Needed for bone development, growth, visual adaptation to darkness, testicular and ovarian function, and as a cofactor in many biochemical processes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Vitamin A in dosages",
"     <b>",
"      not",
"     </b>",
"     exceeding physiologic replacement is well absorbed in the small intestine after oral administration; water miscible preparations are absorbed more rapidly than oil preparations; large oral doses, conditions of fat malabsorption, low protein intake, or hepatic or pancreatic disease reduce oral absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Large amounts concentrate for storage in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted in the small intestine to retinol and further metabolized in the liver; conjugated with glucuronide, undergoes enterohepatic circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In feces via biliary elimination",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 USP vitamin A unit = 0.3 mcg of all-",
"     <i>",
"      trans",
"     </i>",
"     isomer of retinol; 1 RAE (retinol activity equivalent) = 1 mcg of all-",
"     <i>",
"      trans",
"     </i>",
"     -retinol = 12 mcg of dietary beta-carotene (IOM, 2000)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/11/26805/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/11/26805/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Committee on Infectious Diseases, &ldquo;Vitamin A in the Treatment of Measles,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 91(5):1014-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/11/26805/abstract-text/8474793/pubmed\" id=\"8474793\" target=\"_blank\">",
"        8474793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeMaeyer EM, &ldquo;The WHO Programme of Prevention and Control of Vitamin A Deficiency, Xerophthalmia, and Nutritional Blindness,&rdquo;",
"      <i>",
"       Nutr Health",
"      </i>",
"      , 1986, 4(2):105-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/11/26805/abstract-text/3090484/pubmed\" id=\"3090484\" target=\"_blank\">",
"        3090484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hussey GD and Klein M, &ldquo;A Randomized, Controlled Trial of Vitamin A in Children With Severe Measles,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 323(3):160-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/11/26805/abstract-text/2194128/pubmed\" id=\"2194128\" target=\"_blank\">",
"        2194128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2000.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tyson JE, Wright LL, Oh W, et al, \"Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants. National Institute of Child Health and Human Development Neonatal Research Network,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(25):1962-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      WHO Guideline, \"Vitamin A Supplementation in Infants 1&ndash;5 Months of Age,\" Geneva: World Health Organization, 2011a. Available at   file://www.who.int/nutrition/publications/micronutrients/guidelines/vas_infants_1-5/en/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      WHO Guideline, \"Vitamin A Supplementation in Postpartum Women,\" Geneva: World Health Organization, 2011b. Available at   file://www.who.int/nutrition/publications/micronutrients/guidelines/vas_postpartum/en/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      WHO Guideline, \"Vitamin A Supplementation in Pregnant Women,\" Geneva: World Health Organization, 2011c. Available at   file://www.who.int/nutrition/publications/micronutrients/guidelines/vas_pregnant/en/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      WHO Guideline, \"Vitamin A Supplementation in Infants 6-59 Months of Age,\" Geneva: World Health Organization, 2011d. Available at file://www.who.int/nutrition/publications/micronutrients/guidelines/vas_6to59_months/en/index.html",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       WHO Model Formulary",
"      </i>",
"      , 2008. Available at file://apps.who.int/medicinedocs/en/m/abstract/Js16879e/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       WHO Model Formulary for Children",
"      </i>",
"      , 2010. Available at file://apps.who.int/medicinedocs/en/m/abstract/Js17151e/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      WHO/UNICEF/IVACG Task Force,",
"      <i>",
"       Vitamin A Supplements. A Guide to Their Use in the Treatment and Prevention of Vitamin A Deficiency and Xerophthalmia",
"      </i>",
"      , 2nd ed. Geneva: World Health Organization, 1997. Available at file://www.who.int/nutrition/publications/micronutrients/vitamin_a_deficiency/9241545062/en/",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12883 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26805=[""].join("\n");
var outline_f26_11_26805=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234440\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062927\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675815\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062922\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234422\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234408\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062930\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062925\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062929\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234464\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234461\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062933\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062921\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300220\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234417\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234419\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234431\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062920\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062932\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062934\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12883\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12883|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/59/24502?source=related_link\">",
"      Vitamin A: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/34/11812?source=related_link\">",
"      Vitamin A: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_11_26806="Fingolimod: Drug information";
var content_f26_11_26806=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fingolimod: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/43/18101?source=see_link\">",
"    see \"Fingolimod: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13655214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Labeling Revised with Stronger Cardiovascular Warnings and Recommendations (May 2012) Updated",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) completed its review of a report of a patient who died after the first dose of fingolimod (Gilenya&reg;). Clinical trial and postmarketing data for the drug were also reviewed, including reports of patients who died of cardiovascular events or unknown causes. Although the FDA could not definitively conclude that fingolimod was related to any of the deaths, it remains concerned about the drug's cardiovascular effects after administration of the first dose. The FDA continues to recommend monitoring for signs of bradycardia for at least 6 hours after the first dose, and additionally recommends hourly pulse and blood pressure measurements for all patients initiating therapy. Electrocardiogram (ECG or EKG) testing should be performed prior to dosing and at the end of the observation period, and cardiovascular monitoring should continue until any symptoms resolve. In addition, extended cardiovascular monitoring (&gt;6 hours) is recommended in patients who are at higher risk for or who may not tolerate bradycardia; extended monitoring should include continuous ECG monitoring overnight. High-risk patients may include those who:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - develop severe bradycardia (HR &lt;45 bpm) after the first dose of fingolimod",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - have certain pre-existing conditions where bradycardia would be poorly tolerated",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - have QT prolongation prior to fingolimod initiation or during the monitoring period",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - take other medications that can slow the heart rate or atrioventricular conduction",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       - take other medications that prolong the QT interval or can cause torsade de pointes",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       Based on the FDA&rsquo;s findings, fingolimod (Gilenya&reg;) is now contraindicated in patients with certain preexisting or recent (within the past 6 months) heart conditions or stroke, or in those who are taking certain antiarrhythmic medications. Similar to the FDA, Health Canada has announced that the Canadian product monograph has been updated with stronger recommendations regarding cardiovascular monitoring with initial dosing and use in patients with pre-existing cardiovascular disease. Further information may be found at:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       U.S.:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm303192.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm303192.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"       Canada: file://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/gilenya_hpc-cps-eng.php",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10824425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gilenya&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12724975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gilenya&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10829448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Sphingosine 1-Phosphate (S1P) Receptor Modulator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10829906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Multiple sclerosis:",
"     </b>",
"     Oral: 0.5 mg once daily; doses &gt;0.5 mg/day associated with increased adverse events and no additional benefit",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10829907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14228118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10829908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: No dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution and closely monitor; exposure is doubled in severe hepatic impairment. Use is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10829927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gilenya&reg;: 0.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10829446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at file://www.pharma.us.novartis.com/product/pi/pdf/gilenya_pmg.pdf, must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10829909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10829506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and delay disability progression",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10829844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (14%), AST increased (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (6%), bradycardia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Depression (8%), dizziness (7%), migraine (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (4%), eczema (3%), pruritus (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Gastroenteritis (5%), weight loss (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphopenia (4%), leukopenia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: GGT increased (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (5%), weakness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (4%), eye pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (10%), bronchitis (8%), dyspnea (8%), sinusitis (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Herpes infection (9%), tinea infection (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Asystole, AV block, death, lymphoma, macular edema (incidence increased in patients with uveitis or diabetes mellitus), QT prolongation, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10829511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval &ge;500 msec; concurrent use of a class Ia or III antiarrhythmic; Mobitz Type II second- or third-degree AV block or sick sinus syndrome (unless patient has functioning pacemaker); any of the following within 6 months prior to treatment initiation: MI, unstable angina, stroke, TIA, decompensated heart failure (requiring hospitalization) or NYHA class III/IV heart failure",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to fingolimod or any component of the formulation; patients at increased risk for opportunistic infections (eg, immunosuppressed patients); severe active infections, active chronic bacterial, fungal or viral infections; known active malignancy (excluding basal cell carcinoma); severe hepatic impairment (Child-Pugh class C)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10829524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse reactions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; AV block: May result in transient AV conduction delays which typically resolve within 24 hours of treatment initiation; recurrence may be observed following discontinuation (&gt;2 weeks) and subsequent resumption of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bradycardia:",
"     <b>",
"      Initiation must occur in a setting with resources and personnel capable of appropriately managing symptomatic bradycardia.",
"     </b>",
"     Decreased heart rate (mean: 13 beat per minute) may occur with initiation of therapy.  Following the first dose, heart rate may decrease as soon as 1 hour postdose with the maximal decrease usually occurring ~6 hours postdose but may occur up to 24 hours postdose in some patients. Heart rate typically returns to baseline after 1 month of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertension: Increased blood pressure may occur ~1 month after initiation of therapy; monitor blood pressure throughout treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immune suppression: May increase risk of infection due to dose-dependent reduction of lymphocytes; lymphocyte counts may be decreased for up to 2 months following discontinuation of therapy. Monitor for signs and symptoms of infection; consider therapy interruption in patients who develop an infection during therapy. Do not initiate treatment in patients with acute or chronic infections until the infection has resolved. Use with caution in patients receiving concomitant immunosuppressant, immune modulating, or antineoplastic medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Macular edema: Macular edema may occur typically in the first 3-4 months of treatment. Patients may present with blurred vision, decreased visual acuity, or without symptoms. Signs and symptoms generally improve or resolve with discontinuation of treatment. Use with caution in patients with a history of diabetes mellitus or uveitis. Ophthalmologic exams should be performed prior to therapy and 3-4 months after treatment initiation; more frequent examination is warranted in patients with diabetes or a history of uveitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Respiratory effects: Reductions of FEV",
"     <sub>",
"      1",
"     </sub>",
"     and diffusion lung capacity for carbon monoxide (DLCO) are dose-dependent and may occur within the first month of therapy. FEV",
"     <sub>",
"      1",
"     </sub>",
"     changes may be reversible with drug discontinuation. Use in MS patients with compromised respiratory function has not been evaluated. If clinically necessary, spirometric evaluation of respiratory function and evaluation of DLCO should be performed during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT prolongation: May cause QT prolongation; patients with a prolonged QT interval at baseline (males: &gt;450 msec; females: &gt;470 msec), who develop QT prolongation during the first 6 hours of treatment initiation, or are at an increased risk of QT prolongation (eg, hypokalemia, hypomagnesemia, concomitant QT-prolonging drugs, congenital long-QT syndrome) require continuous overnight ECG monitoring in a medical facility after the initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular: Due to the risk of bradycardia and AV conduction delays, an ECG is required prior to initiation of therapy and after the initial observation period (6 hours) in all patients.  Patients receiving concomitant antiarrhythmics including beta blockers and calcium channel blockers, or with other cardiac risk factors (eg, AV block, sick sinus syndrome, prolonged QT interval, ischemic cardiac disease, heart failure, cerebrovascular disease, recurrent syncope, severe sleep apnea [untreated]), unless contraindicated, require continuous overnight ECG monitoring in a medical facility after the first dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution and closely monitor patients with severe hepatic impairment (contraindicated in the Canadian labeling). Increased risk of adverse effects may occur, including elevated liver enzymes. Obtain baseline liver enzymes in all patients prior to therapy initiation; monitor liver enzymes in patients who develop symptoms of hepatic dysfunction (eg, nausea, vomiting, abdominal pain, fatigue, anorexia, jaundice, dark urine). Discontinue treatment with confirmation of liver injury; transaminases tend to return to normal within 2 months of discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Varicella zoster virus (VZV): Consider varicella zoster virus vaccination prior to initiation of treatment in VZV-antibody negative patients; postpone fingolimod treatment for 1 month after varicella zoster vaccination.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F10894405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10890728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class Ia): Fingolimod may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class III): Fingolimod may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase serum concentrations of the active metabolite(s) of Fingolimod. Ketoconazole (Systemic) may increase the serum concentration of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Fingolimod may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Fingolimod may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10829507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10829508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and adverse effects have been observed in animal reproduction studies. Elimination of fingolimod takes approximately 2 months; to avoid potential fetal harm, women of childbearing potential should avoid pregnancy during and for 2 months after discontinuing treatment. Healthcare providers are encouraged to enroll pregnant women, or pregnant women may enroll themselves, in the Gilenya&trade; Pregnancy Registry (1-877-598-7237 or www.gilenyapregnancyregistry.com).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10829509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10829510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10829924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Gilenya Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (28): $5562.23",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10829925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC (baseline and periodically thereafter); ECG (baseline; repeat after initial dose observation period); heart rate, blood pressure and signs and symptoms of bradycardia (hourly for 6 hours following first dose; continued observation (until resolved) required if 6-hour postdose heart rate is either &lt;45 bpm, is lowest post-baseline measurement, or new-onset second degree or higher AV block occurs on repeat ECG ); continuous (until symptoms resolved) ECG monitoring if postdose symptomatic bradycardia occurs (overnight continuous ECG in a medical facility and repeat observation period for second dose if pharmacologic intervention for bradycardia necessary)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Initial monitoring procedures (ECG, heart rate, blood pressure) must be repeated for",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - treatment interruption of &ge;1 day during the first 2 weeks after treatment initiation, or",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - treatment interruption of &gt;7 days during weeks 3-4 after treatment initiation, or",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - treatment interruption of &gt;14 days after &ge;1 month of treatment initiation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Ophthalmologic exam at baseline and 3-4 months after initiation of treatment (continue periodic examinations for duration of therapy in patients with diabetes or history of uveitis); baseline AST/ALT (obtained &le;6 months prior to treatment initiation) and bilirubin, repeat if clinically indicated; respiratory function (FEV",
"     <sub>",
"      1",
"     </sub>",
"     , DLCO); VZV antibodies (patients with no history of chickenpox or previous VZV vaccination)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gilenya (AR, AU, BR, CH, CZ, DE, DK, EE, FR, GB, HK, IE, IL, KP, NO, NZ, SE, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10829866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fingolimod-phosphate, active metabolite of fingolimod, binds to sphingosine 1-phosphate receptors 1, 3, 4, and 5. The amount of lymphocytes available to the central nervous system are decreased which reduces central inflammation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10829868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1200 &plusmn; 260 L: distributes into red blood cells (86%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99.7% (fingolimod and fingolimod-phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP4F2 to fingolimod-phosphate (active) and other metabolites (inactive); CYP2D6, 2E1, 3A4, and 4F12 also contribute to metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 6-9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 12-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~81% as inactive metabolites); feces (fingolimod and fingolimod phosphate: &lt;2.5% of dose)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brinkmann V, &ldquo;FTY720 (Fingolimod) in Multiple Sclerosis: Therapeutic Effects in the Immune and the Central Nervous System,&rdquo;",
"      <i>",
"       Br J Pharmacol",
"      </i>",
"      ,  2009, 158(5):1173-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/11/26806/abstract-text/19814729/pubmed\" id=\"19814729\" target=\"_blank\">",
"        19814729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chun J and Hartung HP, &ldquo;Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis,&rdquo;",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 2010, 33(2):91-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/11/26806/abstract-text/20061941/pubmed\" id=\"20061941\" target=\"_blank\">",
"        20061941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16078 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26806=[""].join("\n");
var outline_f26_11_26806=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655214\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824425\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12724975\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829448\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829906\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829907\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14228118\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829908\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829927\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829446\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829909\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829506\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829844\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829511\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829524\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10894405\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10890728\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829507\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829508\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829509\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829510\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829924\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322867\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829925\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276708\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829866\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10829868\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16078\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16078|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/43/18101?source=related_link\">",
"      Fingolimod: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_11_26807="Manifestations and treatment of extrapulmonary coccidioidomycosis";
var content_f26_11_26807=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Manifestations and treatment of extrapulmonary coccidioidomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/11/26807/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26807/contributors\">",
"     John N Galgiani, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/11/26807/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26807/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/11/26807/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26807/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/11/26807/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioidomycosis is caused by the dimorphic fungi, Coccidioides immitis, or Coccidioides posadasii. These organisms are endemic to certain arid regions of the western hemisphere. Infection is virtually always acquired by inhalation, and primary infection frequently goes unrecognized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Dissemination of infection beyond the lungs can occur, but it is difficult to estimate the incidence of overt disseminated disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H2#H2\">",
"     \"Primary coccidioidal infection\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary coccidioidal infection\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The manifestations and treatment of extrapulmonary coccidioidomycosis other than involvement of the central nervous system will be reviewed here. Primary infection, laboratory diagnosis, pulmonary sequelae, coccidioidal meningitis, and infection in immunocompromised hosts are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13751?source=see_link\">",
"     \"Laboratory diagnosis of coccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39734?source=see_link\">",
"     \"Management of pulmonary sequelae and complications of coccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=see_link\">",
"     \"Coccidioidal meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE OF DISSEMINATED INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioidomycosis occasionally spreads from the initial pulmonary lesion to other parts of the body. Estimates of this risk vary from approximately 4.7 percent of recognized infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/3\">",
"     3",
"    </a>",
"    ] to 0.2 percent of all respiratory exposures to Coccidioides spp [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/4\">",
"     4",
"    </a>",
"    ]. This substantial range in estimates is probably due to the under recognition of mild infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For extrapulmonary complications, patient groups at risk include those of African or Filipino ancestry and immunosuppressed patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated infection represents a progression of primary infection, frequently becoming evident within weeks and usually within two years after the initial exposure. Thus, it is common for dissemination to be clinically evident at the time infection is first diagnosed in those who develop extrapulmonary coccidioidomycosis.",
"   </p>",
"   <p>",
"    Extrapulmonary dissemination is usually the result of hematogenous spread of the organism. It is possible that some infections occur by Coccidioides spp gaining access to the bloodstream directly from venous drainage of the lungs. However, hilar adenopathy is a frequent feature of coccidioidal pneumonia, and progression of infection to paratracheal and even supraclavicular lymph nodes prior to the development of extrapulmonary lesions is well documented. The common involvement of lymph nodes suggests that some, if not most, disseminated infections result from lymphatic drainage, eventually to the common lymphatic duct into the inferior vena cava and from there to the rest of the body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sites of disseminated lesions are [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin or subcutaneous soft tissue",
"     </li>",
"     <li>",
"      Meninges of the brain and spinal cord",
"     </li>",
"     <li>",
"      Skeleton",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To a lesser degree, other sites of dissemination may include: endocrine glands [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/13\">",
"     13",
"    </a>",
"    ], kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], genital organs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/16-20\">",
"     16-20",
"    </a>",
"    ], the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], and the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/23\">",
"     23",
"    </a>",
"    ]. Lesions have rarely been noted in the subserosal intestines, the heart, and the urinary bladder. Of all sites of dissemination, meningitis is the most uniformly serious and poses special problems in management that will be addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=see_link\">",
"     \"Coccidioidal meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lesions typically become evident in a subacute or chronic fashion. The timing and nature of the symptoms may depend upon the exact location and number of individual lesions. Symptoms usually reflect the site of infection and are often indistinguishable from infection of these organs due to other pathogens. Because of the indolent nature of the infection and lack of specificity of symptoms including pain, the diagnosis of extrapulmonary coccidioidomycosis is frequently delayed by weeks or even months. This is especially true if the initial pulmonary infection has not yet been recognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL DRUG SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Infectious Diseases Society of America (IDSA) published treatment guidelines for coccidioidomycosis in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/24\">",
"     24",
"    </a>",
"    ]. The following principles are covered in the consensus statement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral azole antifungal agents are the customary initial drugs of choice.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      is usually reserved for patients with lesions that are worsening rapidly or are located in vital sites, such as the spine.",
"     </li>",
"     <li>",
"      Surgical debridement or stabilization, in some cases, is important and even critical as adjunctive treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Azole therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consensus statement is pointedly silent with respect to which oral azole should be used. Of the commercially available azoles, only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    has been approved for the treatment of coccidioidomycosis by the United States Food and Drug Administration (FDA). However, the NIAID Mycoses Study Group has published descriptions of large prospective clinical trials using either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    as treatment of coccidioidomycosis. These reports indicate that both drugs are efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Although neither itraconazole nor fluconazole has been compared directly with ketoconazole, they are now commonly used in the treatment of coccidioidal infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Itraconazole versus fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized, blinded comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    in the treatment of progressive nonmeningeal coccidioidal infections provides the most complete data to address the selection of antifungal agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with chronic pulmonary, soft tissue, or skeletal lesions were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 mg once daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg twice daily). The primary comparison of the two drugs was performed after eight months, although protocol treatment was continued for a full year. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      responded by eight months, although the difference was not statistically significant (61 of 97 [63 percent] versus 47 of 94 [50 percent], p = 0.08).",
"     </li>",
"     <li>",
"      In a secondary analysis, most of the apparent difference in response rates occurred in patients with skeletal lesions; 12 of 23 (52 percent) receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      responded compared with only 7 of 27 (26 percent) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In another secondary analysis, the difference in response rates between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      widened further after 12 months of therapy, with itraconazole appearing to be better.",
"     </li>",
"     <li>",
"      Relapse rates were similar irrespective of the azole given in patients who completed protocol therapy and had therapy stopped.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This trial suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    are quite similar for treating chronic pulmonary and soft tissue coccidioidal lesions. However, itraconazole may be more potent at the doses studied than fluconazole for treating skeletal lesions. A report of successful itraconazole treatment in two children with bone involvement is consistent with these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    is a novel triazole agent that has potent in vitro activity against a wide range of fungal pathogens, including both yeasts and molds. Published data are limited but suggest efficacy as illustrated by the following findings.",
"   </p>",
"   <p>",
"    In an open-label study of 15 patients with chronic refractory coccidioidomycosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    (800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses) produced a complete response in four and a partial response in seven [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/29\">",
"     29",
"    </a>",
"    ]. The sites of involvement included lungs, bones, joints, skin, soft tissue, lymph nodes, central nervous system, eye, and heart valves.",
"   </p>",
"   <p>",
"    Similar findings were noted in a series of 20 patients with chronic pulmonary or nonmeningeal disseminated coccidioidomycosis who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/30\">",
"     30",
"    </a>",
"    ]. Seventeen had a treatment response, defined as any reduction in Mycoses Study Group (MSG) score by week 16 and a &ge;50 percent reduction in the MSG score by week 24.",
"   </p>",
"   <p>",
"    A retrospective study that included 16 patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    for the treatment of refractory coccidioidomycosis showed that many, but not all, patients experienced improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    has had limited use in patients with coccidioidomycosis, especially those with refractory infections. There are case reports suggesting that voriconazole may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In a review of disseminated coccidioidal infections, some patients were managed successfully with voriconazole treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/35\">",
"     35",
"    </a>",
"    ]. Similarly, a retrospective study that included 21 patients who received voriconazole for the treatment of refractory coccidioidomycosis showed that many, but not all, patients experienced improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACHES FOR SPECIFIC LOCATIONS OF DISSEMINATED INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IDSA guidelines recommend that most patients with disseminated infections should be treated and that optimal management may require combined medical and surgical interventions. However, it is frequently difficult to determine the need for surgery in management because of the diversity of possible locations and severity of coccidioidal lesions; guidelines cannot address all of the various situations that might be seen. The following specific examples have been commonly encountered by clinicians at the Valley Fever Center for Excellence (",
"    <a class=\"external\" href=\"file://www.vfce.arizona.edu/\">",
"     www.vfce.arizona.edu/",
"    </a>",
"    ) and are illustrative of approaches followed within that program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Supraclavicular adenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As indicated above, the presence of enlarged supraclavicular nodes probably represents lymphatic drainage from the lung rather than hematogenous spread. However, to reach the supraclavicular region reflects exceptional progression of infection along the lymphatic chain, indicating that host defenses are not effectively limiting the infection to the lungs. Thus, supraclavicular adenopathy is usually treated in a similar fashion to that used for disseminated lesions. One or more such nodes may be evident at the time of diagnosis. These lymph nodes occasionally drain spontaneously but with therapy often resolve without requiring surgical resection. Retropharyngeal abscesses also occur but more likely represent extension of cervical osteomyelitis rather then lymphangitic spread from the mediastinum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Solitary cutaneous lesions in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single small skin lesion is occasionally biopsied or excised entirely and found histologically to be the result of coccidioidal infection. Most clinicians would recommend beginning treatment in adults based upon this finding alone. However, in an otherwise healthy child with no other evidence of disseminated infection, some pediatricians familiar with coccidioidomycosis have elected to observe the patient closely rather than initiating therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prostatic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients have been discovered to have an asymptomatic coccidioidal infection of the prostate; such infections are usually discovered during the evaluation of an elevated serum prostate-specific antigen level or less commonly during a fine needle biopsy of a palpable prostatic nodule. We have followed several such patients without treatment, using periodic office visits and coccidioidal serologies yearly or twice yearly as monitors. To date, none of the prostatic lesions have become symptomatic, nor has any patient developed a new lesion elsewhere.",
"   </p>",
"   <p>",
"    In contrast, if coccidioidal involvement of the prostate is discovered as the result of a transurethral or radical prostatectomy, the greater anatomic disruption of those procedures compared to a fine needle biopsy greatly increases the risk of subsequent complications from the infection. In these situations, antifungal therapy would be appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Monoarticular arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated coccidioidomycosis frequently involves only a single joint. Monoarticular infection of the knee is the most common, with a presentation that mimics a degenerative or traumatically injured joint. This has led to an unexpected diagnosis at the time of arthroscopy and even after total knee replacement. The infection may be limited completely to the synovium, and, in such cases, antifungal treatment without surgical intervention is often quite effective in completely resolving the signs and symptoms of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vertebral osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebrae are a common site for coccidioidal osteomyelitis. Lesions may be single or multiple, occasionally also involving the sacrum and ileum. There may be no other identified lesions of disseminated infection in some cases of multiple vertebral lesions, which suggests either a predilection for vertebral osteomyelitis in certain patients, a tropism for the spine among certain strains of C. immitis, or spread to the vertebrae through venous channels of Batson's plexus.",
"   </p>",
"   <p>",
"    The management of these lesions is especially important because of their potential impact on the spinal cord and mobility. There is no doubt that some of these lesions require surgical debridement and stabilization to control the infection. However, determining which lesions will benefit from surgery is not always clear, and practices among different clinicians vary substantially in managing these lesions. Radionuclide bone scans are useful to identify possible areas of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/36\">",
"     36",
"    </a>",
"    ]. Magnetic resonance (MR) imaging with gadolinium enhancement has been especially useful in defining the extent of individual lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once these studies and a careful neurologic evaluation are completed, patients are initially managed depending upon immediate or pending cord impingement and stability of the vertebral bodies. For those with evidence of cord impingement, immediate surgical decompression is usually recommended. For other patients without cord compression and with stable vertebrae, medical treatment is often initiated without immediate surgical intervention. Subsequent management depends upon the evolution of lesions as evidenced by neurologic examination and repeated MR imaging (often within one or two months). For progressive lesions, surgical options are reconsidered. For those that are stable or show improvement, medical management alone is continued with repeated MR imaging at progressively longer intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT DISCONTINUATION AND RISK OF RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who respond to antifungal therapy, there is a significant potential for relapse once drug treatment is discontinued. In the comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    treatment cited above, relapse rates following the completion of 12 months of therapy were 28 and 18 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/27\">",
"     27",
"    </a>",
"    ]. However, many responding patients continued therapy off protocol. Moreover, a subanalysis indicated that patients continuing therapy were more likely to have had prior relapses, higher serologic titers, and greater extent of disease. These results suggest that relapse rates might be even higher than those recorded in patients whose therapy was discontinued.",
"   </p>",
"   <p>",
"    Although the risk of relapse is substantial, perhaps as many as two-thirds of patients who complete therapy do not relapse; thus it would seem reasonable to discontinue therapy at least once. This practice is reinforced by the observation that most relapses occur at the site of previously identified lesions rather than at new sites. On the other hand, if the site of any of the initial lesions is particularly critical, then recurrence, even if detected early, might be seriously deleterious to the patient. Thus, in cases of vertebral infection, for example, treatment durations are often extended well beyond 12 months; occasionally, a physician may be unwilling to ever attempt discontinuing treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE INTERFERON-GAMMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because cellular immunity is important in the immune control of coccidioidal infection, there has been interest in using interferon-gamma for patients with disseminated infection or other serious complications, although the efficacy of this approach has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/38\">",
"     38",
"    </a>",
"    ]. A case of disseminated coccidioidomycosis in a patient with an interferon-gamma receptor mutation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/39\">",
"     39",
"    </a>",
"    ]. This mutation has previously been associated with atypical mycobacterial infections and, in fact, this patient had a history of Mycobacterium chelonae and Mycobacterium kansasii infections. For patients with this mutation, interferon-gamma is thought to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26807/abstract/40\">",
"     40",
"    </a>",
"    ]. These observations are likely to stimulate additional study of specific mutations that may predispose patients to disseminated coccidioidomycosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/19/13617?source=see_link\">",
"       \"Patient information: Valley Fever (coccidioidomycosis) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coccidioidomycosis is caused by the dimorphic fungi, Coccidioides immitis, or Coccidioides posadasii. These organisms are endemic to certain arid regions of the western hemisphere. Infection is virtually always acquired by inhalation, and primary infection frequently goes unrecognized. Dissemination of infection beyond the lungs can occur, but it is difficult to estimate the incidence of overt disseminated disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated infection represents a progression of primary infection, frequently becoming evident within weeks and usually within two years after the initial exposure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extrapulmonary dissemination is usually the result of hematogenous spread of the organism. The common involvement of lymph nodes suggests that some, if not most, disseminated infections result from lymphatic drainage, eventually to the common lymphatic duct and from there to the rest of the body. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common sites of disseminated lesions are skin, subcutaneous soft tissue, meninges, and skeleton. Of all sites of dissemination, meningitis is the most serious and poses special problems in management, which are addressed separately. &nbsp;(See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=see_link\">",
"       \"Coccidioidal meningitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lesions typically become evident in a subacute or chronic fashion. The timing and nature of the symptoms may depend upon the exact location and number of individual lesions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Infectious Diseases Society of America (IDSA) published treatment guidelines for coccidioidomycosis in 2005. The following principles are covered in the consensus statement:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oral azole antifungal agents are the customary initial drugs of choice.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      is usually reserved for patients with lesions that are worsening rapidly or are located in vital sites, such as the spine.",
"     </li>",
"     <li>",
"      Surgical debridement or stabilization, in some cases, are important and even critical as adjunctive treatment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antifungal drug selection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with disseminated infections should be treated; optimal management may require combined medical and surgical interventions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management approaches for specific locations of disseminated infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the risk of relapse is substantial, as many as two-thirds of patients who complete therapy do not relapse; thus for many patients, it would seem reasonable to discontinue therapy at least once. On the other hand, if the site of any of the initial lesions is particularly critical, then recurrence, even if detected early, might be seriously deleterious to the patient. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment discontinuation and risk of relapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/1\">",
"      Smith CE, Beard RR. Varieties of Coccidioidal Infection in Relation to the Epidemiology and Control of the Diseases. Am J Public Health Nations Health 1946; 36:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/2\">",
"      Smith CE. Epidemiology of Acute Coccidioidomycosis with Erythema Nodosum (\"San Joaquin\" or \"Valley Fever\"). Am J Public Health Nations Health 1940; 30:600.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson RH, Caldwell JW, Welch G, et al. The great coccidioidomycosis epidemic: Clinical features. In: Einstein HE, Catanzaro A, eds. Coccidioidomycosis. Proceedings of the 5th International Conference. Washington: National Foundation for Infectious Diseases; 1996:77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/4\">",
"      Barnato AE, Sanders GD, Owens DK. Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis 2001; 7:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/5\">",
"      Chang DC, Anderson S, Wannemuehler K, et al. Testing for coccidioidomycosis among patients with community-acquired pneumonia. Emerg Infect Dis 2008; 14:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/6\">",
"      Crum NF, Lederman ER, Stafford CM, et al. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) 2004; 83:149.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson RH, Caldwell D. State of the art lecture. Extra-pulmonary nonmeningeal coccidioidomycosis. In: Coccidioidomycosis. Proceedings of the Fifth International Conference, edited by H. Einstein and A. Catanzaro, Bethesda MD:National Foundation for Infectious Diseases, 1996, p. 347-358.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/8\">",
"      Papadopoulos KI, Castor B, Klingspor L, et al. Bilateral isolated adrenal coccidioidomycosis. J Intern Med 1996; 239:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/9\">",
"      Smilack JD, Argueta R. Coccidioidal infection of the thyroid. Arch Intern Med 1998; 158:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/10\">",
"      Rodenbiker HT, Ganley JP. Ocular coccidioidomycosis. Surv Ophthalmol 1980; 24:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/11\">",
"      Cunningham ET Jr, Seiff SR, Berger TG, et al. Intraocular coccidioidomycosis diagnosed by skin biopsy. Arch Ophthalmol 1998; 116:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/12\">",
"      Stone JL, Kalina RE. Ocular coccidioidomycosis. Am J Ophthalmol 1993; 116:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/13\">",
"      Goldberg B, Loeffler AM. Respiratory distress and a liver mass. Pediatr Infect Dis J 1999; 18:1105.",
"     </a>",
"    </li>",
"    <li>",
"     Huntington RW. Pathology of coccidioidomycosis. In: Coccidioidomycosis: A text, Stevens DA (Ed), Plenum Medical Book Co, New York City 1980. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/15\">",
"      Baden LR, Digumarthy SR, Guimaraes AS, Branda JA. Case records of the Massachusetts General Hospital. Case 35-2009. A 60-year-old male renal-transplant recipient with renal insufficiency, diabetic ketoacidosis, and mental-status changes. N Engl J Med 2009; 361:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/16\">",
"      Kuntze JR, Herman MH, Evans SG. Genitourinary coccidioidomycosis. J Urol 1988; 140:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/17\">",
"      Liao JC, Reiter RE. Coccidioidomycosis presenting as testicular mass. J Urol 2001; 166:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/18\">",
"      Dykes TM, Stone AB, Canby-Hagino ED. Coccidioidomycosis of the epididymis and testis. AJR Am J Roentgenol 2005; 184:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/19\">",
"      Halsey ES, Rasnake MS, Hospenthal DR. Coccidioidomycosis of the male reproductive tract. Mycopathologia 2005; 159:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/20\">",
"      Sohail MR, Andrews PE, Blair JE. Coccidioidomycosis of the male genital tract. J Urol 2005; 173:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/21\">",
"      Lawrence MA, Ginsberg D, Stein JP, et al. Coccidioidomycosis prostatitis associated with prostate cancer. BJU Int 1999; 84:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/22\">",
"      Niku SD, Dalgleish G, Devendra G. Coccidioidomycosis of the prostate gland. Urology 1998; 52:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/23\">",
"      Phillips P, Ford B. Peritoneal coccidioidomycosis: case report and review. Clin Infect Dis 2000; 30:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/24\">",
"      Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/25\">",
"      Catanzaro A, Galgiani JN, Levine BE, et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med 1995; 98:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/26\">",
"      Graybill JR, Stevens DA, Galgiani JN, et al. Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. Am J Med 1990; 89:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/27\">",
"      Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000; 133:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/28\">",
"      Homans JD, Spencer L. Itraconazole treatment of nonmeningeal coccidioidomycosis in children: two case reports and review of the literature. Pediatr Infect Dis J 2010; 29:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/29\">",
"      Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/30\">",
"      Catanzaro A, Cloud GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007; 45:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/31\">",
"      Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011; 53:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/32\">",
"      Prabhu RM, Bonnell M, Currier BL, Orenstein R. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis 2004; 39:e74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/33\">",
"      Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother 2004; 48:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/34\">",
"      Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003; 36:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/35\">",
"      Adam RD, Elliott SP, Taljanovic MS. The spectrum and presentation of disseminated coccidioidomycosis. Am J Med 2009; 122:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/36\">",
"      Stadalnik RC, Goldstein E, Hoeprich PD, et al. Diagnostic value of gallium and bone scans in evaluation of extrapulmonary coccidioidal lesions. Am Rev Respir Dis 1980; 121:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/37\">",
"      Erly WK, Carmody RF, Seeger JF, Lund PJ. Magnetic resonance imaging of coccidioidal spondylitis. Int J Neuroradiol 1997; 3:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/38\">",
"      Kuberski TT, Servi RJ, Rubin PJ. Successful treatment of a critically ill patient with disseminated coccidioidomycosis, using adjunctive interferon-gamma. Clin Infect Dis 2004; 38:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/39\">",
"      Vinh DC, Masannat F, Dzioba RB, et al. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. Clin Infect Dis 2009; 49:e62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26807/abstract/40\">",
"      Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000; 11:321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2449 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26807=[""].join("\n");
var outline_f26_11_26807=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE OF DISSEMINATED INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANTIFUNGAL DRUG SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Azole therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Itraconazole versus fluconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT APPROACHES FOR SPECIFIC LOCATIONS OF DISSEMINATED INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Supraclavicular adenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Solitary cutaneous lesions in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prostatic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monoarticular arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vertebral osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT DISCONTINUATION AND RISK OF RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ADJUNCTIVE INTERFERON-GAMMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=related_link\">",
"      Coccidioidal meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=related_link\">",
"      Coccidioidomycosis in compromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13751?source=related_link\">",
"      Laboratory diagnosis of coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39734?source=related_link\">",
"      Management of pulmonary sequelae and complications of coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/19/13617?source=related_link\">",
"      Patient information: Valley Fever (coccidioidomycosis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_11_26808="Mixed cell versus lymphocyte depletion HL";
var content_f26_11_26808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Hodgkin lymphoma variants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Mixed cellularity variant. The characteristic background infiltrate of reactive cells (eosinophils, lymphocytes) and uninucleate Reed-Sternberg cells is present in this field (red arrow). Right panel: Lymphocyte depletion variant. Diffuse fibrosis is seen, and a diagnostic binucleate Reed-Sternberg cell is present (blue arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26808=[""].join("\n");
var outline_f26_11_26808=null;
var title_f26_11_26809="Drowning (submersion injuries)";
var content_f26_11_26809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drowning (submersion injuries)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/11/26809/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26809/contributors\">",
"     Dipak Chandy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26809/contributors\">",
"     Gerald L Weinhouse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/11/26809/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26809/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/11/26809/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26809/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/11/26809/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every year, drowning accounts for at least 500,000 deaths worldwide, including approximately 4000 fatalities in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Statistics for nonfatal drowning are more difficult to obtain, but nonfatal drowning events may occur several hundred times as frequently as reported drowning deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drowning and its management are reviewed here. The management of specific complications of nonfatal drowning (eg, hypothermia, acute respiratory distress syndrome, and bradycardia), complications of SCUBA diving, and the general management of trauma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link\">",
"     \"Accidental hypothermia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=see_link\">",
"     \"Treatment of hypothermia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link\">",
"     \"Complications of scuba diving\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple definitions of drowning, nonfatal drowning, and submersion injury have been proposed in the medical literature, creating confusion and underlining the need for a more consistent approach to reporting and studying these incidents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/1\">",
"     1",
"    </a>",
"    ]. Nonfatal drowning generally is defined as survival, at least temporarily, after suffocation by submersion in a liquid medium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/5\">",
"     5",
"    </a>",
"    ]. Most authors include the loss of consciousness while submerged as a criterion for the syndrome.",
"   </p>",
"   <p>",
"    However, some authors have argued that since pulmonary complications may follow the aspiration of water without the loss of consciousness, nonfatal drowning should be defined as survival, at least temporarily, after aspiration of fluid into the lungs (\"wet nonfatal drowning\") or after a period of asphyxia secondary to laryngospasm (\"dry nonfatal drowning\") [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In its 2010 resuscitation guidelines, the American Heart Association recommends that the Utstein definitions and methods of data reporting for drowning and related events be used to improve consistency in reporting and research [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. According to the Utstein guidelines, drowning refers to: &ldquo;a process resulting in primary respiratory impairment from submersion or immersion in a liquid medium&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/7\">",
"     7",
"    </a>",
"    ]. The Utstein guidelines further suggest that ambiguous or confusing terms such as &ldquo;near-drowning,&rdquo; &ldquo;secondary drowning,&rdquo; and &ldquo;wet drowning&rdquo; should not be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drowning is a common cause of accidental death in the United States and an important cause of childhood fatalities worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Low and middle-income countries have the highest rates of drowning, accounting for over 90 percent of such fatalities.",
"   </p>",
"   <p>",
"    In the United States, drowning is a major cause of accidental death among persons under the age of 45 years and a leading cause in children under 5 years of age in states where swimming pools or beaches are more accessible, such as California, Arizona, and Florida [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/10,15,16\">",
"     10,15,16",
"    </a>",
"    ]. The highest incidence of drowning occurs among males, African-Americans, children between the ages of one and five years, persons with low-socioeconomic status, and among residents of Southern states [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. Drowning is much more common during the summer months.",
"   </p>",
"   <p>",
"    The age distribution of submersion injury is bimodal. The first peak occurs among children less than five years of age who are inadequately supervised in swimming pools, bathtubs, or around other liquid-filled containers; approximately 7 percent of these incidents appear related to child abuse or neglect. The second age peak is seen among males between 15 and 25 years old, and these episodes tend to occur at rivers, lakes, and beaches [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors increase the risk of drowning [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/2,10,18-27\">",
"     2,10,18-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability to swim or overestimation of swimming capabilities",
"     </li>",
"     <li>",
"      Risk-taking behavior",
"     </li>",
"     <li>",
"      Use of alcohol and illicit drugs (more than 50 percent of adult drowning deaths are believed to be alcohol-related)",
"     </li>",
"     <li>",
"      Inadequate adult supervision",
"     </li>",
"     <li>",
"      Hypothermia, which can lead to rapid exhaustion or cardiac arrhythmias (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link\">",
"       \"Accidental hypothermia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Concomitant trauma, stroke, or myocardial infarction",
"     </li>",
"     <li>",
"      Seizure disorder or",
"      <span class=\"nowrap\">",
"       developmental/behavioral",
"      </span>",
"      disorders in children [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Undetected primary cardiac arrhythmia (may be a more common cause of drowning than generally appreciated) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/29\">",
"       29",
"      </a>",
"      ]. As an example, cold water immersion and exercise can cause fatal arrhythmias in patients with the congenital long QT syndrome type 1. Similarly, mutations in the cardiac ryanodine receptor (RyR)-2 gene, which is associated with familial polymorphic VT in the absence of structural heart disease or QT prolongation, have been identified in some individuals with unexplained drowning [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical features of congenital long QT syndrome\", section on 'Triggers of arrhythmia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H3#H3\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Catecholaminergic polymorphic VT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperventilation prior to a shallow dive. Swimmers commonly hyperventilate in order to prolong the duration of underwater swimming, and by so doing they reduce the arterial partial pressure of carbon dioxide (PaCO2) while the content of oxygen (CaO2) does not increase appreciably. As the individual swims, oxygen is consumed and the partial pressure of oxygen (PaO2) falls to 30 to 40 mmHg before the PaCO2 rises sufficiently to trigger the urge to breathe. This can lead to cerebral hypoxia, seizures, and loss of consciousness, which can result in drowning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"       \"Control of ventilation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatal and nonfatal drowning typically begins with a period of panic, loss of the normal breathing pattern, breath-holding, air hunger, and a struggle by the victim to stay above the water. Reflex inspiratory efforts eventually occur, leading to hypoxemia by means of either aspiration or reflex laryngospasm that occurs when water contacts the lower respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/2,3,30-33\">",
"     2,3,30-33",
"    </a>",
"    ]. Hypoxemia in turn affects every organ system, with the major component of morbidity and mortality being related to cerebral hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The literature formerly emphasized the distinction between salt water and fresh water drowning [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/34\">",
"     34",
"    </a>",
"    ]. It was believed that the hypertonicity of salt water caused plasma to be drawn into the pulmonary interstitium and alveoli, leading to massive pulmonary edema and hypertonic serum. Drowning in fresh water was thought to create the opposite effect, with aspirated hypotonic fluid rapidly passing through the lungs and into the intravascular compartment, leading to volume overload and dilutional effects on serum electrolytes.",
"   </p>",
"   <p>",
"    Subsequently, researchers have recognized that this distinction is more apparent among persons who are dead on arrival than among victims who are brought to the hospital alive. Aspiration of more than 11",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of body weight must occur before blood volume changes occur, and more than 22",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    before electrolyte changes take place [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Because it is unusual for nonfatal drowning victims to aspirate more than 3 to 4",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    the distinction between salt water and fresh water drowning is no longer considered important [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Both types of nonfatal drowning result in decreased lung compliance, ventilation-perfusion mismatching, and intrapulmonary shunting, leading to hypoxemia that causes diffuse organ dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/34\">",
"     34",
"    </a>",
"    ]. The temperature of the water and the presence of contaminants may affect patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/3,18,30\">",
"     3,18,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     END ORGAN EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia ultimately produces tissue hypoxia, which affects virtually all tissues and organs within the body.",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) consensus conference report for the detection, correction, and prevention of tissue hypoxia, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid aspiration results in varying degrees of hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/19\">",
"     19",
"    </a>",
"    ]. Both salt water and fresh water wash out surfactant, often producing noncardiogenic pulmonary edema and the acute respiratory distress syndrome (ARDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. Pulmonary insufficiency can develop insidiously or rapidly; signs and symptoms include shortness of breath, crackles, and wheezing. The chest radiograph or computed tomography at presentation can vary from normal to localized, perihilar, or diffuse pulmonary edema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57578 \" href=\"UTD.htm?41/19/42289\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia and ischemia cause neuronal damage, which can produce cerebral edema and elevations in intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/41\">",
"     41",
"    </a>",
"    ]. Some authors consider the progressive rise in intracranial pressure that is sometimes observed approximately 24 hours after injury to reflect the severity of the neurologic insult rather than its cause [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/42\">",
"     42",
"    </a>",
"    ]. Approximately 20 percent of nonfatal drowning victims sustain neurologic damage, limiting functional recovery despite successful cardiopulmonary resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias secondary to hypothermia and hypoxemia are often observed in nonfatal drowning victims. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link&amp;anchor=H6#H6\">",
"     \"Accidental hypothermia in adults\", section on 'General findings and progression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link&amp;anchor=H11#H11\">",
"     \"Accidental hypothermia in adults\", section on 'Electrocardiographic changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial arrhythmias described following nonfatal drowning include sinus tachycardia, sinus bradycardia, and atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, swimming (including diving) can precipitate fatal ventricular arrhythmias in patients with congenital long QT syndrome type 1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Triggers of arrhythmia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acid-base and electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A metabolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory acidosis is often observed. Significant electrolyte imbalances generally do not occur in nonfatal drowning survivors except those submerged in unusual media, such as the Dead Sea, where the extremely concentrated seawater can produce life-threatening hypernatremia, hypermagnesemia, and hypercalcemia due to absorption of swallowed seawater [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal failure rarely can occur after submersion, and is usually due to acute tubular necrosis resulting from hypoxemia, shock, hemoglobinuria, or myoglobinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30425?source=see_link\">",
"     \"Overview of the management of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49705267\">",
"    <span class=\"h2\">",
"     Coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolysis and coagulopathy are rare potential complications of nonfatal drowning [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of drowning victims can be divided into three phases: prehospital care, emergency department (ED) care, and inpatient care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prehospital care and acute interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rescue and immediate resuscitation by bystanders improves the outcome of drowning victims [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/49\">",
"     49",
"    </a>",
"    ]. The need for cardiopulmonary resuscitation (CPR) is determined as soon as possible without compromising the safety of the rescuer or delaying the removal of the victim from the water.",
"   </p>",
"   <p>",
"    Ventilation is the most important initial treatment for victims of submersion injury and rescue breathing should begin as soon as the rescuer reaches shallow water or a stable surface. Note that the priorities of CPR in the drowning victim differ from those in the typical adult cardiac arrest patient, which emphasize immediate uninterrupted chest compressions. If the patient does not respond to the delivery of two rescue breaths that make the chest rise, the rescuer should immediately begin performing high-quality chest compressions. CPR, including the application of an automated external defibrillator, is then performed according to standard guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Cervical spinal cord injury is uncommon in nonfatal drowning victims,",
"    <strong>",
"     unless",
"    </strong>",
"    there are clinical signs of injury or a concerning mechanism (eg, dive into shallow water). According to the 2010 AHA Guidelines for Advanced Cardiac Life Support (ACLS),",
"    <strong>",
"     routine",
"    </strong>",
"    cervical spine immobilization can interfere with essential airway management and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/7\">",
"     7",
"    </a>",
"    ]. A cohort study of 2244 submersion victims reported that 11 (0.5 percent) sustained cervical spine injuries and all had obvious signs of injury and a mechanism (eg, diving, motor vehicle crash) suggestive of spinal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/50\">",
"     50",
"    </a>",
"    ]. Nevertheless, it can be difficult to assess the spine of nonfatal drowning patients with an altered mental status (eg, intoxicated) and clinicians should use caution when deciding to remove spinal immobilization.",
"   </p>",
"   <p>",
"    Drowning patients can present with life-threatening arrhythmias, and these are treated according to ACLS protocols. Pulses may be very weak and difficult to palpate in the hypothermic patient with sinus bradycardia or atrial fibrillation; a careful search for pulses should be performed for at least one minute before initiating chest compressions in the hypothermic patient because these arrhythmias require no immediate treatment. If the patient does not respond to the delivery of two rescue breaths that make the chest rise, the rescuer should immediately begin performing high-quality chest compressions once the absence of a pulse is established in the hypothermic patient. CPR is then performed according to standard BLS guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=see_link\">",
"     \"Guidelines for pediatric advanced life support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link&amp;anchor=H13#H13\">",
"     \"Accidental hypothermia in adults\", section on 'Airway, breathing, circulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link&amp;anchor=H20#H20\">",
"     \"Accidental hypothermia in adults\", section on 'Treatment of arrhythmia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Heimlich maneuver or other postural drainage techniques to remove water from the lungs are of no proven value, and rescue breathing should not be delayed in order to perform these maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/51\">",
"     51",
"    </a>",
"    ]. High-flow supplemental oxygen should be administered to spontaneously breathing patients by facemask; apneic patients should be intubated. Attempts at rewarming hypothermic patients with a core temperature &lt;33&ordm;C should be initiated, either by passive or active means as available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link\">",
"     \"Accidental hypothermia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Emergency department management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prehospital resuscitative efforts should be continued and the airway secured as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the symptomatic patient, indications for intubation include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of neurologic deterioration or inability to protect the airway",
"     </li>",
"     <li>",
"      Inability to maintain a PaO2 above 60 mmHg or oxygen saturation (SpO2) above 90 percent despite high-flow supplemental oxygen",
"     </li>",
"     <li>",
"      PaCO2 above 50 mmHg &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If tracheal intubation is performed, an orogastric tube should be placed to relieve gastric distension, which occurs from aspiration and is common in nonfatal drowning patients.",
"   </p>",
"   <p>",
"    In symptomatic patients who do not require immediate intubation, supplemental oxygen should be provided to maintain the SpO2 above 94 percent. In addition, noninvasive positive pressure ventilation via CPAP (continuous positive airway pressure) or BLPAP (bi-level positive airway pressure) can improve oxygenation and decrease ventilation-perfusion mismatch [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/48\">",
"     48",
"    </a>",
"    ]. Note that positive airway pressure increases intrathoracic pressure and patients must be carefully monitored for possible hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to frequent vital sign measurements and clinical reassessment, monitoring of the symptomatic patient should include continuous oxygen saturation, end-tidal CO2, and cardiac telemetry. A beside glucose measurement should be obtained soon upon arrival. Empiric administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    is reasonable in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"     \"Pulse oximetry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    A trauma evaluation should be performed and appropriate imaging studies obtained as indicated. Injury of the cervical spine is",
"    <strong>",
"     not",
"    </strong>",
"    common in patients with submersion injuries, but precautions should be taken if there is a concerning history or signs of injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Prehospital care and acute interventions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Wet clothing should be removed and rewarming initiated in hypothermic patients. Rewarming methods include passive techniques (use of blankets or other insulators to reduce heat loss), active external rewarming (application of warm blankets, heating pads, radiant heat, forced warm air), or active internal rewarming (pleural and peritoneal irrigation with warm saline, continuous arteriovenous rewarming, and cardiopulmonary bypass). Rewarming techniques are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link\">",
"     \"Accidental hypothermia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the neuroprotective effects of hypothermia, complete recovery of patients with hypothermia and cardiac arrest has been well documented despite prolonged resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/52\">",
"     52",
"    </a>",
"    ]. Therefore, under usual circumstances, resuscitative efforts should be continued indefinitely (occasionally for several hours) until the temperature is 32 to 35&ordm;C (90 to 95&ordm;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/53\">",
"     53",
"    </a>",
"    ]. A low-reading thermometer may be necessary. Induced hypothermia plays no role in the resuscitation of drowning patients. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Neurologic injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49707110\">",
"    <span class=\"h2\">",
"     Patient disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most nonfatal drowning victims are hospitalized because of the severity of illness or concern for clinical deterioration. However, a review of 75 pediatric patients found that all who ultimately developed symptoms did so within seven hours of immersion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/54\">",
"     54",
"    </a>",
"    ]. Based upon that study and similar analyses in adults and children, the following guidelines may be used to triage nonfatal drowning victims in the emergency unit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic patients should be admitted to a monitored setting until symptoms and physiologic disturbances resolve.",
"     </li>",
"     <li>",
"      Electrocardiography, measurement of serum electrolytes and creatinine, and serum and urine assays for alcohol and illicit drugs are generally recommended in asymptomatic, as well as symptomatic, adolescent and adult patients. Measurement of blood counts and a prothrombin time are reasonable in the symptomatic patient. Additional testing may be useful in specific circumstances (eg, troponin to assess myocardial injury).",
"     </li>",
"     <li>",
"      Asymptomatic patients should be closely observed for approximately eight hours and admitted if any deterioration occurs. If vital signs, pulse oximetry, and all studies, including a chest radiograph obtained close to the end of the observation period, are normal and no clinical deterioration develops during this period, the patient may be discharged with appropriate follow-up. Clear verbal and written instructions to return to the emergency department immediately for any respiratory or other problems must be given, and the patient must be accompanied by a responsible adult.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inpatient management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic patients require hospitalization for supportive care and treatment of organ-specific complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Neurologic injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major determinants of neurologic outcome are the duration of loss of consciousness and the neurologic state of the patient upon presentation. The goal of hospital management is to prevent secondary neurologic injuries due to ongoing ischemia, cerebral edema, hypoxemia, fluid and electrolyte imbalances, acidosis, and seizure activity. Useful modalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild hyperventilation to maintain a PaCO2 of approximately 30 to 35 mmHg may be used as a temporizing measure to reduce intracranial pressure by decreasing intracranial blood volume. Excessive hyperventilation should be avoided because it can cause vasoconstriction, decreasing cerebral blood flow and worsening cerebral ischemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The head of the bed should be elevated to 30 degrees if potential cervical spine injuries have been excluded. More aggressive measures to reduce elevated intracranial pressure, as well as intracranial pressure monitoring, have not been documented to improve outcomes and are rarely undertaken [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diuretics can be used to avoid hypervolemia, but care should be taken to avoid volume depletion, which can lower cardiac output and cerebral perfusion.",
"     </li>",
"     <li>",
"      Seizure activity, which increases cerebral oxygen consumption and blood flow, should be aggressively controlled.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      is the preferred anticonvulsant because it does not depress consciousness and thereby, complicate neurologic assessment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/9/10394?source=see_link&amp;anchor=H2#H2\">",
"       \"Perioperative care of the surgical patient with neurologic disease\", section on 'Seizure disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuromuscular blocking agents should be avoided, if possible, because they can mask neurologic signs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"       \"Use of neuromuscular blocking medications in critically ill patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both hypoglycemia and hyperglycemia may be harmful to the brain, and euglycemia should be meticulously maintained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"       \"Glycemic control and intensive insulin therapy in critical illness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of barbiturates and controlled hypothermia in unconscious nonfatal drowning victims was reported in 1979 to decrease mortality and neurologic morbidity in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/57\">",
"     57",
"    </a>",
"    ]. However, subsequent studies failed to show any benefit from this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/33\">",
"     33",
"    </a>",
"    ]. As an example, one study of 31 comatose, drowned children did not show a difference in outcomes between those treated with mild hypothermia alone, and those treated with mild hypothermia plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of therapeutic hypothermia in the postresuscitation period following nonfatal drowning has been largely abandoned because no clear improvement in outcome has been demonstrated, and the treatment has been associated with an increased incidence of sepsis, probably secondary to cold-induced immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/43,59\">",
"     43,59",
"    </a>",
"    ]. Normothermia is desirable, as hyperthermia increases cerebral metabolic demands and lowers the seizure threshold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Respiratory failure or infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs may not reflect the severity of the pulmonary involvement and should be performed only when indicated by symptoms. Bronchospasm is often seen in nonfatal drowning victims, and management is treated similarly to acute asthma; most cases rapidly improve with inhaled beta-adrenergic agonists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=see_link\">",
"     \"Acute asthma exacerbations in children: Inpatient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no good evidence to support the routine use of glucocorticoids or prophylactic antibiotics in nonfatal drowning victims [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/30,38,48\">",
"     30,38,48",
"    </a>",
"    ]. Antibiotics should be used only in cases of clinical pulmonary infection or if the victim was submerged in grossly contaminated water. If pneumonia follows nonfatal drowning, a high suspicion for water-borne pathogens, such as Aeromonas, Pseudomonas, and Proteus, must be maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23943?source=see_link&amp;anchor=H14#H14\">",
"     \"Aeromonas infections\", section on 'Therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=see_link&amp;anchor=H9#H9\">",
"     \"Pseudomonas aeruginosa pneumonia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical ventilatory strategies are similar to those employed in other types of acute lung injury. There are case reports of extracorporeal membrane oxygenation (ECMO) being used to treat drowning victims, but high-quality evidence supporting this approach is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=see_link\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Researchers have investigated the use of exogenous surfactant to treat submersion injury with respiratory failure, with the rationale of replacing surfactant that has been washed out [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Although there are case reports of surfactant treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/65\">",
"     65",
"    </a>",
"    ], no trials have been performed in nonfatal drowning victims, and there is no high-quality evidence that pulmonary function improves with surfactant therapy in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link&amp;anchor=H3#H3\">",
"     \"Novel therapies for the acute respiratory distress syndrome\", section on 'Surfactant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons with hypothermia can have significant hypovolemia and hypotension due to a \"cold diuresis.\" This occurs because during the early phase of vasoconstriction, blood moves to the core, causing central volume receptors to sense fluid overload and resulting in decreased antidiuretic hormone production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypoxic cardiomyopathy may develop in nonfatal drowning victims [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/66\">",
"     66",
"    </a>",
"    ]. Pulmonary artery catheterization may be useful in cases in which the etiology of hypotension is unclear, as the data that are obtained can assist in optimal fluid replacement and inotropic support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors at presentation have been associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/4,67-75\">",
"     4,67-75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of submersion &gt;10 minutes",
"     </li>",
"     <li>",
"      Time to effective basic life support &gt;10 minutes",
"     </li>",
"     <li>",
"      Resuscitation duration &gt;25 minutes",
"     </li>",
"     <li>",
"      Water temperature &gt;10&ordm;C (50&ordm;F)",
"     </li>",
"     <li>",
"      Age &lt;3 years",
"     </li>",
"     <li>",
"      Glasgow coma scale &lt;5 (comatose)",
"     </li>",
"     <li>",
"      Persistent apnea and requirement of cardiopulmonary resuscitation in the emergency department",
"     </li>",
"     <li>",
"      Arterial blood pH &lt;7.1 upon presentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cold water is beneficial because it tends to decrease the metabolic demands of the body (helping to attenuate the effects of hypoxemia) and activates the diving reflex, a primitive reflex of bradycardia and breath-holding often seen in children that also shunts blood to the vital organs.",
"   </p>",
"   <p>",
"    Approximately 75 percent of drowning victims survive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Of these, approximately 6 percent suffer a residual neurologic deficit. However, the number of neurologically impaired survivors appears to be increasing as the care of nonneurologic complications improves.",
"   </p>",
"   <p>",
"    There are no accurate early predictors of poor neurologic outcomes that assist in the decision to discontinue resuscitative efforts, and substantial neurologic recovery can occur following prolonged submersion and anoxia, particularly in cold water [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/33,78,79\">",
"     33,78,79",
"    </a>",
"    ]. However, the absence of spontaneous, purposeful movements at 24 hours is an ominous sign; one study of 44 children with drowning found that all patients in whom such recovery of function did not occur, died or suffered severe neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drowning is preventable in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. As an example, secure fencing and gating of swimming pools can exclude virtually all children under the age of four and potentially decrease swimming pool drowning by 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/10,81\">",
"     10,81",
"    </a>",
"    ]. The importance of adequate adult supervision, swimming with a partner, appropriate use of personal flotation devices, and avoidance of alcohol and illicit drugs while swimming or boating also should be stressed by physicians and public health authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/10,33\">",
"     10,33",
"    </a>",
"    ]. Parents must also be warned that toddlers can drown in shallow areas, including toilets and buckets of water, if not adequately supervised [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26809/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9385417\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drowning is the third most common cause of accidental death in the United States and an important cause of childhood fatalities worldwide. Risk factors for drowning include: inability to swim or overestimation of swimming capabilities, risk-taking behavior, use of alcohol and illicit drugs, inadequate adult supervision, hypothermia, seizures, and developmental disorders in children. Drowning ultimately produces tissue hypoxia, which affects virtually all tissues and organs within the body. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'End organ effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventilation is the most important initial treatment for victims of submersion injury and rescue breathing should begin as soon as the rescuer reaches shallow water or a stable surface. If the patient does not respond to the delivery of two rescue breaths that make the chest rise, the rescuer should immediately begin performing cardiopulmonary resuscitation (CPR). The Heimlich maneuver or other postural drainage techniques to remove water from the lungs are of no proven value, and rescue breathing should not be delayed in order to perform these maneuvers. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prehospital care and acute interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical spinal cord injury is uncommon in nonfatal drowning victims,",
"      <strong>",
"       UNLESS",
"      </strong>",
"      there are clinical signs of injury or a concerning mechanism (eg, dive into shallow water).",
"     </li>",
"     <li>",
"      Pulses may be difficult to palpate in the hypothermic patient with sinus bradycardia or atrial fibrillation; a careful search for pulses should be performed for at least one minute before initiating chest compressions in the hypothermic patient because these arrhythmias require no immediate treatment. Because of the neuroprotective effects of hypothermia, complete recovery of patients with hypothermia and cardiac arrest has been well documented despite prolonged resuscitation (sometimes up to several hours).",
"     </li>",
"     <li>",
"      In critically ill patients, standard practices are employed to reduce the risk of brain injury and other morbidities. Common interventions are described in the text. There is no good evidence to support the routine use of glucocorticoids or prophylactic antibiotics in nonfatal drowning victims. Mechanical ventilatory strategies are similar to those employed in other types of acute lung injury. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Neurologic injuries'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Respiratory failure or infection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the symptomatic patient, indications for intubation include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Signs of neurologic deterioration or inability to protect the airway",
"     </li>",
"     <li>",
"      Inability to maintain a PaO2 above 60 mmHg or oxygen saturation (SpO2) above 90 percent despite high-flow supplemental oxygen",
"     </li>",
"     <li>",
"      PaCO2 above 50 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In symptomatic patients who do not require immediate intubation, supplemental oxygen should be provided to maintain the SpO2 above 94 percent. In addition, noninvasive positive pressure ventilation via CPAP (continuous positive airway pressure) or BLPAP (bi-level positive airway pressure) can improve oxygenation and decrease ventilation-perfusion mismatch. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Emergency department management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wet clothing should be removed and rewarming initiated in hypothermic patients. Rewarming techniques are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link\">",
"       \"Accidental hypothermia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Guidelines for patient disposition are provided in the text; symptomatic patients should be admitted. (See",
"      <a class=\"local\" href=\"#H49707110\">",
"       'Patient disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94242354\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/1\">",
"      Papa L, Hoelle R, Idris A. Systematic review of definitions for drowning incidents. Resuscitation 2005; 65:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/2\">",
"      Salomez F, Vincent JL. Drowning: a review of epidemiology, pathophysiology, treatment and prevention. Resuscitation 2004; 63:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/3\">",
"      Bierens JJ, Knape JT, Gelissen HP. Drowning. Curr Opin Crit Care 2002; 8:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/4\">",
"      Orlowski JP. Drowning, near-drowning, and ice-water drowning. JAMA 1988; 260:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/5\">",
"      Modell JH. Drown versus near-drown: a discussion of definitions. Crit Care Med 1981; 9:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/6\">",
"      Golden FS, Tipton MJ, Scott RC. Immersion, near-drowning and drowning. Br J Anaesth 1997; 79:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/7\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/8\">",
"      Idris AH, Berg RA, Bierens J, et al. Recommended guidelines for uniform reporting of data from drowning: the \"Utstein style\". Circulation 2003; 108:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/9\">",
"      Youn CS, Choi SP, Yim HW, Park KN. Out-of-hospital cardiac arrest due to drowning: An Utstein Style report of 10 years of experience from St. Mary's Hospital. Resuscitation 2009; 80:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/10\">",
"      Brenner RA. Prevention of drowning in infants, children, and adolescents. Pediatrics 2003; 112:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/11\">",
"      Quan L, Cummings P. Characteristics of drowning by different age groups. Inj Prev 2003; 9:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/12\">",
"      Cohen RH, Matter KC, Sinclair SA, et al. Unintentional pediatric submersion-injury-related hospitalizations in the United States, 2003. Inj Prev 2008; 14:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/13\">",
"      Peden MM, McGee K. The epidemiology of drowning worldwide. Inj Control Saf Promot 2003; 10:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Drowning--United States, 2005-2009. MMWR Morb Mortal Wkly Rep 2012; 61:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Nonfatal and fatal drownings in recreational water settings--United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2004; 53:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/16\">",
"      Bowman SM, Aitken ME, Robbins JM, Baker SP. Trends in US pediatric drowning hospitalizations, 1993-2008. Pediatrics 2012; 129:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/17\">",
"      Ellis AA, Trent RB. Hospitalizations for near drowning in California: incidence and costs. Am J Public Health 1995; 85:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/18\">",
"      DeNicola LK, Falk JL, Swanson ME, et al. Submersion injuries in children and adults. Crit Care Clin 1997; 13:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/19\">",
"      Olshaker JS. Near drowning. Emerg Med Clin North Am 1992; 10:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/20\">",
"      Quan L, Gore EJ, Wentz K, et al. Ten-year study of pediatric drownings and near-drownings in King County, Washington: lessons in injury prevention. Pediatrics 1989; 83:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/21\">",
"      CRAIG AB Jr. Causes of loss of consciousness during underwater swimming. J Appl Physiol 1961; 16:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/22\">",
"      Cummings P, Quan L. Trends in unintentional drowning: the role of alcohol and medical care. JAMA 1999; 281:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/23\">",
"      Tester DJ, Kopplin LJ, Creighton W, et al. Pathogenesis of unexplained drowning: new insights from a molecular autopsy. Mayo Clin Proc 2005; 80:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/24\">",
"      Diekema DS, Quan L, Holt VL. Epilepsy as a risk factor for submersion injury in children. Pediatrics 1993; 91:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/25\">",
"      Brehaut JC, Miller A, Raina P, McGrail KM. Childhood behavior disorders and injuries among children and youth: a population-based study. Pediatrics 2003; 111:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/26\">",
"      Smith GS, Keyl PM, Hadley JA, et al. Drinking and recreational boating fatalities: a population-based case-control study. JAMA 2001; 286:2974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/27\">",
"      Brenner RA, Saluja G, Smith GS. Swimming lessons, swimming ability, and the risk of drowning. Inj Control Saf Promot 2003; 10:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/28\">",
"      Bell GS, Gaitatzis A, Bell CL, et al. Drowning in people with epilepsy: how great is the risk? Neurology 2008; 71:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/29\">",
"      Kenny D, Martin R. Drowning and sudden cardiac death. Arch Dis Child 2011; 96:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/30\">",
"      Ibsen LM, Koch T. Submersion and asphyxial injury. Crit Care Med 2002; 30:S402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/31\">",
"      Karpovich, PV. Water in the lungs in drowned animals. Arch Pathol 1933; 15:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/32\">",
"      Giammona ST. Drowning: pathophysiology and management. Curr Probl Pediatr 1971; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/33\">",
"      Modell JH. Drowning. N Engl J Med 1993; 328:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/34\">",
"      Battaglia JD, Lockhart CH. Drowning and near-drowning. Pediatr Ann 1977; 6:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/35\">",
"      Modell JH, Davis JH. Electrolyte changes in human drowning victims. Anesthesiology 1969; 30:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/36\">",
"      Modell JH, Moya F. Effects of volume of aspirated fluid during chlorinated fresh water drowning. Anesthesiology 1966; 27:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/37\">",
"      Modell JH, Moya F, Newby EJ, et al. The effects of fluid volume in seawater drowning. Ann Intern Med 1967; 67:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/38\">",
"      Orlowski JP, Szpilman D. Drowning. Rescue, resuscitation, and reanimation. Pediatr Clin North Am 2001; 48:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/39\">",
"      Harries MG. Drowning in man. Crit Care Med 1981; 9:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/40\">",
"      Harries M. Near drowning. BMJ 2003; 327:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/41\">",
"      McGillicuddy JE. Cerebral protection: pathophysiology and treatment of increased intracranial pressure. Chest 1985; 87:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/42\">",
"      Sarnaik AP, Preston G, Lieh-Lai M, Eisenbrey AB. Intracranial pressure and cerebral perfusion pressure in near-drowning. Crit Care Med 1985; 13:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/43\">",
"      Gonzalez-Rothi RJ. Near drowning: consensus and controversies in pulmonary and cerebral resuscitation. Heart Lung 1987; 16:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/44\">",
"      Rivers JF, Orr G, Lee HA. Drowning. Its clinical sequelae and management. Br Med J 1970; 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/45\">",
"      Yagil Y, Stalnikowicz R, Michaeli J, Mogle P. Near drowning in the dead sea. Electrolyte imbalances and therapeutic implications. Arch Intern Med 1985; 145:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/46\">",
"      Fandel I, Bancalari E. Near-drowning in children: clinical aspects. Pediatrics 1976; 58:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/47\">",
"      Bonnor R, Siddiqui M, Ahuja TS. Rhabdomyolysis associated with near-drowning. Am J Med Sci 1999; 318:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/48\">",
"      Layon AJ, Modell JH. Drowning: Update 2009. Anesthesiology 2009; 110:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/49\">",
"      Venema AM, Groothoff JW, Bierens JJ. The role of bystanders during rescue and resuscitation of drowning victims. Resuscitation 2010; 81:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/50\">",
"      Watson RS, Cummings P, Quan L, et al. Cervical spine injuries among submersion victims. J Trauma 2001; 51:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/51\">",
"      Rosen P, Stoto M, Harley J. The use of the Heimlich maneuver in near drowning: Institute of Medicine report. J Emerg Med 1995; 13:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/52\">",
"      Giesbrecht GG. Cold stress, near drowning and accidental hypothermia: a review. Aviat Space Environ Med 2000; 71:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/53\">",
"      Jolly BT, Ghezzi KT. Accidental hypothermia. Emerg Med Clin North Am 1992; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/54\">",
"      Noonan L, Howrey R, Ginsburg CM. Freshwater submersion injuries in children: a retrospective review of seventy-five hospitalized patients. Pediatrics 1996; 98:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/55\">",
"      Pratt FD, Haynes BE. Incidence of \"secondary drowning\" after saltwater submersion. Ann Emerg Med 1986; 15:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/56\">",
"      Causey AL, Tilelli JA, Swanson ME. Predicting discharge in uncomplicated near-drowning. Am J Emerg Med 2000; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/57\">",
"      Conn AW, Edmonds JF, Barker GA. Cerebral resuscitation in near-drowning. Pediatr Clin North Am 1979; 26:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/58\">",
"      Nussbaum E, Maggi JC. Pentobarbital therapy does not improve neurologic outcome in nearly drowned, flaccid-comatose children. Pediatrics 1988; 81:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/59\">",
"      Bohn DJ, Biggar WD, Smith CR, et al. Influence of hypothermia, barbiturate therapy, and intracranial pressure monitoring on morbidity and mortality after near-drowning. Crit Care Med 1986; 14:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/60\">",
"      Ender PT, Dolan MJ. Pneumonia associated with near-drowning. Clin Infect Dis 1997; 25:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/61\">",
"      Guenther U, Varelmann D, Putensen C, Wrigge H. Extended therapeutic hypothermia for several days during extracorporeal membrane-oxygenation after drowning and cardiac arrest Two cases of survival with no neurological sequelae. Resuscitation 2009; 80:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/62\">",
"      Thalmann M, Trampitsch E, Haberfellner N, et al. Resuscitation in near drowning with extracorporeal membrane oxygenation. Ann Thorac Surg 2001; 72:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/63\">",
"      Pearn J. Pathophysiology of drowning. Med J Aust 1985; 142:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/64\">",
"      Anker AL, Santora T, Spivey W. Artificial surfactant administration in an animal model of near drowning. Acad Emerg Med 1995; 2:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/65\">",
"      Varisco BM, Palmatier CM, Alten JA. Reversal of intractable hypoxemia with exogenous surfactant (calfactant) facilitating complete neurological recovery in a pediatric drowning victim. Pediatr Emerg Care 2010; 26:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/66\">",
"      Hildebrand CA, Hartmann AG, Arcinue EL, et al. Cardiac performance in pediatric near-drowning. Crit Care Med 1988; 16:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/67\">",
"      Bierens JJ, van der Velde EA, van Berkel M, van Zanten JJ. Submersion in The Netherlands: prognostic indicators and results of resuscitation. Ann Emerg Med 1990; 19:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/68\">",
"      Orlowski JP. Prognostic factors in pediatric cases of drowning and near-drowning. JACEP 1979; 8:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/69\">",
"      Biggart MJ, Bohn DJ. Effect of hypothermia and cardiac arrest on outcome of near-drowning accidents in children. J Pediatr 1990; 117:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/70\">",
"      Dean JM, Kaufman ND. Prognostic indicators in pediatric near-drowning: the Glasgow coma scale. Crit Care Med 1981; 9:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/71\">",
"      Lavelle JM, Shaw KN. Near drowning: is emergency department cardiopulmonary resuscitation or intensive care unit cerebral resuscitation indicated? Crit Care Med 1993; 21:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/72\">",
"      Levin DL, Morriss FC, Toro LO, et al. Drowning and near-drowning. Pediatr Clin North Am 1993; 40:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/73\">",
"      Quan L, Wentz KR, Gore EJ, Copass MK. Outcome and predictors of outcome in pediatric submersion victims receiving prehospital care in King County, Washington. Pediatrics 1990; 86:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/74\">",
"      Suominen P, Baillie C, Korpela R, et al. Impact of age, submersion time and water temperature on outcome in near-drowning. Resuscitation 2002; 52:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/75\">",
"      Habib DM, Tecklenburg FW, Webb SA, et al. Prediction of childhood drowning and near-drowning morbidity and mortality. Pediatr Emerg Care 1996; 12:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/76\">",
"      Weinstein MD, Krieger BP. Near-drowning: epidemiology, pathophysiology, and initial treatment. J Emerg Med 1996; 14:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/77\">",
"      Oakes DD, Sherck JP, Maloney JR, Charters AC 3rd. Prognosis and management of victims of near-drowning. J Trauma 1982; 22:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/78\">",
"      Christensen DW, Jansen P, Perkin RM. Outcome and acute care hospital costs after warm water near drowning in children. Pediatrics 1997; 99:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/79\">",
"      Gonzalez-Luis G, Pons M, Cambra FJ, et al. Use of the Pediatric Risk of Mortality Score as predictor of death and serious neurologic damage in children after submersion. Pediatr Emerg Care 2001; 17:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/80\">",
"      Bratton SL, Jardine DS, Morray JP. Serial neurologic examinations after near drowning and outcome. Arch Pediatr Adolesc Med 1994; 148:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/81\">",
"      Smith, DS. Notes on drowning: The misunderstood preventable tragedy. Phys Sports Med 1984; 12:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/82\">",
"      O'Flaherty JE, Pirie PL. Prevention of pediatric drowning and near-drowning: a survey of members of the American Academy of Pediatrics. Pediatrics 1997; 99:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26809/abstract/83\">",
"      Modell JH. Prevention of needless deaths from drowning. South Med J 2010; 103:650.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 180 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26809=[""].join("\n");
var outline_f26_11_26809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9385417\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      END ORGAN EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acid-base and electrolytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49705267\">",
"      Coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prehospital care and acute interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Emergency department management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49707110\">",
"      Patient disposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Neurologic injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Respiratory failure or infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9385417\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94242354\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/180\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/180|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/19/42289\" title=\"diagnostic image 1\">",
"      CT scan of pulmonary edema from near-drowning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=related_link\">",
"      Accidental hypothermia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=related_link\">",
"      Acute asthma exacerbations in children: Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23943?source=related_link\">",
"      Aeromonas infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=related_link\">",
"      Basic life support in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30425?source=related_link\">",
"      Overview of the management of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/9/10394?source=related_link\">",
"      Perioperative care of the surgical patient with neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7530?source=related_link\">",
"      Treatment of hypothermia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_11_26810="Acute traumatic spinal cord injury";
var content_f26_11_26810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute traumatic spinal cord injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/11/26810/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26810/contributors\">",
"     Robert R Hansebout, MD, FRCS(C), FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26810/contributors\">",
"     Edward Kachur, MD, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/11/26810/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26810/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26810/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/11/26810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/11/26810/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/11/26810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord injury has become epidemic in modern society. Despite advances made in the understanding of the pathogenesis and improvements in early recognition and treatment, it remains a devastating event, often producing severe and permanent disability. With a peak incidence in young adults, traumatic spinal cord injury remains a costly problem for society; direct medical expenses accrued over the lifetime of one patient range from 500,000 to 2 million US dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews acute traumatic spinal cord injury. The anatomy and clinical localization of spinal cord disease, other diseases affecting the spinal cord, and the chronic complications of spinal cord injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most demographic and epidemiological data related to traumatic spinal cord injury (TSCI) in the United States have been collected by the Model Spinal Cord Care Systems and are published by the National Spinal Cord Injury Statistical Center [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United States, the incidence of TSCI is about 40 per million persons per year, with approximately 250,000 living survivors of TSCI in the United States in July 2005. Similar figures are reported in Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes of TSCI in the United States are [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Motor vehicle accidents: 47 percent",
"     </li>",
"     <li>",
"      Falls: 23 percent",
"     </li>",
"     <li>",
"      Violence (especially gunshot wounds): 14 percent",
"     </li>",
"     <li>",
"      Sports accidents: 9 percent",
"     </li>",
"     <li>",
"      Other: 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Statistics differ somewhat in other countries. In Canada and western Europe, TSCI due to violence is rare, while in developing countries, violence is even more common [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for TSCI have been identified. Prior to 2000, the most frequent victim was a young male with a median age of 22. Since that time, the average age has increased in the United States to 38 years, presumably as a reflection of the aging population. Males continue to make up 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]. Alcohol plays a role in at least 25 percent of TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Underlying spinal disease can make some patients more susceptible to TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. These conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cervical spondylosis",
"     </li>",
"     <li>",
"      Atlantoaxial instability",
"     </li>",
"     <li>",
"      Congenital conditions, eg, tethered cord",
"     </li>",
"     <li>",
"      Osteoporosis",
"     </li>",
"     <li>",
"      Spinal arthropathies, including ankylosing spondylitis or rheumatoid arthritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical manifestations of ankylosing spondylitis in adults\", section on 'Neurologic manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"       \"Cervical subluxation in rheumatoid arthritis\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most spinal cord injuries are produced in association with injury to the vertebral column. These can include any one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fracture of one or more of the bony elements",
"     </li>",
"     <li>",
"      Dislocation at one or more joints",
"     </li>",
"     <li>",
"      Tearing of ligament(s)",
"     </li>",
"     <li>",
"      Disruption",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      herniation of the intervertebral disc",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The injury reflects the force and direction of the traumatic event and subsequent fall, which produces pathologic flexion, rotation, extension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    compression of the spine, as well as the anatomic vulnerability of individual spinal elements. Most vertebral injuries in adults involve both fracture and dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1\">",
"     1",
"    </a>",
"    ]. The type of injury has implications for the stability of the spinal column and the risk for further spinal cord injury (",
"    <a class=\"graphic graphic_table graphicRef52922 \" href=\"UTD.htm?32/28/33228\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms surrounding injury to the spinal cord itself are often discussed in terms of primary and secondary injury. The primary injury refers to the immediate effect of trauma which includes forces of compression, contusion, and shear injury to the spinal cord. In the absence of cord transection or frank hemorrhage (both relatively rare in nonpenetrating injuries), the spinal cord may appear pathologically normal immediately after trauma. Penetrating injuries (eg, knife and gunshot injuries) usually produce a complete or partial transection of the spinal cord. An increasingly described phenomenon, however, is a spinal cord injury following a gunshot wound that does not enter the spinal canal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/9\">",
"     9",
"    </a>",
"    ]. Presumably, the spinal cord injury in these cases results from kinetic energy emitted by the bullet.",
"   </p>",
"   <p>",
"    A secondary, progressive mechanism of cord injury usually follows, beginning within minutes and evolving over several hours after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1,10-13\">",
"     1,10-13",
"    </a>",
"    ]. The processes propagating this phenomenon are complex and incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Possible mechanisms include ischemia, hypoxia, inflammation, edema, excitotoxicity, disturbances of ion homeostasis, and apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1,14,16\">",
"     1,14,16",
"    </a>",
"    ]. The phenomenon of secondary injury is sometimes clinically manifest by neurologic deterioration over the first 8 to 12 hours in patients who initially present with an incomplete cord syndrome.",
"   </p>",
"   <p>",
"    As a result of these secondary processes, spinal cord edema develops within hours of injury, becomes maximal between the third and sixth day after injury, and begins to recede after the ninth day. This is gradually replaced by a central hemorrhagic necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with a cord injury typically has pain at the site of the spinal fracture. This is not always a reliable feature to exclude traumatic spinal cord injury (TSCI). Patients with TSCI often have associated brain and systemic injuries (eg, hemothorax, extremity fractures, intra-abdominal injury) that may limit the patient's ability to report localized pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. These also complicate the initial evaluation and management of patients with TSCI, and affect prognosis.",
"   </p>",
"   <p>",
"    About half of TSCIs involve the cervical cord and as a result present with quadriparesis or quadriplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. The severity of cord syndromes are classified using the American Spinal Injury Association (ASIA) Scale (",
"    <a class=\"graphic graphic_table graphicRef60383 \" href=\"UTD.htm?14/56/15243\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complete cord injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a complete cord injury (ASIA grade A), there will be a rostral zone of spared sensory levels (eg, the C5 and higher dermatomes spared in a C5-6 fracture-dislocation), reduced sensation in the next caudal level, and no sensation in levels below, including none in the sacral segments, S4-S5. Similarly, there will be reduced muscle power in the level immediately below the injury, followed by complete paralysis in more caudal myotomes. In the acute stage, reflexes are absent, there is no response to plantar stimulation, and muscle tone is flaccid. A male with a complete TSCI may have priapism. The bulbocavernosus reflex is usually absent. Urinary retention and bladder distension occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H15#H15\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Segmental syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incomplete injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In incomplete injuries (ASIA grades B through D), there are various degrees of motor function in muscles controlled by levels of the spinal cord caudal to the injury. Sensation is also partially preserved in dermatomes below the area of injury. Usually sensation is preserved to a greater extent than motor function because the sensory tracts are located in more peripheral, less vulnerable areas of the cord. The bulbocavernosus reflex and anal sensation are often present.",
"   </p>",
"   <p>",
"    The relative incidence of incomplete versus complete spinal cord injury has increased over the last half century [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1\">",
"     1",
"    </a>",
"    ]. This trend has been attributed to improved initial care and retrieval systems that emphasize the importance of immobilization after injury (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Initial evaluation and treatment'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Central cord syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute central cord syndrome, characterized by disproportionately greater motor impairment in upper compared with lower extremities, bladder dysfunction, and a variable degree of sensory loss below the level of injury, is described after relatively mild trauma in the setting of preexisting cervical spondylosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=see_link&amp;anchor=H3#H3\">",
"     \"Cervical spondylotic myelopathy\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=see_link&amp;anchor=H15#H15\">",
"     \"Cervical spondylotic myelopathy\", section on 'Acute deterioration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H19#H19\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Central cord syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anterior cord syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions affecting the anterior or ventral two-thirds of the spinal cord, sparing the dorsal columns, usually reflect injury to the anterior spinal artery. When this occurs in TSCI, it is believed that this more often represents a direct injury to the anterior spinal cord by retropulsed disc or bone fragments rather than primary disruption of the anterior spinal artery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H17#H17\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Ventral (anterior) cord syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transient paralysis and spinal shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after a spinal cord injury, there may be a physiological loss of all spinal cord function caudal to the level of the injury, with flaccid paralysis, anesthesia, absent bowel and bladder control, and loss of reflex activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In males, especially those with a cervical cord injury, priapism may develop. There may also be bradycardia and hypotension not due to causes other than the spinal cord injury. This altered physiologic state may last several hours to several weeks and is sometimes referred to as spinal shock.",
"   </p>",
"   <p>",
"    We believe that this loss of function may be caused by the loss of potassium within the injured cells in the cord and its accumulation within the extra-cellular space, causing reduced axonal transmission. As the potassium levels normalize within the intracellular and extra-cellular spaces, this spinal shock wears off. Clinical manifestations may normalize, but are more usually replaced by a spastic paresis reflecting more severe morphologic injury to the spinal cord.",
"   </p>",
"   <p>",
"    A transient paralysis with complete recovery is most often described in younger patients with athletic injuries. These patients should undergo evaluation for underlying spinal disease before returning to play.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AND TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     In the field",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary assessment of a patient with trauma in the field follows the ABCD prioritization scheme: Airway, Breathing, Circulation, Disability (neurologic status). If the patient has a head injury, is unconscious or confused, or complains of spinal pain, weakness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of sensation, then a traumatic spinal injury should be assumed. Extreme care should be taken to allow as little movement of the spine as possible to prevent more cord injury. Techniques to minimize spine movement include the use of log-roll movements and a backboard for transfer and placement of a rigid cervical collar [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/22\">",
"     22",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     In the emergency department",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management in the emergency department continues to prioritize assessment and stabilization following the ABCD scheme. Life-threatening priorities related to other injuries, such as systemic bleeding, breathing difficulties, or a pneumothorax, can take precedence over the spinal cord injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital signs including heart rate, blood pressure, respiratory status, and temperature require ongoing monitoring. Capnography can provide a useful method of monitoring respiratory status in the emergency department. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"       \"Carbon dioxide monitoring (capnography)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient with a high cervical cord injury may breathe poorly and may require airway suction or intubation. Respiratory mechanical support may be needed; about one-third of patients with cervical injuries require intubation within the first 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/23\">",
"       23",
"      </a>",
"      ]. Rapid-sequence intubation with in-line spinal immobilization is the preferred method when an airway is urgently required. If time is not an issue, intubation over a flexible fiberoptic laryngoscope may be a safer, effective option. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"       \"Rapid sequence intubation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoxia in the face of cord injury can adversely affect neurologic outcome. Arterial oxygenation should be monitored and supplemented as needed.",
"     </li>",
"     <li>",
"      Hypotension may occur due to blood loss from other injuries or due to blood pooling in the extremities lacking sympathetic tone because of the disruption of the autonomic nervous system (neurogenic shock). Prolonged hypoperfusion may adversely affect prognosis. Elevation of the legs, the head-dependent position, blood replacement,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vasoactive agents may be required.",
"     </li>",
"     <li>",
"      Until spinal injury has been ruled out (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging'",
"      </a>",
"      below), immobilization of the neck and body must be maintained using cervical collar, straps, tape, and blocks. Athletic headgear should be left on.",
"     </li>",
"     <li>",
"      A neurologic examination should be completed as soon as possible to determine the level and severity of the injury, both of which impact prognosis and treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H14#H14\">",
"       \"Anatomy and localization of spinal cord disorders\", section on 'Clinical localization'",
"      </a>",
"      .) An evaluation of mental status and cranial nerve function should be included, as many patients with TSCI have also suffered a head injury.",
"     </li>",
"     <li>",
"      The patient must be checked for bladder distension by palpation or ultrasound. A urinary catheter should be inserted as soon as possible, if not done previously, to avoid harm due to bladder distension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many centers, a full set of cervical spine films are required on all trauma patients before a cervical collar can be removed. Data from the National Emergency X-Radiography Utilization Study (NEXUS) allow this requirement to be modified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients without neurologic deficits, who are alert and not confused, who are not intoxicated, and who have no neck or midline pain or tenderness or other injury that is distracting to the patient are unlikely to have a cervical spine injury. In the NEXUS study, these five criteria had a 99.8 percent negative predictive value for cervical spine injury (sensitivity 99 percent; specificity 12.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/24\">",
"     24",
"    </a>",
"    ]. Similar results have been reported in other large series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are not clinically evaluable for SCI because of obtundation or confusion should be assumed to have a SCI until proven otherwise. In one meta-analysis of studies looking at such patients, the incidence of spine injury was 7.5 percent; 42 percent of these had unstable injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Plain x-rays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain x-rays provide a rapid assessment of alignment, fractures, and soft tissue swelling and are, in general, the first method of assessment of traumatic spinal cord injury (TSCI). A complete set of cervical x-rays includes anteroposterior, lateral, and open-mouth odontoid views. Oblique views may be necessary if one suspects a lateral mass or facet injury or damage. All cervical vertebrae and the top of T1 must be visualized. In muscular males with a neck injury, pulling the shoulders down by pulling down on the wrists in a straight line and downward towards the feet may better allow visualization of the lower cervical vertebrae. A swimmer's view should be performed if the lower cervical levels and the top of T1 are not adequately visualized. While there are reports of missed cervical spine injury with plain films, it is rare to miss significant injuries with adequate performance and interpretation of plain films of the occiput through the top of T1 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurologic signs and symptoms of cervical spine injury in the setting of normal plain x-rays warrant further imaging studies.",
"   </p>",
"   <p>",
"    Patients who have pain in the thoracic or lumbar areas, especially with an appropriate neurologic deficit, also require lateral, anteroposterior, and sometimes oblique plain x-rays of either the thoracic spine, lumbar region, or both. Such spinal injuries, especially with a neurologic deficit, require further imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helical computed tomographic scanning (CT) with coronal and sagittal reconstructions may replace plain films for screening assessment in centers in which it is readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/29\">",
"     29",
"    </a>",
"    ]. Prospective case series report a higher sensitivity for detecting spinal fracture when compared with plain x-rays; this is particularly true for cervical spine fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/28,30-33\">",
"     28,30-33",
"    </a>",
"    ]. This study can also be done without moving the patient out of the supine position. When head CT is required to rule out head injury, it may be most cost and time efficient to use CT as the initial imaging study of the neck as well.",
"   </p>",
"   <p>",
"    All abnormalities on screening plain films or CT are followed up with a more detailed CT scan of the area in question, with fine, 2 mm cuts as needed. Areas not well visualized on plain films should be further imaged as well. This test is very sensitive for defining bone fractures in the spine. Because CT is more sensitive than plain films, patients who are suspected to have a spinal injury and have normal plain films should also undergo CT. CT also has advantages over plain films in assessing the patency of the spinal canal. CT also provides some assessment of the paravertebral soft tissues and perhaps of the spinal cord as well, but is inferior in that regard to magnetic resonance imaging (MRI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Myelography",
"    </span>",
"    &nbsp;&mdash;&nbsp;When MRI is available, myelography is rarely if ever used, but remains an alternative in combination with CT when MRI cannot be performed and spinal canal compromise is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for MRI in the evaluation of acute TSCI have not been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chief advantage of MRI is that it provides a detailed image of the spinal cord as well as spinal ligaments, intervertebral discs, and paraspinal soft tissues that is superior to CT and is more sensitive for detecting epidural hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/34,36-39\">",
"     34,36-39",
"    </a>",
"    ]. CT, however, is better than MRI in assessing bony structures. In the absence of a cord transection or intramedullary hemorrhage, MRI is not perfectly sensitive to cord damage in the earliest stages of TSCI. MRI has other disadvantages: it is contraindicated in the setting of a cardiac pacemaker and metallic foreign bodies, life support equipment may be incompatible with the performance of MRI, and the patient is enclosed during the study, which can pose some risk for monitoring vital signs and for maintaining an airway. In some centers, MRI is not always available because of resource and personnel issues.",
"   </p>",
"   <p>",
"    Nonetheless, if the patient's clinical status permits, MRI can provide valuable information that complements CT regarding the extent and mechanism of spinal cord injury, which can influence treatment and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/34,40\">",
"     34,40",
"    </a>",
"    ]. MRI is also indicated in patients with negative CT scan who are suspected to have TSCI, in order to detect occult ligamentous or disc injury or epidural hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/41\">",
"     41",
"    </a>",
"    ]. In a systematic review of reported case series, 5.8 percent of individuals with negative CT scan who went on to have an MRI were found to have a traumatic spine injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/42\">",
"     42",
"    </a>",
"    ]. While it has been suggested that nonalert patients require MRI in addition to CT to exclude TSCI, one case series suggests that if obtunded patients are observed to have grossly normal motor movement in all extremities, CT scan is sufficient in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Spinal cord injury without radiographic abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A category of TSCI called spinal cord injury without radiographic abnormality (SCIWORA) originated prior to the use of MRI and referred to patients with a myelopathy without evidence of traumatic vertebral injury on plain x-rays or CT. Because MRI provides superior imaging of the spinal cord, it can detect injuries to the cord that exist despite the apparent absence of bony abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A common explanation for this phenomenon is transient ligamentous deformation with spontaneous reduction. This is more often described in children who have weak paraspinal muscles, elastic spinal ligaments, and lax soft tissues, which fail to protect the spinal cord from force, but has also been described in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4951?source=see_link&amp;anchor=H26107899#H26107899\">",
"     \"Spinal cord injury without radiographic abnormality (SCIWORA) in children\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\", section on 'Evaluation for ligamentous injury and SCIWORA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other possible mechanisms for SCIWORA include radiographically occult intravertebral disc herniation, epidural or intramedullary hemorrhage, fibrocartilaginous emboli from an intervertebral disc that has ruptured into the radicular artery, and traumatic aortic dissection with spinal cord infarction. MRI is invaluable for the diagnosis of these conditions.",
"   </p>",
"   <p>",
"    Diagnostic evaluation of this phenomenon in the obtunded patient is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\", section on 'Evaluation for ligamentous injury and SCIWORA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Medical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with traumatic spinal cord injury (TSCI) require intensive medical care and continuous monitoring of vital signs, cardiac rhythm, arterial oxygenation, and neurologic signs in the intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/45\">",
"     45",
"    </a>",
"    ]. A number of systemic as well as neurologic complications are common in the first days and weeks after TSCI, contribute substantively to prognosis, and are potentially avoidable or ameliorated with early intervention.",
"   </p>",
"   <p>",
"    The management of medical issues specific to spinal cord injury is discussed here. The general medical care of the trauma patient is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=see_link\">",
"     \"Overview of inpatient management in the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25317479\">",
"    <span class=\"h3\">",
"     Cardiovascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurogenic shock refers to hypotension, usually with bradycardia, attributed to interruption of autonomic pathways in the spinal cord causing decreased vascular resistance. Patients with TSCI may also suffer from hemodynamic shock related to blood loss and other complications. An adequate blood pressure is believed to be critical in maintaining adequate perfusion to the injured spinal cord and thereby limiting secondary ischemic injury. Albeit with little empiric supporting data, guidelines currently recommend maintaining mean arterial pressures of at least 85 to 90 mmHg, using intravenous fluids, transfusion, and pharmacologic vasopressors as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Maintenance of blood pressure intraoperatively is also important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Patients with multiple injuries often receive large amounts of intravenous fluids for various reasons. Excess fluids cause further cord swelling and increased damage. Therefore, fluid administration, urinary output, and electrolyte levels must be carefully monitored.",
"   </p>",
"   <p>",
"    Bradycardia may require external pacing or administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    . This complication usually occurs in severe, high cervical (C1 through C5) lesions in the first two weeks after TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autonomic dysreflexia is usually a later complication of TSCI, but may appear in the hospital setting, requiring acute management [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/51\">",
"     51",
"    </a>",
"    ]. This phenomenon is characterized by episodic paroxysmal hypertension with headache, bradycardia, flushing, and sweating. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H4#H4\">",
"     \"Chronic complications of spinal cord injury\", section on 'Autonomic dysreflexia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25317487\">",
"    <span class=\"h3\">",
"     Respiratory complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications, including respiratory failure, pulmonary edema, pneumonia, and pulmonary embolism, are the most frequent category of complications during acute hospitalization after TSCI and contribute substantively to early morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/36,52-54\">",
"     36,52-54",
"    </a>",
"    ]. The incidence of these complications is highest with higher cervical lesions (up to 84 percent), but they are also common with thoracic lesions (65 percent).",
"   </p>",
"   <p>",
"    Weakness of the diaphragm and chest wall muscles leads to impaired clearance of secretions, ineffective cough, atelectasis, and hypoventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23321?source=see_link\">",
"     \"Respiratory physiologic changes following spinal cord injury\"",
"    </a>",
"    .) Signs of impending respiratory failure, such as increased respiratory rate, declining forced vital capacity, rising pCO2, or falling pO2, indicate urgent intubation and ventilation with positive pressure support [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/36,54\">",
"     36,54",
"    </a>",
"    ]. Rapid-sequence intubation with in-line spinal immobilization is the preferred method of intubation when an airway is urgently required. If time is not an issue, intubation over a flexible fiberoptic scope may be a safer, effective option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .) Tracheostomy is performed within 7 to 10 days, unless extubation is imminent.",
"   </p>",
"   <p>",
"    With a goal of preventing atelectasis and pneumonia, chest physiotherapy should be instituted as soon as possible; patients may also need frequent suctioning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25317506\">",
"    <span class=\"h3\">",
"     Venous thromboembolism and pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep venous thrombosis (DVT) is a common complication of TSCI, occurring in 50 to 100 percent of untreated patients, with the greatest incidence between 72 hours and 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The level and severity of TSCI does not clearly have an impact on the risk for DVT; all patients should receive prophylactic treatment.",
"   </p>",
"   <p>",
"    Low-molecular-weight (LMW)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is considered the treatment of choice for patients with TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Combining this treatment with pneumatic compression stockings may provide additional benefits, but this has not been studied. Use of either low-dose unfractionated heparin therapy or pneumatic compression stockings as monotherapy is considered inadequate protection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/60\">",
"     60",
"    </a>",
"    ], but combination therapy with these two approaches may be considered an alternative to LMW heparin. Inferior vena cava filters should be inserted for patients for whom anticoagulation is contraindicated. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H34#H34\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Group specific recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25317521\">",
"    <span class=\"h3\">",
"     Other medical complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain control. After spinal injuries, patients usually require pain relief. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"       \"Pain control in the critically ill adult patient\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      When using opiates with potential sedating properties, the need for pain control must be balanced with the need for ongoing clinical assessment, particularly in patients with concomitant head injury. Pain is often reduced by realignment and stabilization of the cervical fracture by surgery or external orthosis (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Decompression and stabilization'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Pressure sores. Pressure sores are most common on the buttocks and heels and can develop quickly (within hours) in immobilized patients. Backboards should be used only to transport patients with potentially unstable spinal injury and discontinued as soon as possible. After spinal stabilization, the patient should be turned side to side (log-rolled) every two to three hours to avoid pressure sores. Rotating beds designed for the patient with spinal cord injury should be used in the interim, if available.",
"     </li>",
"     <li>",
"      Urinary catheterization. Initially, an indwelling urinary catheter must be used to avoid bladder distension. Three or four days after injury, intermittent catheterization should be substituted, as this reduces the incidence of bladder infections.",
"     </li>",
"     <li>",
"      Gastrointestinal stress ulceration. Patients with TSCIs, particularly those that affect the cervical cord, are at high risk for stress ulceration [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/61\">",
"       61",
"      </a>",
"      ]. Prophylaxis with proton pump inhibitors is recommended upon admission for four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"       \"Stress ulcer prophylaxis in the intensive care unit\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paralytic ileus. Bowel motility may be silent for a few days to weeks after TSCI. Patients should be monitored for bowel sounds and bowel emptying, and should not ingest food or liquid until motility is restored [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Temperature control. Patients with a cervical spinal cord injury may lack vasomotor control and cannot sweat below the lesion. Their temperature may vary with the environment and need to be maintained.",
"     </li>",
"     <li>",
"      Functional recovery. Occupational and physiotherapy should be started as soon as possible. Psychological counseling is also best offered to patients and relatives as early as possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     Methylprednisolone",
"    </a>",
"    is the only treatment that has been suggested in clinical trials to improve outcomes in patients with acute, nonpenetrating TSCI. However, the evidence is limited, and its use is debated.",
"   </p>",
"   <p>",
"    In animal experiments, administration of glucocorticoids after a spinal cord injury reduces edema, prevents intracellular potassium depletion, and improves neurologic recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. The best results were observed with administration within the first eight hours after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/11\">",
"     11",
"    </a>",
"    ]. Some authors believe that the main effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    on the spinal cord recovery was the inhibition of lipid peroxidation, and that late administration of steroids may have little effect on lipid peroxidation and interfere with regenerative processes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two blinded, randomized controlled trials have studied the efficacy of glucocorticoid therapy in patients with acute TSCI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Acute Spinal Cord Injury Study (NASCIS) II compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenous [IV], followed by 5.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour over 23 more hours),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      , and placebo in 427 acute TSCI patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/65\">",
"       65",
"      </a>",
"      ]. At one year, there was no significant difference in neurologic function among treatment groups. However, within the subset of patients treated within eight hours, those who received methylprednisolone had a modest improvement in motor recovery compared with those who received placebo. Wound infections were somewhat more common in patients who received methylprednisolone.",
"     </li>",
"     <li>",
"      NASCIS III compared three treatment groups:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      administered for 48 hours, methylprednisolone administered for 24 hours, and tirilazad mesylate (a potent lipid peroxidation inhibitor) administered for 48 hours in patients with acute complete or incomplete TSCI [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/66\">",
"       66",
"      </a>",
"      ]. All 499 patients received an initial IV bolus of 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      methylprednisolone and were treated within eight hours of TSCI. For patients treated within three hours, there was no difference in outcomes among treatment groups at one year. For patients treated between three to eight hours, 48 hours of methylprednisolone was associated with a greater motor but not functional recovery, compared with other treatments. Patients who received the longer duration infusion of methylprednisolone had more severe sepsis and severe pneumonia compared with the shorter duration of infusion; mortality was similar in all treatment groups [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of NASCIS II with two other small trials (one positive and one negative) concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    administered within eight hours of spinal cord injury resulted in improved motor recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While administration of glucocorticoids has become a standard treatment in many centers for patients with acute TSCI, other centers are unconvinced [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/11,69-72\">",
"     11,69-72",
"    </a>",
"    ]. The beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    compared with placebo is seen as linked to a post hoc subgroup analysis in one study (NASCIS II), although the investigators assert that early versus late treatment was an a priori hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/70,73\">",
"     70,73",
"    </a>",
"    ]. The cut-off times of eight hours and three hours have been seen as arbitrary. Actual gain in motor scores seen in treated patients can be interpreted as marginal. Some clinicians also believe that the potential adverse effects of glucocorticoid administration have been underemphasized, particularly with the longer, 48-hour administration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2002, based upon the available evidence, the American Association of Neurological Surgeons and Congress of Neurological Surgeons concluded that the use of glucocorticoids in acute spinal cord injury is recommended only at the level of a treatment option [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/74\">",
"     74",
"    </a>",
"    ]. Position statements from the Canadian Association of Emergency Physicians, and endorsed by the American Academy of Emergency Medicine, concur that treatment with glucocorticoids is a treatment option and not a treatment standard [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. A Consortium for Spinal Cord medicine similarly concluded that \"no clinical evidence exists to definitely recommend\" the use of steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/78\">",
"     78",
"    </a>",
"    ]. In a survey of 305 neurosurgeons in the United States, 91 percent used glucocorticoids to treat patients with nonpenetrating TSCI within eight hours of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are little data regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    with penetrating injuries. However, retrospective studies suggest a higher rate of complications and no evidence of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Most clinicians do not use glucocorticoids for penetrating spinal cord injury.",
"   </p>",
"   <p>",
"    Similarly, the results of NASCIS II and III studies may not apply to individuals with multisystem trauma, in whom the risk of complications is likely higher than those with isolated spinal cord injury. Patients with multisystem trauma were not specifically excluded from these trials, but may have been somewhat under-represented [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Decompression and stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no standards regarding the role, timing, and method of vertebral decompression in acute spinal cord injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/16\">",
"     16",
"    </a>",
"    ]. Options include closed reduction using traction and open surgical procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Closed reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cervical spine fracture with subluxation, closed reduction methods are a treatment option. Thoracic and lumbar fractures do not respond to closed treatment methods.",
"   </p>",
"   <p>",
"    This technique involves use of traction using skull tongs or a halo headpiece. An initial weight of 5 to 15 pounds is applied; this is increased in five-pound increments, taking lateral x-rays after each increment is applied. The more rostral the dislocation, the less weight is used, usually about three to five pounds per vertebral level. While weights up to 70 pounds are sometimes used, we suggest that after 35 pounds is applied, patients be observed for at least an hour with repeat cervical spine x-rays before the weight is cautiously increased further. Administration of a muscle relaxant or analgesic, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , may help facilitate reduction.",
"   </p>",
"   <p>",
"    Closed reduction may obviate surgery and promote neurologic improvement in some cases. Early reports raised a concern that closed reduction in the setting of associated disc disruption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    herniation has the potential to exacerbate neurologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. However, more recent prospective case series and a systemic literature review suggest that this is probably not an important concern [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. In one series of 82 patients with cervical subluxation injuries, early rapid closed reduction was achieved in 98 percent, failing in just two patients who required open surgical reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/84\">",
"     84",
"    </a>",
"    ]. The average time to achieve reduction was two hours. Disc herniation and disruption were noted in 46 percent of post-procedure MRIs, but these did not affect neurologic outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goals for surgical intervention in TSCI include stabilization of the spine, as well as reduction of dislocations and decompression of neural elements. There are no evidence-based guidelines regarding the indications for or timing of surgery in TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/87\">",
"     87",
"    </a>",
"    ]. In general, the specific management of cervical, thoracic, and lumbar spine and spinal cord injuries depends to a large extent on a surgeon's personal experience and practice norms in his or her center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25317529\">",
"    <span class=\"h4\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for cervical spine surgery include significant cord compression with neurologic deficits, especially those that are progressive, that are not amenable or do not respond to closed reduction, or an unstable vertebral fracture or dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/88\">",
"     88",
"    </a>",
"    ]. Neurologically intact patients are treated nonoperatively unless there is instability of the vertebral column. Most penetrating injuries require surgical exploration to ensure that there are no foreign bodies imbedded in the tissue, and also to clean the wound to prevent infection.",
"    <br/>",
"    <br/>",
"    Defining surgical indications for closed thoracolumbar fractures has been somewhat more challenging, in part because of difficulties defining spinal instability in these lesions. The Denis anatomic-based classification based on a three-column model of spinal stability has somewhat limited clinical utility, as it does not clearly accommodate all fracture types [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/89\">",
"     89",
"    </a>",
"    ]. The Thoracolumbar Injury Severity Score has been proposed as an alternative and uses a scoring system of three variables: the morphology of the injury, the integrity of the posterior ligamentous complex, and the neurologic status of the patient (",
"    <a class=\"graphic graphic_table graphicRef82245 \" href=\"UTD.htm?9/45/9948\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/90\">",
"     90",
"    </a>",
"    ]. A total score of less than four indicates a nonoperative injury; more than four, an operative injury; and four, an injury that is operative at the surgeon's discretion. This algorithm has good intrarater and interrater reliability [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/91\">",
"     91",
"    </a>",
"    ]. The clinical efficacy of the algorithm itself remains to be prospectively evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25317560\">",
"    <span class=\"h4\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of surgical intervention is not defined and remains somewhat controversial. Animal studies suggest that early relief of spinal cord compression (within eight hours) leads to a better neurologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/92-95\">",
"     92-95",
"    </a>",
"    ]. However, older clinical reports suggested that early surgery led to increased medical complications and poorer neurologic outcome, perhaps as a reflection of the vulnerability of the acutely injured cord [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. More contemporary studies suggest that medical complication rates are actually lower in patients who undergo early surgery, which allows for earlier mobilization and reduced intensive care unit and length of hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/99-103\">",
"     99-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trial randomly assigned patients with complete or incomplete cervical TSCI to \"early\" (within 72 hours) or \"late\" (more than five days) surgery and found no significant difference in the improvement of American Spinal Injury Association (ASIA) grade or motor scores between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/104\">",
"     104",
"    </a>",
"    ]. A systematic review analyzed published data regarding the timing of surgical decompression and concluded that early decompression, within 72 hours, can be performed safely, without increasing systemic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/92\">",
"     92",
"    </a>",
"    ]. An impact on neurologic outcome of early versus late surgery could not be determined from the available data. It may be that 72 hours represents too late a cut-off time to define early surgery.",
"   </p>",
"   <p>",
"    A meta-analysis that included patients from nonrandomized case series compared neurologic outcomes in 1687 patients with TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/105\">",
"     105",
"    </a>",
"    ]. Those who received decompressive surgery within 24 hours had a better outcome than either those treated conservatively or with delayed surgery. An analysis of homogeneity suggested that the data in this analysis was not reliable for patients with complete TSCI.",
"   </p>",
"   <p>",
"    Most clinicians consider deteriorating neurologic function after incomplete TSCI to be an indication to perform surgery as early as possible if there are no contraindications (eg, hemorrhagic shock, blood dyscrasias).",
"   </p>",
"   <p>",
"    The role of early surgery with a complete TSCI (ASIA grade A) is debatable given the overall poor prognosis of these patients. While many surgeons operate to stabilize the spine, most defer the surgery to a less immediate time frame. However, many series show that a small percentage of these patients can improve, and it is possible that potential benefits for surgical decompression in this group may be maximized by earlier rather than later surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2010 survey of spine surgeons, the majority (&gt;80 percent of 971 respondents) reported a preference to decompress the spine within 24 hours of TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/106\">",
"     106",
"    </a>",
"    ]. Shorter time intervals (within 6 to 12 hours) are preferred by the majority of surgeons for certain lesions, including incomplete cervical TSCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25317567\">",
"    <span class=\"h4\">",
"     Technical aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all surgical cases require decompression, and not all decompression cases require instrumentation and fusion. The technical aspects of the surgery are tailored to the individual case.",
"   </p>",
"   <p>",
"    In the case of a cervical fracture with a cervical spinal cord injury, the anesthesiologist usually performs a fiberoptic intubation, done with the patient awake to reduce any further cord injury that potentially could be caused by a regular intubation with neck movement and extension [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/107\">",
"     107",
"    </a>",
"    ]. There is a risk for regurgitation and aspiration with the patient in a head-dependent position. Anesthetists are also usually involved in the postoperative care of patients with TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Investigational treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of strategies are being investigated as potential treatments of acute TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/14\">",
"     14",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spinal cord cooling [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/109,110\">",
"       109,110",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Electrical stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/111\">",
"       111",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autologous macrophages [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/112\">",
"       112",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thyrotropin-releasing hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/113\">",
"       113",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neuronal growth factors [",
"      <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gangliosides are endogenous compounds in cell membranes, which are believed to have the potential to protect nerve cells and promote axon growth. GM-1 ganglioside treatment has been studied in two randomized clinical trials. In one study, 34 patients were treated within 72 hours of TSCI for 18 to 32 days. Treatment was associated with a higher likelihood of improving by at least two grades compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/114\">",
"     114",
"    </a>",
"    ]. However, in a follow-up trial of 797 patients with TSCI, there was no difference between placebo and treated patients in a similar outcome measure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/115\">",
"     115",
"    </a>",
"    ]. Gangliosides are not recommended in the treatment of TSCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early death rates after admission for traumatic spinal cord injury (TSCI) range from 4 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/1,3,117,118\">",
"     1,3,117,118",
"    </a>",
"    ]. The patient's age, spinal cord level of injury, and neurologic grade predict survival. Severe systemic injuries, traumatic brain injury, and medical comorbidity also increase mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/119\">",
"     119",
"    </a>",
"    ]. Compared with spinal cord injuries in the thoracic cord or lower, patients with C1 to C3 injuries have a 6.6-fold increased risk of death, C4 to C5 injuries a 2.5 increased risk, and C6 to C8 a 1.5 increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/52\">",
"     52",
"    </a>",
"    ]. Survivors of TSCI have a reduced life expectancy as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic complications of spinal cord injury\", section on 'Life expectancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rates of motor score improvements are also related to the initial severity and level of injury of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/120-122\">",
"     120-122",
"    </a>",
"    ]. The greatest degrees of improvement are seen in those with incomplete injury. Among patients with complete TSCI (ASIA grade A), 10 to 15 percent improve, 3 percent to ASIA grade D [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/36\">",
"     36",
"    </a>",
"    ]; less than 10 percent will be ambulatory at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/122\">",
"     122",
"    </a>",
"    ]. Among patients with an initial ASIA grade B, 54 percent recover to grade C or D, and 40 percent regain some ambulatory ability. Independent ambulation is possible for 62 and 97 percent of patients with an initial ASIA grade of C and D, respectively. Most recovery in patients with incomplete TSCI takes place in the first six months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/123\">",
"     123",
"    </a>",
"    ]. The general expectations for functional recovery based on motor level are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef73350 \" href=\"UTD.htm?42/53/43868\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/11/26810/abstract/124\">",
"     124",
"    </a>",
"    ]. These assume an uncomplicated, complete SCI followed by appropriate rehabilitation interventions in a healthy, motivated individual.",
"   </p>",
"   <p>",
"    Patients with TSCI are at risk for a number of medical complications. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=see_link\">",
"       \"Patient information: Paraplegia and quadriplegia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic spinal cord injury (TSCI) is a problem that largely affects young male adults as a consequence of motor vehicle accidents, falls, or violence. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most TSCI occurs with injury to the vertebral column, producing mechanical compression or distortion of the spinal cord with secondary injuries resulting from ischemic, inflammatory, and other mechanisms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most TSCI is associated with injury to brain, limbs,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      viscera, which can obscure its presentation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The neurologic injury produced by TSCI is classified according to the spinal cord level and the severity of neurologic deficits (",
"      <a class=\"graphic graphic_table graphicRef60383 \" href=\"UTD.htm?14/56/15243\">",
"       table 2",
"      </a>",
"      ). Half of TSCIs involve the cervical spinal cord and produce quadriparesis or quadriplegia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation and management of patients with TSCI in the field and emergency department focuses on the ABCDs (airway, breathing, circulation, and disability), evaluating the extent of traumatic injuries, and immobilizing the potentially injured spinal column. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial evaluation and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with suspected TSCI because of neck pain or neurologic deficits and all trauma victims with impaired alertness or potentially distracting systemic injuries require continued immobilization until imaging studies exclude an unstable spine injury. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All patients with potential TSCI should receive complete spinal imaging with plain x-rays or helical computed tomography (CT) scan.",
"     </li>",
"     <li>",
"      Patients with abnormal screening imaging studies or in whom TSCI remains strongly suspect despite normal screening imaging studies should have follow-up CT scanning with fine cuts through the region of interest (based on localized pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurologic signs).",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) can be useful to further define the extent of TSCI and should be performed on stable patients with TSCI as well as on patients suspected to have TSCI (because of neck pain or neurologic deficits) despite a normal CT scan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with TSCI require urgent neurosurgical consultation to manage efforts at decompression and stabilization. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Decompression and stabilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon the above studies and major society guidelines, neither giving nor not giving glucocorticoids can be considered wrong. We suggest administration of intravenous (IV)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      for patients who present within eight hours of isolated, nonpenetrating TSCI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The standard dose is 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV bolus, followed by an infusion of 5.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour for 23 hours. Glucocorticoid therapy may increase the risk of complications, and neurologic benefits are uncertain and potentially small. As such, risk-benefit assessment in individual patients is advised. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute TSCI require admission to an intensive care unit for monitoring and treatment of potential acute, life-threatening complications, including cardiovascular instability and respiratory failure. Patients with TSCI should receive prophylaxis to protect against deep venous thrombosis and pulmonary embolism (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Medical care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92370232\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/1\">",
"      Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976) 2001; 26:S2.",
"     </a>",
"    </li>",
"    <li>",
"     The National Spinal Cord Injury Statistical Center. file://www.spinalcord.uab.edu/show.asp?durki=21446 (Accessed on May 11, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/3\">",
"      Lenehan B, Street J, Kwon BK, et al. The epidemiology of traumatic spinal cord injury in British Columbia, Canada. Spine (Phila Pa 1976) 2012; 37:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/4\">",
"      Ackery A, Tator C, Krassioukov A. A global perspective on spinal cord injury epidemiology. J Neurotrauma 2004; 21:1355.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Paraplegic Association. file://www.canparaplegic.org/en/SCI_Facts_67/items/6.html (Accessed on May 11, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/6\">",
"      Hasler RM, Exadaktylos AK, Bouamra O, et al. Epidemiology and predictors of cervical spine injury in adult major trauma patients: a multicenter cohort study. J Trauma Acute Care Surg 2012; 72:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/7\">",
"      Vitale MG, Goss JM, Matsumoto H, Roye DP Jr. Epidemiology of pediatric spinal cord injury in the United States: years 1997 and 2000. J Pediatr Orthop 2006; 26:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/8\">",
"      Myers ER, Wilson SE. Biomechanics of osteoporosis and vertebral fracture. Spine (Phila Pa 1976) 1997; 22:25S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/9\">",
"      Mirovsky Y, Shalmon E, Blankstein A, Halperin N. Complete paraplegia following gunshot injury without direct trauma to the cord. Spine (Phila Pa 1976) 2005; 30:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/10\">",
"      Ambrozaitis KV, Kontautas E, Spakauskas B, Vaitkaitis D. [Pathophysiology of acute spinal cord injury]. Medicina (Kaunas) 2006; 42:255.",
"     </a>",
"    </li>",
"    <li>",
"     Hansebout RR. Spinal injury and spinal cord blood flow, The Effect of Early Treatment and Local Cooling. In: Spinal Cord Dysfunction: Intervention and Treatment, Illis LS (Ed), Oxford Press, 1992. Vol 2, p.58.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/12\">",
"      Allen AR. Remarks on the histopathological changes in the spinal cord due to impact an experimental study. J Ner Ment Dis 1914; 41:141.",
"     </a>",
"    </li>",
"    <li>",
"     Hansebout RR. The Neurosurgical Management of Cord Injuries. In: Management of Spinal Cord Injuries, Bloch R, Basbaum M (Eds), Williams and Wilkins, Rehabilitation Medicine Library, 1986. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/14\">",
"      Janssen L, Hansebout RR. Pathogenesis of spinal cord injury and newer treatments. A review. Spine (Phila Pa 1976) 1989; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/15\">",
"      Tator CH. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol 1995; 5:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/16\">",
"      Fehlings MG, Perrin RG. The role and timing of early decompression for cervical spinal cord injury: update with a review of recent clinical evidence. Injury 2005; 36 Suppl 2:B13.",
"     </a>",
"    </li>",
"    <li>",
"     American Spinal Injury Association. International Standards for Neurological Classification of Spinal Cord Injury. American Spinal Injury Association, Chicago 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/18\">",
"      Morse SD. Acute central cervical spinal cord syndrome. Ann Emerg Med 1982; 11:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/19\">",
"      Ishida Y, Tominaga T. Predictors of neurologic recovery in acute central cervical cord injury with only upper extremity impairment. Spine (Phila Pa 1976) 2002; 27:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/20\">",
"      Ditunno JF, Little JW, Tessler A, Burns AS. Spinal shock revisited: a four-phase model. Spinal Cord 2004; 42:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/21\">",
"      Nankovi V, Snur I, Nankovi S, et al. [Spinal shock. Diagnosis and therapy. Problems and dilemmas]. Lijec Vjesn 1995; 117 Suppl 2:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/22\">",
"      Cervical spine immobilization before admission to the hospital. Neurosurgery 2002; 50:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/23\">",
"      Gardner BP, Watt JW, Krishnan KR. The artificial ventilation of acute spinal cord damaged patients: a retrospective study of forty-four patients. Paraplegia 1986; 24:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/24\">",
"      Hoffman JR, Mower WR, Wolfson AB, et al. Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma. National Emergency X-Radiography Utilization Study Group. N Engl J Med 2000; 343:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/25\">",
"      Gonzalez RP, Cummings GR, Phelan HA, et al. Clinical examination in complement with computed tomography scan: an effective method for identification of cervical spine injury. J Trauma 2009; 67:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/26\">",
"      Halpern CH, Milby AH, Guo W, et al. Clearance of the cervical spine in clinically unevaluable trauma patients. Spine (Phila Pa 1976) 2010; 35:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/27\">",
"      Davis JW, Phreaner DL, Hoyt DB, Mackersie RC. The etiology of missed cervical spine injuries. J Trauma 1993; 34:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/28\">",
"      Berne JD, Velmahos GC, El-Tawil Q, et al. Value of complete cervical helical computed tomographic scanning in identifying cervical spine injury in the unevaluable blunt trauma patient with multiple injuries: a prospective study. J Trauma 1999; 47:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/29\">",
"      Daffner RH, Sciulli RL, Rodriguez A, Protetch J. Imaging for evaluation of suspected cervical spine trauma: a 2-year analysis. Injury 2006; 37:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/30\">",
"      Antevil JL, Sise MJ, Sack DI, et al. Spiral computed tomography for the initial evaluation of spine trauma: A new standard of care? J Trauma 2006; 61:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/31\">",
"      Brohi K, Healy M, Fotheringham T, et al. Helical computed tomographic scanning for the evaluation of the cervical spine in the unconscious, intubated trauma patient. J Trauma 2005; 58:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/32\">",
"      Bailitz J, Starr F, Beecroft M, et al. CT should replace three-view radiographs as the initial screening test in patients at high, moderate, and low risk for blunt cervical spine injury: a prospective comparison. J Trauma 2009; 66:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/33\">",
"      Hennessy D, Widder S, Zygun D, et al. Cervical spine clearance in obtunded blunt trauma patients: a prospective study. J Trauma 2010; 68:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/34\">",
"      Demaerel P. Magnetic resonance imaging of spinal cord trauma: a pictorial essay. Neuroradiology 2006; 48:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/35\">",
"      Radiographic assessment of the cervical spine in symptomatic trauma patients. Neurosurgery 2002; 50:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/36\">",
"      Stevens RD, Bhardwaj A, Kirsch JR, Mirski MA. Critical care and perioperative management in traumatic spinal cord injury. J Neurosurg Anesthesiol 2003; 15:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/37\">",
"      White P, Seymour R, Powell N. MRI assessment of the pre-vertebral soft tissues in acute cervical spine trauma. Br J Radiol 1999; 72:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/38\">",
"      Katzberg RW, Benedetti PF, Drake CM, et al. Acute cervical spine injuries: prospective MR imaging assessment at a level 1 trauma center. Radiology 1999; 213:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/39\">",
"      Benzel EC, Hart BL, Ball PA, et al. Magnetic resonance imaging for the evaluation of patients with occult cervical spine injury. J Neurosurg 1996; 85:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/40\">",
"      Miyanji F, Furlan JC, Aarabi B, et al. Acute cervical traumatic spinal cord injury: MR imaging findings correlated with neurologic outcome--prospective study with 100 consecutive patients. Radiology 2007; 243:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/41\">",
"      Spinal cord injury without radiographic abnormality. Neurosurgery 2002; 50:S100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/42\">",
"      Schoenfeld AJ, Bono CM, McGuire KJ, et al. Computed tomography alone versus computed tomography and magnetic resonance imaging in the identification of occult injuries to the cervical spine: a meta-analysis. J Trauma 2010; 68:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/43\">",
"      Como JJ, Leukhardt WH, Anderson JS, et al. Computed tomography alone may clear the cervical spine in obtunded blunt trauma patients: a prospective evaluation of a revised protocol. J Trauma 2011; 70:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/44\">",
"      Machino M, Yukawa Y, Ito K, et al. Can magnetic resonance imaging reflect the prognosis in patients of cervical spinal cord injury without radiographic abnormality? Spine (Phila Pa 1976) 2011; 36:E1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/45\">",
"      Management of acute spinal cord injuries in an intensive care unit or other monitored setting. Neurosurgery 2002; 50:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/46\">",
"      Vale FL, Burns J, Jackson AB, Hadley MN. Combined medical and surgical treatment after acute spinal cord injury: results of a prospective pilot study to assess the merits of aggressive medical resuscitation and blood pressure management. J Neurosurg 1997; 87:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/47\">",
"      Levi L, Wolf A, Belzberg H. Hemodynamic parameters in patients with acute cervical cord trauma: description, intervention, and prediction of outcome. Neurosurgery 1993; 33:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/48\">",
"      Blood pressure management after acute spinal cord injury. Neurosurgery 2002; 50:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/49\">",
"      Lehmann KG, Lane JG, Piepmeier JM, Batsford WP. Cardiovascular abnormalities accompanying acute spinal cord injury in humans: incidence, time course and severity. J Am Coll Cardiol 1987; 10:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/50\">",
"      Bilello JF, Davis JW, Cunningham MA, et al. Cervical spinal cord injury and the need for cardiovascular intervention. Arch Surg 2003; 138:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/51\">",
"      Silver JR. Early autonomic dysreflexia. Spinal Cord 2000; 38:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/52\">",
"      DeVivo MJ, Kartus PL, Stover SL, et al. Cause of death for patients with spinal cord injuries. Arch Intern Med 1989; 149:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/53\">",
"      Wuermser LA, Ho CH, Chiodo AE, et al. Spinal cord injury medicine. 2. Acute care management of traumatic and nontraumatic injury. Arch Phys Med Rehabil 2007; 88:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/54\">",
"      Ball PA. Critical care of spinal cord injury. Spine (Phila Pa 1976) 2001; 26:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/55\">",
"      Velmahos GC, Kern J, Chan LS, et al. Prevention of venous thromboembolism after injury: an evidence-based report--part II: analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 2000; 49:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/56\">",
"      Merli GJ, Crabbe S, Paluzzi RG, Fritz D. Etiology, incidence, and prevention of deep vein thrombosis in acute spinal cord injury. Arch Phys Med Rehabil 1993; 74:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/57\">",
"      Slavik RS, Chan E, Gorman SK, et al. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial. J Trauma 2007; 62:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/58\">",
"      Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/59\">",
"      Deep venous thrombosis and thromboembolism in patients with cervical spinal cord injuries. Neurosurgery 2002; 50:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/60\">",
"      Chung SB, Lee SH, Kim ES, Eoh W. Incidence of deep vein thrombosis after spinal cord injury: a prospective study in 37 consecutive patients with traumatic or nontraumatic spinal cord injury treated by mechanical prophylaxis. J Trauma 2011; 71:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/61\">",
"      Simons RK, Hoyt DB, Winchell RJ, et al. A risk analysis of stress ulceration after trauma. J Trauma 1995; 39:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/62\">",
"      Karlsson AK. Autonomic dysfunction in spinal cord injury: clinical presentation of symptoms and signs. Prog Brain Res 2006; 152:1.",
"     </a>",
"    </li>",
"    <li>",
"     Lewin MG, Pappius HM, Hansebout RR. Effects of steroids on edema associated with injury of the spinal cord. In: Steroids and Brain Edema, Springer-Verlag, 1972. p.101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/64\">",
"      Lewin MG, Hansebout RR, Pappius HM. Chemical characteristics of traumatic spinal cord edema in cats. Effects of steroids on potassium depletion. J Neurosurg 1974; 40:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/65\">",
"      Bracken MB, Shepard MJ, Collins WF Jr, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg 1992; 76:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/66\">",
"      Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg 1998; 89:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/67\">",
"      Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997; 277:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/68\">",
"      Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev 2012; 1:CD001046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/69\">",
"      Hurlbert RJ. Strategies of medical intervention in the management of acute spinal cord injury. Spine (Phila Pa 1976) 2006; 31:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/70\">",
"      Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000; 93:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/71\">",
"      Sayer FT, Kronvall E, Nilsson OG. Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature. Spine J 2006; 6:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/72\">",
"      Eck JC, Nachtigall D, Humphreys SC, Hodges SD. Questionnaire survey of spine surgeons on the use of methylprednisolone for acute spinal cord injury. Spine (Phila Pa 1976) 2006; 31:E250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/73\">",
"      Bracken MB. Methylprednisolone and acute spinal cord injury: an update of the randomized evidence. Spine (Phila Pa 1976) 2001; 26:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/74\">",
"      Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery 2002; 50:S63.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Association of Emergency Physicians. Position statement: Steroids in acute spinal cord injury. Available online at: www.caep.ca (Accessed on January 24, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/76\">",
"      Hugenholtz H, Cass DE, Dvorak MF, et al. High-dose methylprednisolone for acute closed spinal cord injury--only a treatment option. Can J Neurol Sci 2002; 29:227.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Emergency Medicine. Position statement: Steroids in acute spinal cord injury. Available online at: www.aaem.org/positionstatements (Accessed on January 24, 2008).",
"    </li>",
"    <li>",
"     Consortium for Spinal Cord Medicine. Early Acute Management in Adults with Spinal Cord Injury: A Clinical Practice Guideline for Health-Care 2008; Paralyzed Veterans of America. Available online at: file://www.pva.org/site/News2?page=NewsArticle&amp;id=8407/ (Accessed on August 24, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/79\">",
"      Prendergast MR, Saxe JM, Ledgerwood AM, et al. Massive steroids do not reduce the zone of injury after penetrating spinal cord injury. J Trauma 1994; 37:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/80\">",
"      Levy ML, Gans W, Wijesinghe HS, et al. Use of methylprednisolone as an adjunct in the management of patients with penetrating spinal cord injury: outcome analysis. Neurosurgery 1996; 39:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/81\">",
"      Heary RF, Vaccaro AR, Mesa JJ, et al. Steroids and gunshot wounds to the spine. Neurosurgery 1997; 41:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/82\">",
"      Doran SE, Papadopoulos SM, Ducker TB, Lillehei KO. Magnetic resonance imaging documentation of coexistent traumatic locked facets of the cervical spine and disc herniation. J Neurosurg 1993; 79:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/83\">",
"      Rizzolo SJ, Piazza MR, Cotler JM, et al. Intervertebral disc injury complicating cervical spine trauma. Spine (Phila Pa 1976) 1991; 16:S187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/84\">",
"      Grant GA, Mirza SK, Chapman JR, et al. Risk of early closed reduction in cervical spine subluxation injuries. J Neurosurg 1999; 90:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/85\">",
"      Lu K, Lee TC, Chen HJ. Closed reduction of bilateral locked facets of the cervical spine under general anaesthesia. Acta Neurochir (Wien) 1998; 140:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/86\">",
"      Initial closed reduction of cervical spine fracture-dislocation injuries. Neurosurgery 2002; 50:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/87\">",
"      Bagnall AM, Jones L, Duffy S, Riemsma RP. Spinal fixation surgery for acute traumatic spinal cord injury. Cochrane Database Syst Rev 2008; :CD004725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/88\">",
"      Huang YH, Yang TM, Lin WC, et al. The prognosis of acute blunt cervical spinal cord injury. J Trauma 2009; 66:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/89\">",
"      Denis F. The three column spine and its significance in the classification of acute thoracolumbar spinal injuries. Spine (Phila Pa 1976) 1983; 8:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/90\">",
"      Vaccaro AR, Zeiller SC, Hulbert RJ, et al. The thoracolumbar injury severity score: a proposed treatment algorithm. J Spinal Disord Tech 2005; 18:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/91\">",
"      Harrop JS, Vaccaro AR, Hurlbert RJ, et al. Intrarater and interrater reliability and validity in the assessment of the mechanism of injury and integrity of the posterior ligamentous complex: a novel injury severity scoring system for thoracolumbar injuries. Invited submission from the Joint Section Meeting On Disorders of the Spine and Peripheral Nerves, March 2005. J Neurosurg Spine 2006; 4:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/92\">",
"      Fehlings MG, Perrin RG. The timing of surgical intervention in the treatment of spinal cord injury: a systematic review of recent clinical evidence. Spine (Phila Pa 1976) 2006; 31:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/93\">",
"      Dimar JR 2nd, Glassman SD, Raque GH, et al. The influence of spinal canal narrowing and timing of decompression on neurologic recovery after spinal cord contusion in a rat model. Spine (Phila Pa 1976) 1999; 24:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/94\">",
"      Carlson GD, Gorden CD, Oliff HS, et al. Sustained spinal cord compression: part I: time-dependent effect on long-term pathophysiology. J Bone Joint Surg Am 2003; 85-A:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/95\">",
"      Rabinowitz RS, Eck JC, Harper CM Jr, et al. Urgent surgical decompression compared to methylprednisolone for the treatment of acute spinal cord injury: a randomized prospective study in beagle dogs. Spine (Phila Pa 1976) 2008; 33:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/96\">",
"      Heiden JS, Weiss MH, Rosenberg AW, et al. Management of cervical spinal cord trauma in Southern California. J Neurosurg 1975; 43:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/97\">",
"      Marshall LF, Knowlton S, Garfin SR, et al. Deterioration following spinal cord injury. A multicenter study. J Neurosurg 1987; 66:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/98\">",
"      Wilmot CB, Hall KM. Evaluation of the acute management of tetraplegia: conservative versus surgical treatment. Paraplegia 1986; 24:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/99\">",
"      Albert TJ, Kim DH. Timing of surgical stabilization after cervical and thoracic trauma. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine 2005; 3:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/100\">",
"      Papadopoulos SM, Selden NR, Quint DJ, et al. Immediate spinal cord decompression for cervical spinal cord injury: feasibility and outcome. J Trauma 2002; 52:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/101\">",
"      Duh MS, Shepard MJ, Wilberger JE, Bracken MB. The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment. Neurosurgery 1994; 35:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/102\">",
"      Schinkel C, Anastasiadis AP. The timing of spinal stabilization in polytrauma and in patients with spinal cord injury. Curr Opin Crit Care 2008; 14:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/103\">",
"      Dimar JR, Carreon LY, Riina J, et al. Early versus late stabilization of the spine in the polytrauma patient. Spine (Phila Pa 1976) 2010; 35:S187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/104\">",
"      Vaccaro AR, Daugherty RJ, Sheehan TP, et al. Neurologic outcome of early versus late surgery for cervical spinal cord injury. Spine (Phila Pa 1976) 1997; 22:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/105\">",
"      La Rosa G, Conti A, Cardali S, et al. Does early decompression improve neurological outcome of spinal cord injured patients? Appraisal of the literature using a meta-analytical approach. Spinal Cord 2004; 42:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/106\">",
"      Fehlings MG, Rabin D, Sears W, et al. Current practice in the timing of surgical intervention in spinal cord injury. Spine (Phila Pa 1976) 2010; 35:S166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/107\">",
"      Wong SY, Wong KM, Chao AS, et al. Awake fiberoptic intubation for cesarean section in a parturient with odontoid fracture and atlantoaxial subluxation. Chang Gung Med J 2003; 26:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/108\">",
"      Babinski MF. Anesthetic considerations in the patient with acute spinal cord injury. Crit Care Clin 1987; 3:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/109\">",
"      Hansebout RR, Tanner JA, Romero-Sierra C. Current status of spinal cord cooling in the treatment of acute spinal cord injury. Spine (Phila Pa 1976) 1984; 9:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/110\">",
"      Cappuccino A, Bisson LJ, Carpenter B, et al. The use of systemic hypothermia for the treatment of an acute cervical spinal cord injury in a professional football player. Spine (Phila Pa 1976) 2010; 35:E57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/111\">",
"      Shapiro S, Borgens R, Pascuzzi R, et al. Oscillating field stimulation for complete spinal cord injury in humans: a phase 1 trial. J Neurosurg Spine 2005; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/112\">",
"      Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 2005; 3:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/113\">",
"      Pitts LH, Ross A, Chase GA, Faden AI. Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma 1995; 12:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/114\">",
"      Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal-cord injury--a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 1991; 324:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/115\">",
"      Geisler FH, Coleman WP, Grieco G, et al. The Sygen multicenter acute spinal cord injury study. Spine (Phila Pa 1976) 2001; 26:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/116\">",
"      Chinnock P, Roberts I. Gangliosides for acute spinal cord injury. Cochrane Database Syst Rev 2005; :CD004444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/117\">",
"      Daverat P, Gagnon M, Dartigues JF, et al. Initial factors predicting survival in patients with a spinal cord injury. J Neurol Neurosurg Psychiatry 1989; 52:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/118\">",
"      Claxton AR, Wong DT, Chung F, Fehlings MG. Predictors of hospital mortality and mechanical ventilation in patients with cervical spinal cord injury. Can J Anaesth 1998; 45:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/119\">",
"      Varma A, Hill EG, Nicholas J, Selassie A. Predictors of early mortality after traumatic spinal cord injury: a population-based study. Spine (Phila Pa 1976) 2010; 35:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/120\">",
"      Marino RJ, Ditunno JF Jr, Donovan WH, Maynard F Jr. Neurologic recovery after traumatic spinal cord injury: data from the Model Spinal Cord Injury Systems. Arch Phys Med Rehabil 1999; 80:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/121\">",
"      Harrop JS, Naroji S, Maltenfort MG, et al. Neurologic improvement after thoracic, thoracolumbar, and lumbar spinal cord (conus medullaris) injuries. Spine (Phila Pa 1976) 2011; 36:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/122\">",
"      van Middendorp JJ, Hosman AJ, Donders AR, et al. A clinical prediction rule for ambulation outcomes after traumatic spinal cord injury: a longitudinal cohort study. Lancet 2011; 377:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/11/26810/abstract/123\">",
"      Waters RL, Adkins RH, Yakura JS, Sie I. Motor and sensory recovery following incomplete tetraplegia. Arch Phys Med Rehabil 1994; 75:306.",
"     </a>",
"    </li>",
"    <li>",
"     Braddom R. Physical medicine and rehabilitation, 2nd, WB Saunders Company, Philadelphia 2000. p.1236.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4819 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-8377BC303A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26810=[""].join("\n");
var outline_f26_11_26810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complete cord injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incomplete injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Central cord syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anterior cord syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transient paralysis and spinal shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIAL EVALUATION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      In the field",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      In the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Plain x-rays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Myelography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Spinal cord injury without radiographic abnormality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Medical care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25317479\">",
"      - Cardiovascular complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25317487\">",
"      - Respiratory complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25317506\">",
"      - Venous thromboembolism and pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25317521\">",
"      - Other medical complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Decompression and stabilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Closed reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25317529\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25317560\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25317567\">",
"      Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Investigational treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92370232\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4819|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/28/33228\" title=\"table 1\">",
"      Spine injury classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/56/15243\" title=\"table 2\">",
"      Spinal cord injury grading scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9948\" title=\"table 3\">",
"      Thoracolumbar spinal cord injury score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/53/43868\" title=\"table 4\">",
"      Functional recovery after SCI by level",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27944?source=related_link\">",
"      Cervical spondylotic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=related_link\">",
"      Evaluation and acute management of cervical spinal column injuries in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=related_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=related_link\">",
"      Respiratory complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23321?source=related_link\">",
"      Respiratory physiologic changes following spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=related_link\">",
"      Spinal column injuries in adults: Definitions, mechanisms, and radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4951?source=related_link\">",
"      Spinal cord injury without radiographic abnormality (SCIWORA) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_11_26811="Infxn acalculous cholecystitis";
var content_f26_11_26811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infections predisposing to acalculous cholecystitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Ascaris lumbricoides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucella species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campylobacter jejuni",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candida species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clostridium perfringens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxiella burnetii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptosporidium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus granulosus, E multilocularis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epstein-Barr virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flavivirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis A and B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isospora",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptospira species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium tuberculosis, M bovis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasmodium species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella species (S enterica, S typhi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typhoid fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vibrio cholerae",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26811=[""].join("\n");
var outline_f26_11_26811=null;
var title_f26_11_26812="Pathogens causing adult diarrhea developing world";
var content_f26_11_26812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common pathogens causing diarrhea in adults in the developing world",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common pathogens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        <strong>",
"         Acute watery diarrhea",
"        </strong>",
"       </td>",
"       <td>",
"        Enterotoxigenic",
"        <em>",
"         Escherichia coli",
"        </em>",
"        (ETEC)",
"       </td>",
"       <td>",
"        Most common cause of acute watery diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Vibrio cholerae",
"        </em>",
"        O1 or O139",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norovirus",
"       </td>",
"       <td>",
"        Vomiting may be a prominent feature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campylobacter species",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nontyphoidal",
"        <em>",
"         Salmonella enterica",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aeromonas species",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroaggregative",
"        <em>",
"         Escherichia coli",
"        </em>",
"        (EAEC)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterotoxigenic",
"        <em>",
"         Bacteroides fragilis",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        <strong>",
"         Acute bloody diarrhea",
"        </strong>",
"       </td>",
"       <td>",
"        Shigella species",
"       </td>",
"       <td>",
"        Most common cause of acute bloody diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campylobacter species",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroinvasive",
"        <em>",
"         Escherichia coli",
"        </em>",
"        (EIEC)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterohemorrhagic",
"        <em>",
"         Escherichia coli",
"        </em>",
"        (EHEC)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nontyphoidal",
"        <em>",
"         Salmonella enterica",
"        </em>",
"       </td>",
"       <td>",
"        Rare&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Entamoeba histolytica",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Schistosoma mansoni",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26812=[""].join("\n");
var outline_f26_11_26812=null;
var title_f26_11_26813="Causes of neonatal hypertension";
var content_f26_11_26813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of neonatal hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal artery stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mid-aortic coarctation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal venous thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal artery compression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic arterial calcification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital rubella syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal parenchymal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polycystic kidney disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multicystic-dysplastic kidney disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberous sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ureteropelvic junction obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unilateral renal hypoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal tubular dysgensis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute tubular necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cortical necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interstitial nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemolytic-Uremic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obstruction (stones, tumors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchopulmonary dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic aortic coarctation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital adrenal hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperaldosteronism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudohypoaldosteronism type II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medications/intoxications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Infant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexamethasone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adrenergic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin D intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Theophylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caffeine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pancuronium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenylephrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Maternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heroin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wilms tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesoblastic nephroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial dysautonomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subdural hematoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Closure of abdominal wall defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercalcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extracorporeal membrane oxygenation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth asphyxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrocalcinosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management, and outcome. Pediatr Nephrol 2011 with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26813=[""].join("\n");
var outline_f26_11_26813=null;
var title_f26_11_26814="Malignant polyp biopsy";
var content_f26_11_26814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cartoon showing that biopsy of a polyp containing a malignant focus is inadequate for excluding malignancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26814=[""].join("\n");
var outline_f26_11_26814=null;
var title_f26_11_26815="Acute cholangitis ERCP";
var content_f26_11_26815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ERCP in acute cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagnosis and treatment of acute cholangitis with ERCP. Left panel: Multiple small stones in the lower common bile duct (arrow). Ultrasonography had shown borderline dilatation of the common bile duct but no stones. Right panel: After sphincterotomy and stone extraction, the common bile duct is free of stones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nezam Afdhal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_11_26815=[""].join("\n");
var outline_f26_11_26815=null;
